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It has been shown that genomes of bacteria, especially members of the 
Streptomyces genus, harbor unprecedented numbers of biosynthetic gene clusters (BGCs) 
potentially encoding novel compounds. However, cloning and controlled expression of 
these large BGCs in a heterologous host require tedious optimization on a case-by-case 
basis. This dissertation presents a synthetic biology platform to rapidly reconstitute BGCs 
by refactoring and physically piecing DNA fragments together in a hierarchical manner. 
The two core technologies are (i) a high-throughput DNA assembly pipeline for high GC 
organisms and (ii) synthetic genetic elements to control gene expression in Streptomyces. 
As a proof of concept, a small library of synthetic gene clusters was constructed to encode 
ent-atisanoic acid, a late-stage intermediate of the neuroprotectant serofendic acid. We 
successfully controlled the relative expression level of individual genes, identified the 
tailoring enzyme required for the oxidation as well as demonstrated the utility of this DNA 
assembly pipeline. Next, we rationally optimize isoprenoid biosynthesis by perturbing 
relative expression of eight enzymes in the methylerythritol phosphate (MEP) pathway. 
One of the Design of Experiment (DoE) methods called Plackett-Burman design was used 
to guide the optimization effort for this eight-gene system. A five-level Plackett-Burman 
design was used to guide the design of 125 unique synthetic gene clusters encoding the 
MEP pathway, which was required to fully screen the effects of expression of each gene 
on the output measured by isoprenoid titer. In the eight-gene pathway, each gene has one 
of five expression levels. Total screening of the entire pathway variants has revealed a 
surprising degree of robustness in actinobacterial secondary metabolism. In sum, the DNA 
assembly pipeline will become a powerful tool to fuel future rational optimization efforts of 
multi-gene systems, including large BGCs. 
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Chapter 1 Introduction 
 
1.1 Exploring the Biosynthetic Potential of Streptomyces through 
Combinatorial Design of Uncharacterized Biosynthetic Gene Clusters 
1.1.1 General Introduction 
With the advent of DNA sequencing [1] and de novo synthesis [2], the molecular 
toolkits available to engineer biology have quickly expanded. One of the growing 
applications of these techniques is in the genome mining field [3], especially in efforts to 
access previously untapped biosynthetic potential in Streptomyces genomes [4]–[7]. 
Streptomyces biosynthetic genes have a particular organization as “biosynthetic gene 
clusters (BGCs)”, which are genes grouped together in a genome that concertedly encode 
specialized molecules. More than 60% of clinically used antibiotics are derived from 
Streptomyces-produced natural products [8], [9]. There have been a substantial number 
of biosynthetic gene clusters identified through bioinformatics approaches [10], estimated 
to encode hundreds of thousands of future drug leads [11]. However there has been little 
success at expressing the BGCs under laboratory conditions [12], therefore their products 
and properties remain unknown. 
A conventional technique for characterizing these silent BGC is called 
heterologous expression [13]. During heterologous expression, a target BGC is 
transferred to a non-native host for its functional characterization. However, several 
caveats prevent heterologous expression from becoming a universal application. First, the 
traditional approach is to select expression hosts that are genetically close to the native 
host, but subtle genetic and metabolic differences between the native host and the 
expression hosts can cause unexpected expression levels [14]. Natural BGCs often have 
complex internal regulatory elements embedded in the sequences that interact with non-
native host’s cellular machinery via complex mechanisms [15], [16]. Several examples of 
expressing identical multi-gene constructs in several heterologous hosts of the same 
genus leads to drastic changes in the behaviors [17], [18]. Second, the productivity of the 
multi-gene system in the non-native host is usually different from wild type activity [19], 
[20]. Transferring BGCs to a heterologous host without modification leads to unpredictable 
changes in gene expression.  In addition, our current understanding of the regulation of 




core regulatory elements. Many heterologous expression studies require substantial 
optimization on a case-by-case basis, which is laborious and time-consuming. Properly 
tuned expression levels in a multi-gene pathway is important for maximizing its 
performance as well as identifying the encoded molecules and understanding the 
biosynthetic pathway. Thus, it is imperative to develop a systematic approach for tuning 
gene expression levels in BGCs to access novel natural products. 
There are many innovative strategies to overcome the challenges of investigating 
BGCs via heterologous expression [21]. One of the emerging approaches is re-designing 
the genetics of uncharacterized BGCs. This approach is based on using abstraction 
hierarchy to simplify these complex systems. Abstraction hierarchy [22] refers to viewing 
complex systems as composites of simpler functional devices, which are in turn composed 
of even simpler parts. In biological systems, including BGCs, functional devices include 
individual operons or monocistronic expression units and are composed of genetic parts 
(promoters, ribosome, coding DNA sequences (CDSs), and terminators). A technique 
called refactoring aims to systematically rewrite the underlying genetics without changing 
the functionality by (1) deconstructing native complex regulatory elements, (2) introducing 
well characterized genetic parts, and (3) reconstituting the functionality of BGCs [23]–[25]. 
The “parts approach” in synthetic biology exploits interchangeability of genetic parts to 
build large libraries of BGC variants for functional characterization. The goals of such 
libraries can be to explore combinatorial genetic design space [26], [27], to optimize 
expression for BGC characterization[28], and even to produce analogs of natural products 
via combinatorial biosynthesis [29], [30]. In this chapter, I will focus on large-scale 
reengineering BGCs and outline the considerations of codon composition, cis-acting 
regulatory elements, combinatorial design and algorithmic DNA assembly that are 
important for re-designing multi-part systems in Streptomyces.  
 
1.1.2 Design of Codon Usage 
The degeneracy of the genetic code offers ample opportunities to recode CDSs 
without changing the primary structure of the encoded protein. However, such changes 
can impact important aspects of heterologous expression including gene expression levels, 
construct stability, and ease of DNA assembly. Codon usage in Streptomyces is highly 
GC-biased (65 – 70 % on average) [31]. Traditionally, codon optimization substitutes 




host [32]–[34]. Alternatively, codon composition is adjusted to mirror that of similar genes 
in the host organisms according to codon adaptation index (CAI) [32]. Recent work 
demonstrated an alternative strategy that uses rare codons to increase protein expression 
[35]. Goodman et al. measured more than 14,000 combinations of promoter, RBSs and 
N-terminal codon usage to express a synthetic reporter gene in Escherichia coli. 
Surprisingly, the N-terminal peptide sequence encoding most rare codon variants show 
increased protein expression by 15-fold on average. Although changing codon 
composition using synonymous codon pairs maintained the amino acid sequence, the 
change in mRNA transcript secondary structure has substantial impact on protein 
expression. The analysis of the mRNA transcripts showed reduced mRNA structure at the 
+10 region is most correlated with expression increase.  
Codon randomization, which is based on the random assignment of codons to 
genes of interest according to a codon table, uses a weighted frequency distribution of the 
codons in the host genome or a subset of highly expressed genes [36]. Codon 
randomization aims to create variant CDSs whose sequences are as divergent from wild 
type as possible. The benefits of codon randomization include more flexible codon 
selection and elimination of internal regulatory elements, repetitive sequences and internal 
restriction sites.   
Another interesting study demonstrated unique regulation of codon availability in 
Streptomyces. A tRNA gene bldA is needed to decode a rare leucine codon, TTA, during 
translation [37]. bldA is only expressed during the stationary phase in Streptomyces, and 
many genes required for sporulation contain this rare TTA codon. Overall, this is a 
mechanism of post-transcriptional regulation, where bldA availability limits the translation 
of developmental genes that are transcribed too early. This developmental regulation 
should be accounted for when designing the codon composition of genes of interest for 
heterologous expression in Streptomyces [38]–[41].  
Besides the considerations for CDS composition, other parameters need to be 
considered in genetic design for efficient translation, including local GC content [42], local 
context of a given codon and presence of mRNA sequence motifs [43]–[45]. Overall, 
design of codon composition of BGCs for heterologous expression can be used to control 




1.1.3 Design of Cis-acting Regulatory Elements 
Non-coding DNA elements including intergenic regions, promoters, ribosomal 
binding sites (RBSs) and terminators have substantial effects on gene expression.  In 
natural BGCs, these elements often overlap each other or CDSs, making it difficult to 
replace them without unintended side-effects [46]–[49].  To make BGC engineering more 
feasible, applying a “parts approach” to these genetic regulatory elements allows (1) 
decoupling intrinsic complex pathway regulation embedded in the natural sequence and 
(2) introducing a modular organization, in which characterized regulatory elements can be 
easily swapped in or out. 
Promoter swapping, or replacing the native promoters with strong, characterized 
constitutive promoters is often used to increase expression level [50]. Several novel 
molecules were isolated by promoter swapping to transcriptionally activate 
uncharacterized silent BGCs in Streptomyces albus J1074 (which was reclassified as 
Streptomyces albidoflavus J1074) [51]. Additionally, in the context of multi-gene systems, 
balancing relative expression levels of biosynthetic enzymes is more important than 
maximal overexpression of the entire gene cluster [52]. Expressing every gene in a BGC 
as strongly as possible can lead to sub-optimal stoichiometries of relative gene expression 
that negatively impact the flux of metabolites through a pathway. It is possible that the flux 
imbalance leads to accumulation of shunt metabolites or accumulation of intermediates to 
toxic levels, both of which affect productivity and/or host fitness [53], [54]. Thus, it is highly 
desirable to have a platform where the expression of separate genes can be individually 
tuned to optimize flux. 
There is ongoing effort to build and characterize large libraries of regulatory 
elements for use is synthetic biology. These include synthetic promoters [55] and 
terminators [56], as well as models for designing and predicting the strength of RBSs de 
novo [26]. Part libraries often provide control of gene expression that spans several orders 
of magnitude, providing varying strengths to increase the range of tuning relative 
expression levels in a  multi-gene system [56], [57]. In addition, there are more sequence-
based tools to tune the translational efficiency including synthetic Streptomyces 
riboswitches [58] and RBSs [59]. Recent sequence-based biophysical models of gene 
regulation and expression, such as RBS calculator developed by the Salis et al., are 





1.1.4 Redesigning Gene Clusters to Aid in Construction and Permutation 
Although we have numerous tools to design underlying genetics and predict the 
multi-gene expression dynamics in silico, the technical capabilities remain limited to 
physically fabricate large-scale libraries of complex, large multi-part variants. Furthermore, 
the size of natural BGCs ranges from 10 to 100 kilobases [7], [11], [61]. As a result, the 
refactored BGC variants encompassing multiple synthetic regulatory elements and coding 
sequences can be quite large. There are two alternative strategies for producing a large 
synthetic genetic construct: de novo synthesis and ligation-based assembly. Either are 
technically possible for constructs the size of BGCs. Indeed, entire bacterial genomes 
have been synthesized de novo. However, de novo synthesis is cost-prohibitive for the 
production of large libraries of constructs. Additionally, the high GC bias of the coding 
sequences in Streptomyces also complicates preparation of DNA fragments by PCR or 
de novo synthesis. For these reasons, ligation-based DNA assembly is preferred for the 
construction of large combinatorial libraries. 
Strategies for DNA assembly have evolved in the past decade with the growth of 
Synthetic Biology. The conventional approach is to tailor a DNA assembly plan according 
to the sequence characteristics of a particular BGC of interest, which is time-consuming, 
low-throughput, and requires optimization on a case-by-case basis. Recently, many 
techniques have been developed for large multi-part assembly for biosynthetic pathways 
from small DNA fragments including MoClo[62], Gibson assembly [63], and Golden Gate 
assembly. There is an emerging trend to establish systematic pipelines that incorporate 
genetic design rules, assembly standards, and hierarchical assembly methods that can 
be extended to any BGC re-engineering project. This “one-pipeline-fits-all” approach can 
be called “algorithmic DNA assembly.” An essential factor for fast and reliable engineering 
of complex systems is standardization and modularity of its basic parts. This accelerates 
the design-build-test cycle by allowing diverse BGC designs to be built from a relatively 
small collection of genetic parts. In the context of re-engineering BGCs, standardization 
allows the reuse of previously characterized genetic elements to generate large 
combinatorial libraries of coding sequences as well as variants of their regulatory element 
sequences. Also, standardization facilitates exchange and testing composed parts to 
rapidly optimize multi-part constructs (Figure 1.1).  
Combinatorial DNA assembly can accelerate hypothesis testing by allowing 
diverse genetic designs to be built and screened in parallel. The permutations of regulatory 




those seen in natural systems [64]. For example, a BGC composed of polycistronic 
operons can be redesigned as monocistronic transcription units, with a unique promoter, 
RBS, and terminator controlling the expression of each gene to modulate individual 
expression dynamics. In addition, varying expression of the genes in the constructs can 
also be modulated by gene order. The alternative approach is designing BGC variants as 
artificial operons (in which all the genes are transcriptionally regulated by a single 
promoter), knowing that transcription distance has a linear relationship with the expression 
rate [65]. Permuting gene positions is an effective method to identify the variant with higher 
performance [66]. This technique is especially useful when there are limited genetic parts 
to control transcription and translation.  
 






There are several sequence considerations to building large libraries of multi-gene 
constructs. First, homologous sequences among fragments of the construct should be 
avoided to prevent recombination or deletion when introduced into the expression host. In 
Streptomyces, the BGCs often contain repetitive regions, such as BGCs encoding multi-
domain polyketide synthases that have high sequence homology and repetitive motifs 
[67]–[69]. Codon randomization can be used to eliminate highly similar or identical 
nucleotide sequences. Second, artifacts of repetitive sequences or internal regulatory 
elements in the DNA fragments should be screened before assembly. Repetitive 
sequences can render unexpected secondary structures difficult for cloning, DNA 
synthesis, or translation. This can be prevented by using unique regulatory elements to 
construct biosynthetic pathway variants. Third, internal restriction enzyme recognition 
sites should be eliminated to assist assembly of larger constructs [70]. 
 
1.1.5 Conclusion and Outlook 
Redesigning BGCs at the DNA sequence level has tremendous potential to 
accelerate natural product discovery. Mining the genomes of Streptomyces poses an 
interesting challenge including selection of appropriate cis-acting regulatory elements, 
tuning optimal expression dynamics for multi-part constructs encoding large BGCs, and 
physical preparation and assembly of high-GC DNA fragments for larger constructs. The 
need for innovative strategies to reliably assemble large DNA constructs remains. The 
ability to iterate through ‘design-build-test-learn cycles’ quickly will accelerate efforts to 
understand and engineer natural product biosynthesis. This potential in the natural product 
field is just beginning to be realized.  
 
1.2 Thesis Overview 
The aim of this dissertation is to apply algorithmic DNA assembly methods to 
engineer and understand natural product biosynthesis in Streptomyces. The scope of the 
dissertation is focused on terpenoid biosynthesis in Streptomyces, a genus of Gram-
positive bacteria known for prolific production of antibiotics and specialized metabolites. 
This dissertation presents a synthetic biology platform which integrates a high-throughput 




genetic elements to control gene expression. A refactored gene cluster encoding a novel 
diterpene acid, ent-atiserenoic acid (eAA), is used as a model multi-gene system to 
demonstrate utility of the Streptomyces synthetic biology platform developed during my 
PhD. This dissertation also explored the application of Design of Experiments (DoE) to 
rationally reduce the number of genetic constructs required to identify optimal genetic 
design encoding desired function (in this case, maximal eAA production titer). 
The motivation of this doctoral dissertation is to bridge the gap between the 
promise and the reality of Streptomyces-derived natural products as sources for new drug 
leads. On average, Streptomyces bacteria harbor 40+ biosynthetic gene clusters (BGCs) 
per genome based on the analysis of 1,100 publicly available Streptomyces genomes.[7] 
Hypothetically, there are hundreds, if not thousands, of novel metabolites encoded in the 
Streptomyces genomes waiting to be discovered. However, it is a non-trivial task to 
experimentally validate the products predicted to be associated with these BGCs; the 
number of new natural products empirically characterized through genome mining of 
Streptomyces is far fewer than the number of BGCs identified computationally.[71] One of 
the most prominent challenges in genome mining is to identify conditions for proper 
expression of the BGCs and detect encoded products. Most BGCs encoded in 
Streptomyces strains are not expressed at high-enough levels to detect the corresponding 
metabolites when the strains are cultivated in laboratory conditions. Transferring 
unmodified or partially modified BGCs to heterologous hosts is time consuming and does 
not guarantee proper expression of the associated gene products. With these challenges 
of the genome mining of Streptomyces in mind, I aimed to streamline the workflow of 
BGCs characterization from high-throughput DNA assembly to combinatorial refactoring 
to identify genetic designs for the optimal expression of cryptic or synthetic BGCs in 
Streptomyces. 
While working with Dr. Smanski, I developed two technologies which have laid the 
foundation for combinatorial optimization of multi-gene systems in Streptomyces. The first 
technology is the high-throughput algorithmic DNA assembly pipeline designed for cloning 
high-GC nucleotide sequences (chapters 2 and 3). Standardization of genetic parts, 
including cloning vectors, CDSs, and synthetic regulatory elements, leads to facile 
assembly of large DNA constructs in parallel. The modularity enables permutation of parts 
to be assembled with ease. We have developed a hierarchical assembly pipeline in which 
each step is a one-pot reaction with >95% efficiency. A special feature of this algorithmic 




instead of the BbsI and BsaI used in conventional Modular Cloning.[62] The high GC 
content of Streptomyces genomes leads to an increased frequency of BbsI and BsaI 
restriction sites compared to of AarI and SapI; on average, restriction sites of BbsI and 
BsaI appear 81 times whereas the restriction sites of AarI and SapI appear 28 times per 
50 kB of Streptomyces genomic DNA. By building the algorithmic DNA assembly pipeline 
for high GC genes with SapI and AarI, the domestication of CDSs is more efficient and 
economical, allowing us to target more gene clusters.  
The second technology indispensable to the success of my project is the parts 
library of 19 synthetic promoter-RBSs and 9 transcriptional terminators (Chapters 3 and 
4). The parts library allows controlling and tuning expression levels ranging over three 
orders of magnitude. These synthetic expression control elements with varying strengths 
extend the tuning range of relative expression levels. In addition, using synthetic promoter 
sequences derived from the housekeeping sigma factor-, σhrdB-, dependent 
promoters[72] allow production titer to be decoupled from media components and tightly 
linked with biomass accumulation; the expression level of each promoter-RBS is 
constitutive and consistent in two different media. Furthermore, diverse sequences of the 
DNA parts prevent undesired homologous recombination during physical assembly of 
genetic parts. 
As a proof of concept, a small library of refactored gene clusters encoding eAA 
was constructed using the synthetic biology platform in Streptomyces described in this 
dissertation (Chapter 3). Tuning relative expression levels of nine genes gave several 
insights to the relationship with genotype and chemotype. Following that, I aimed to 
increase the supply of isoprenoid precursor to increase eAA production titer (Chapter 4). 
I applied a DoE methodology called Plackett-Burman design to rationally design the 
expression of eight genes encoding the methylerythritol phosphate (MEP) pathway, an 
isoprenoid precursor pathway that most strongly impact eAA production levels.  
Specifically, a five-level Plackett-Burman design generated 125 unique MEP pathway 
variants which have different relative expression level for each of the eight genes.  
A chapter-by-chapter breakdown of the contents of this thesis follows: 
Chapter 1. This chapter reviews the background of the current approaches to 
study uncharacterized BGCs, particularly in Streptomyces. This chapter also highlights 
untapped opportunities in synthetic biology tool development for Streptomyces, as most 
of the novel molecular and synthetic biology tools are developed for E. coli, 




Chapter 2. The goal of this chapter is to delineate the considerations to design 
and implement an algorithmic DNA assembly pipeline to increase the throughput of 
prototyping multi-gene designs. This chapter covers three new molecular biology 
techniques: PCR ligation, isothermal assembly, and Golden Gate assembly to assemble 
DNA of different sizes. Finally, I present an algorithmic DNA assembly pipeline developed 
during the first year of my PhD in the Smanski group. Specifically, I incorporated all three 
DNA assembly techniques mentioned in this chapter to build large gene clusters from 
small, functional genetic parts. This chapter is adapted from a published book chapter 
“Designing and implementing algorithmic DNA assembly pipelines for multi-gene systems” 
[73] (https://doi.org/10.1007/978-1-4939-7295-1_9)  
Chapter 3. This chapter presents the application of the Streptomyces synthetic 
biology platform for the combinatorial optimization of natural products biosynthesis in 
Streptomyces. As a proof of concept, I constructed a small library of gene clusters to afford 
a synthetic biosynthetic pathway of ent-atiserenoic acid (eAA), a late stage intermediate 
in the total chemical synthesis of serofendic acid. This project demonstrated that the high-
throughput combinatorial genetic refactoring effectively introduced synthetic control over 
individual expression levels, chemical diversity, and the production of desired molecules. 
This chapter is adapted from published work: “Semisynthesis of the Neuroprotective 
Metabolite, Serofendic Acid” [74] (https://doi.org/10.1021/acssynbio.9b00261). 
Chapter 4. This chapter presents the exploration of multivariate statistical 
approaches to identify optimal relative expression level for a synthetic eight-gene cluster 
encoding the methylerythritol phosphate (MEP) pathway, which produces isoprenoid 
precursors. The main hypothesis is that mathematical optimization paradigms, which have 
been long used in industrial and chemical engineering, can be extended to well-defined 
genetic systems. The library design of the MEP pathway was rationally guided by a five-
level Plackett-Burman design, a multivariate design principle which allows screening of 
large number of variables while minimizing the number of tests. The five-level Plackett-
Burman design yielded 125 unique genetic designs which were constructed and screened. 
The analysis identifies dxs as the most important gene affecting isoprenoid titer, which 
corroborated the same conclusions in the MEP pathway literature.  
Chapter 5. This chapter summarizes the major results of my thesis work and 
discusses logical future directions for my specific projects as well as the field of microbial 




Appendices: Additional information is appended and relates to: (i) eAA 
biosynthetic pathway design, and (ii) rational refactoring of MEP pathway: 
Appendix 1. This appendix includes additional information of the refactored eAA 
gene cluster described in chapter 3. Specifically, it documents supplementary methods, 
materials, figures, data, and NMR spectra of novel metabolites and structural analogs of 
serofendic acid. A separate excel file called “Supplementary Data File A1” contains 
supplementary materials of chapter 3.  
Appendix 2. This appendix includes additional information of rational genetic 
design of a synthetic MEP pathway described in chapter 4. Specifically, it documents 
supplementary methods, materials, figures, data and legend of a separate excel file called 





Chapter 2 Designing and Implementing Algorithmic DNA 
Assembly Pipelines for Multi-gene Systems 
 
This chapter is a reformatted reprint of the book chapter Hsu SY and Smanski, M.J. (2018) 
“Designing and Implementing Algorithmic DNA Assembly Pipelines for Multi-Gene Systems” In: 
Jensen M.K., Keasling J.D. (eds) Synthetic Metabolic Pathways. Methods in Molecular Biology, vol 
1671. Humana Press, New York, NY.  
Book chapter hyperlink: 
https://doi.org/10.1007/978-1-4939-7295-1_9 
 
SYH wrote the original draft. SYH and MJS reviewed and edited the manuscript.  
Summary 
Advances in DNA synthesis and assembly technology allow for the high-
throughput fabrication of hundreds to thousands of multi-part genetic constructs in a short 
time. This allows for rapid hypothesis-testing and genetic optimization in multi-gene 
biological systems. Here we discuss key considerations to design and implement an 
algorithmic DNA assembly pipeline that provides the freedom to change nearly any design 
variable in a multi-gene system. In addition to considerations for pipeline design, we 
describe protocols for three useful molecular biology techniques in plasmid construction. 
 
2.1 Introduction 
In the past 50 years, recombinant DNA (rDNA) technology has been applied to 
produce life-saving medicines, herbicide-resistant or nutrient-enriched food crops, and 
has enabled to numerous discoveries in the life sciences. The vast majority of rDNA-
enabled applications rely on rather simple systems comprising one or a few genes. Recent 
advances in DNA synthesis, DNA assembly, and synthetic biology have allowed for the 
engineering of more complex biological capabilities that require the coordinated 
expression of a dozen or more genes. These include multigene systems that control 
cellular computation [75], [76], biosynthesis of structurally complicated drugs [52], [77] and 
enhanced biomaterials [78] and energy systems [79]. The engineering of these massively 
multipart genetic systems is facilitated by integrated pipelines of automated genetic design, 




is facilitated by robust and algorithmic DNA assembly pipelines that allow hundreds of 
variant multigene constructs to be built and tested in parallel. 
DNA synthesis and DNA assembly are two related yet distinct technology areas 
that both have seen tremendous advances in the past decade. We define DNA synthesis 
as the process of polymerizing nucleotide monomers using chemical processes. This is 
most commonly done with phosphoramadite chemistry, but the platforms vary from solid 
phase synthesis on resin to photochemistry on glass slides. DNA synthesis technology 
has been reviewed recently [2] and is not the focus of this chapter. DNA assembly refers 
to the suite of biochemical methods available to combine individual fragments of single- 
or double-stranded DNA into larger composite constructs. DNA assembly has been 
possible for the past half century using restriction enzyme-mediated cloning reactions; 
however, a number of new techniques now allow DNA assembly of many parts with high 
levels of efficiency and complete control over genetic design. For genetic engineering 
projects that require construction and testing of combinatorial libraries of constructs 
composed of the same DNA sequences (e.g. genes in a metabolic pathway), DNA 
assembly is more economical than DNA synthesis alone. A DNA assembly ‘pipeline’ is a 
set of protocols that can be used in succession to go all the way from the individual 
fragments of synthetic DNA to a large multigene construct. 
Refactored systems, in which the genetics have been systematically rewritten to 
enable engineering efforts, can be designed to be compatible with any DNA assembly 
pipeline. The main advantages to working with refactored genetic systems are that (i) 
every functional genetic element is characterized and its role in expression of the system 
is understood, (ii) regulation can be decoupled from host chromosome, for example by 
using orthogonal RNA polymerases, and (iii) they contain a modular genetic architecture. 
This allows the “parts approach” in synthetic biology, where genetic elements like 
promoters and ribosome binding sites are swapped in a combinatorial fashion to control 
gene expression. Many complex systems have been refactored in recent years, including 
bacteriophage [80], nitrogen fixation [64], and natural product biosynthesis pathways [42], 
[81]. Even a 272 kb yeast chromosome has been redesigned and assembled from 
synthetic oligonucleotides [82]. 
An important facet of refactored systems is that they can be designed to 
accommodate the DNA synthesis and assembly protocols used for fabrication. This 
contrasts with modification of plasmids encoding wild-type sequences, which is highly 




overlapping nature of encoded genetic elements. This means that unique DNA assembly 
routes had to be created for each recombinant plasmid design on a case-by-case basis. 
With refactored systems, it is possible to pre-define a set of robust DNA assembly 
protocols that will be used repeatedly to build any construct via an algorithmic, efficient 
pipeline. In other words, the DNA sequence is adjusted to accommodate the DNA 
assembly, not vice versa. Diversity in the genetic designs is controlled by varying the 
substrate DNA fragments that are included in each assembly reaction. 
Recently, many novel assembly techniques have been developed for large multi-
part assembly for multi-gene systems from small DNA fragments, including isothermal 
assembly [83], Golden Gate assembly [84], and yeast recombination [67]. These cloning 
methods can be coupled with standardized vector designs to provide hierarchical DNA 
assembly systems, such as Modular Cloning [62], GoldenBraid [85], BioBrick/Bglbrick [86], 
and TNT-cloning [87]. However, understanding the strengths and weaknesses of each 
cloning method allows the genetic engineering to customize a DNA assembly system to 
meet the design constraints of a specific multigene engineering project.  
This review covers major design considerations of an algorithmic DNA assembly 
pipeline and three useful DNA assembly techniques that can be incorporated in the 
assembly pipeline that fit individual assembly projects. We describe protocols to design 
primers and perform PCR-ligation, isothermal assembly, and Golden Gate assembly, and 
provides example of an algorithmic DNA assembly pipeline that integrates all three 
techniques. Lastly, we will discuss the advantages and limitations of each assembly 
technique so that the users are aware how to design, implement, test, and troubleshoot 
an algorithmic pipeline for given DNA assembly applications (see Note 2.4.3).  
  
2.2 Materials 
Prepare all the enzymatic reactions in PCR tubes and on ice. Prevent unnecessary 
thawing and freezing of the buffers and enzymes, for which are generally heat labile and 
therefore should always be kept at -15 to -25°C. When preparing reactions, the enzymes 
can be kept on ice or small freezer boxes for a brief amount of time. Always prepare 
reactions using ultrapure water (which is often purified by Milli-Q® water purification 
system) that has resistivity of 18.2 MΩ·cm. All the buffers and enzymatic reactions should 





2.2.1 Computational and Instrumental Requirements 
1. Plasmid editing software facilitates primer design and visualization of 
intermediate and final constructs. Free software that the authors recommend 
includes ApE (A Plasmid Editor) for computers running the Windows operating 
system. The software can be downloaded at  
http://biologylabs.utah.edu/jorgensen/wayned/ape/. For Mac users we 
recommend SnapGene (http://www.snapgene.com/). 
2. Nanodrop or similar spectrophotometer 
3. Thermocycler 
4. DNA gel electrophoresis equipment 
5. Gel imaging system 
 
2.2.2 PCR-ligation 
1. NEB T4 DNA ligase (400,000 units/ml; Catalog No. M0202S) 
2. NEB T4 DNA polynucleotide kinase (10,000 units/ml; Catalog No. M0201S) 
3. NEB 10x T4 ligase buffer 
4. NEB DpnI (20,000 units/ml; Catalog No. R0176S) 
5. Q5® High-Fidelity PCR Kit (200 reactions; Catalog No. E0555L)  
6. Deoxynucleotide (dNTP) Solution Mix  
7. Plasmid template(s) 
8. Primers 
9. PCR tubes 
10. Zymoclean™ Gel DNA Recovery Kit (200 preps; Catalog No. D4002) 
11. Agarose gel for DNA gel electrophoresis 
12. 6X DNA loading Dye 
13. 1 Kb DNA plus ladder (250 µg; Catalog No. 10787018) 
 
2.2.3 Isothermal Assembly 
1. NEB DpnI (20,000 units/ml; Catalog No. R0176S) 
2. Q5® High-Fidelity PCR Kit (200 reactions; Catalog No. E0555L)  
3. Deoxynucleotide (dNTP) Solution Mix  
4. NEB Gibson Assembly 2X Master mix (50 reactions; Catalog No. E2611L) 




6. Up to eight DNA fragments with 20-40 bp overlapping sequences 
7. PCR tubes 
8. Plasmid template(s) 
9. Primers 
10. PCR tubes 
 
2.2.4 Golden Gate Assembly 
1. Type IIS restriction endonuclease  
2. Promega T4 DNA ligase (HC) (500 U; Catalog No. M1794) 
3. 10X T4 DNA ligase buffer 
4. Plasmid DNA with Type IIS restriction recognition sites flaking the desired 
sequences and compatible 5′ overhangs 
5. Primers 
6. PCR tubes 
 
2.3 Methods 
2.3.1 Key Considerations for Designing an Algorithmic DNA Assembly Pipeline  
Developing a customized DNA assembly pipeline can be organized into three 
stages. The first stage is definition of design parameters for genetic constructs needed for 
the research project (Figure 2.1). For example, what types of genetic elements (promoters, 
ribosomal binding sites (RBSs), insulator sequences, etc) will be varied during library 
design? Where are scar sequences (vestigial DNA sequences that remain as a result of 
the cloning strategy, for example, restriction recognition sequences) between genetic 
elements to be tolerated, and how large can these scars be? Will higher-level architectural 
variables including operon occupancy, gene order, or gene orientation be permuted? 
Libraries that contain more design constraints can often be constructed with more 
streamlined assembly pipelines compared with libraries that encode diverse designs.  In 
the second stage, the DNA assembly methods most suited to the assembly needs are 
selected. In the Notes section below, we discuss the advantages, limitations, failure 
modes and troubleshooting methods for three DNA assembly techniques: PCR-ligation, 
isothermal assembly, and Golden Gate assembly. Other assembly techniques have been 




components that will be used for DNA assembly (see Note 2.4.1). This is particularly 
important for Golden Gate assembly, where there are many type IIS restriction enzymes 
that could be used in a pipeline, the selection of which will impact genetic part 
domestication. Aside from restriction enzyme choice, other components to determine 
include molecular features of cloning and expression vectors, antibiotic resistance 
cassette as selectable markers, and reporter genes for rapid and efficient screening of 
correct construct in each step of the pipeline. With these variables set, it is possible to 
construct all required vector plasmids needed for the assembly system. The third stage is 
to plan how intermediate and final constructs will be validated. Plasmid verification can 
take even more time and resources than DNA assembly, and the unique failure modes of 
each technique dictate different verification methods (see Note 2.4.2). The following 
subsections cover three useful DNA assembly methods that can be integrated into an 
algorithmic pipeline.  
 
2.3.2 PCR-ligation  
PCR-ligation is useful for adding or modifying short DNA sequences (1-200 bp) in 
existing plasmids. The entire plasmid is amplified in a single PCR reaction, with new 
sequences added via the 5′-ends of the forward and/or reverse primers (Figure 2.2A). 
Intramolecular blunt-end ligation of the linear PCR product re-circularizes the plasmid and 
readies it for transformation. PCR-ligation is particularly useful to build libraries of small 
functional DNA sequences such as promoters, RBS, and terminators with flanking 
sequences that will allow them to enter later stages of an assembly pipeline. 
 
2.3.2.1 Primer Design 
1. The 3’-ends of both the forward and reverse primer should have sufficient 
complementarity to the template to provide a Tm of 55°C-70°C (usually 18- 35 bp 
that will hybridize to the template; this can be checked using New England Biolabs’ 
Tm calculator, http://tmcalculator.neb.com). Note that the primers should anneal 
at the regions of the template plasmid that allow the user to amplify molecular 
features that the user wants to include in the final construct.  
2. New DNA sequence is added to the 5′ end of either forward primer, reserve primer 




use plasmid editing software to construct the desired final sequences in silico 
before designing primers.  
 
(A) A wild type gene cluster. Arrows represent genes. Grey arrows are the genes not essential to 
gene functions. (B) Example of three libraries with different design parameters. 
2.3.2.2 Protocol 
1. Thaw dNTPs, Q5 PCR buffer, primers and template DNA on ice. 
2. Prepare the PCR mix on ice according to the standard NEB Q5® polymerase PCR 
protocol (Table 2.1). Add Q5 polymerase to the mix the last and avoid letting 
polymerase warm above -20°C. 
3. Calculate the appropriate annealing temperature for specific primer pairs using 
NEB Tm calculator (http://tmcalculator.neb.com/#!/). Make sure to select “Q5” 




under product group drop down menu, “Q5 High-Fidelity DNA Polymerase” under 
polymerase/Kit drop down menu. Type “500” in Primer concentration (nM) box. 
Only input DNA sequences that anneal to the template. Otherwise the calculated 
anneal temperature will be overestimated if input is the entire primer sequence. 
4. Calculate the extension time for your construct. Q5 DNA polymerase extends at 
20-30 seconds per kilobase. 




Figure 2.2. Overall schematics of PCR-ligation, isothermal assembly, and Golden Gate 
assembly. 
(A) Key steps for PCR-ligation. Half arrows represent oligonucleotide primers. Red color denotes 
new DNA sequence being added to the final construct (bottom). (B) Isothermal assembly. The 
double stranded lines with different colors denote PCR products with unique set of oligonucleotide 
primers. (C) Golden Gate assembly. Red rectangle represents arbitrary type IIS restriction 
recognition sequences. Red triangle represents arbitrary cleavage site. The single line highlighted 

























5X Q5 Reaction Buffer 5 µl 1X 
10 mM dNTPs 0.5 µl 200 µM 
10 µM Forward Primer 1.25 µl 0.5 µM 
10 µM Reverse Primer 1.25 µl 0.5 µM 
Template DNA variable < 1,000 ng 
Q5 High-Fidelity DNA Polymerase 0.25 µl 0.02 U/µl 
5X Q5 High GC Enhancer (optional) (5 µl) (1X) 




Table 2.2. Thermocycling program for Q5 reaction. 
Step Temperature Time 
Initial Denaturation 98°C 30 seconds 
25–35 Cycles 98°C 5-10 seconds 
*50–72°C 10-30 seconds 
72°C 20-30 seconds/kb 
Final Extension 72°C 2 minutes 
Hold 4–10°C ∞ 
 
6. Once the PCR is finished, freeze the mixture in the -20oC or proceed to the step 
7. 
7. Analyze the presence of PCR product by DNA gel electrophoresis: mix 4 µL PCR 
and with 0.6 µL 6x DNA loading dye. Load the PCR mixture and 1 Kb DNA ladder 
on a 1% agarose TAE gel to check for expected product size. 
8. DpnI digest to remove template plasmid: add 1 µL DpnI to the remaining PCR 
mixture and incubate at 37°C for 30 minutes to one hour. Heat inactivate DpnI at 
80°C for 20 minutes.  
9. Purify the digested mixture using Zymoclean Gel Extraction Kit: Add 5 volume of 
DNA binding buffer to your PCR and load to the column. Spin down for 30 
seconds. Discard flow-through. Wash each column using 200 µL column wash 
buffer two times. Add minimal amount of water (≥ 6.5 µL) to elute the purified 
PCR product so it is as concentrated as possible. 
10. Perform T4 DNA ligation reaction: For each ligation, add the entire purified PCR 
product, 1 µL T4 ligase, 5 units T4 polynucleotide kinase (PNK), 1 µL T4 ligase 
buffer, and add water to bring up the final reaction volume to 10 µL. T4 ligase 
and T4 PNK should be added to the reaction last. Incubate the ligation mixture 
at room temperature for 1 hour. Transform 1-5 µL of the ligation mixture into 20-





2.3.3 Isothermal Assembly  
Isothermal assembly [83], also known as Gibson assembly, is a homology-based, 
restriction enzyme-independent method for stitching together multiple pieces of linear 
DNA (Figure 2.2B). The reaction utilizes a master mix of a 5′ exonuclease to ‘chew back’ 
one strand of the double stranded DNA, a DNA polymerase that fills in the gaps that are 
created and eventually overtake the exonuclease, and a DNA ligase that covalently joins 
independent pieces by repairing nicks. This method is fast, efficient, and reliable for 
multipart DNA assembly reactions, and has been used in the complete chemical synthesis 
of a bacterial genome [88]. 
 
2.3.3.1 Primer Design  
1. Primers for adjoining DNA fragments must encode 20-40 bases of overlapping 
sequence for annealing and ligation. We highly recommend designing the final 
construct sequences in silico prior to primer design. For each DNA fragment to 
be assembled, first design annealing 3′-ends of both the forward and reverse 
primers. They should have sufficient complementarity to the template to provide 
a Tm of 55°C-70°C (usually 18-35 bp that will anneal to the template). 
2. Overlap sequences of 20-40 nucleotides from neighboring DNA fragments are 
added into 5′ end of both forward and reverse primers to allow for annealing of 
overhangs.  
3. For sections of DNA that must be completely synthesized de novo, single 
stranded oligos can be used directly by ‘tiling’ them with successive 20 bp 
overlaps. The key to this single-stranded Gibson assembly is that the terminal 
oligo on each end must create a 3′ overhang.  
4. Alternatively, the primers can be designed by NEBuilder, a web-based Gibson 
assembly visualization tool provided by NEB. This can be found on 
http://nebuilder.neb.com.  
 
2.3.3.2 Protocol  
1. Perform PCR with primers designed to incorporate overlapping ends as 
described in PCR protocol in Method 2.3.2.2, including DpnI digestion and 
purification.  




3. Thaw 10 µL Gibson assembly master mix on ice.  
4.  Add 100 ng of the vector and equimolar amounts of other DNA and add water 
to bring the final volume up to 20 µL. 
5. Incubate the isothermal reaction mixture at 50°C for 1 hour. 
6. Transform 1-5 µL of the isothermal reaction into 20-50 µL chemically 
competent cells. 
 
2.3.4 Golden Gate Assembly  
Golden Gate assembly [84] utilize type IIS restriction enzymes to generate 3-4 bp 
sticky ends outside their recognition sequences that can be subsequently joined by T4 
ligase (Figure 2.2C) in a one-pot reaction. That type IIS restriction enzymes cleave 
outside their recognition site provides several advantages. First, the overhangs generated 
upon cleavage can be customized because they are independent of the restriction 
recognition sequences, allowing for scarless assemblies or combinatorial assembly 
between user-defined 3-4 base junctions. Also, because recognition sites are not present 
in the final assembled product, Golden Gate assembly can proceed in a one-pot 
digestion/ligation reaction with substantially higher efficiency than traditional cloning. 
Golden Gate reactions can routinely be used to incorporate several (>5) fragments into 
large (>25 kb) plasmid designs. An advanced version of Golden Gate assembly utilizes 
two type IIS restriction enzymes alternating between assembly stages to build an “infinite 
cloning loop” (Figure 2.3). 
 
2.3.4.1 Primer Design 
As with Isothermal assembly reactions, we suggest creating a plasmid sequence 
file of the final construct before designing primers. Here we discuss two aspects of Golden 
Gate assembly that require extra attention: the orientation of restriction recognition 
sequence and the position and design of scar site. Note that unlike isothermal reactions, 
it is possible and even preferable to start with circular plasmid substrates instead of linear 
fragments. Whether using circular or linear substrates, it is essential to design the 
orientation of restriction recognition sites and overhangs correctly. 
1. For each DNA fragment, design annealing 3′ ends of both the forward and 
reverse primers. They should have sufficient complementarity to the template to 






Figure 2.3. Schematic of an iterative Golden Gate assembly. 
(A) Alternating between two arbitrary type IIS restriction enzyme allows infinite cloning loop.  The 
oval in different colors denotes DNA part. The arbitrary antibiotic resistance cassette on the donor 
and destination vector are highlighted in orange and purple. Type IIS restriction recognition 
sequence is represented as rectangle. The cleavage site is represented as triangle. (B) Two design 
strategies of customizable scar sites. The left diagram shows that the directionality of BbsI and 
BsaI recognition sequence embedded in the plasmid share the same cut site. The right diagram 
shows different scar sites generated by BsaI or BbsI site. The cohesive ends can be customized 
based on how the recognition sites are positioned relative to each other and the Type IIS 
recognition sequence. Pink box: BbsI regognition sequence. Green box: BsaI recognition sequence. 
Orange and yellow box: scar sequence generated by either BbsI or BsaI cleavage. 
 
2. Orientation of the restriction recognition site: Type IIS restriction recognition sites 
are not palindromic, and DNA cleavage occurs on one side of the site 
(represented by carrot symbols in Figure 2.2C). It is important to orient each 
restriction recognition site so that cleavage occurs between the recognition site 
and the fragment to be assembled. Cleavage with the Type IIS restriction 




3. Design of annealing cohesive ends: The spacing between restriction recognition 
sequence and cleavage site depends on the choice of type IIS enzyme. Similar 
cohesive ends should be avoided in a single Golden Gate reaction, and the 
likelihood of two cohesive ends to join during the digestion/ligation reaction can 
be predicted using thermodynamic models [89].  
 
2.3.4.2 Protocol  
1. Measure the DNA concentration of each fragment to be assembled on a 
NanoDrop spectrophotometer.  
2. Calculate the mass of each DNA fragment equivalent to 20 fmol: dilute the DNA 
stock so each DNA fragment is approximately 20 fmol / µL 
3. Prepare a 10 µL reaction mixture by adding the DNA fragments, water and 1 µL 
10X T4 ligase buffer. Finally, add type IIS restriction enzyme (10U) and T4 ligase 
(10U). If performing many reactions in parallel, the water, buffer, and enzymes 
can be combined to form a master mix immediately before adding the DNA 
fragments. 
4. Mix the reaction by pipetting up and down 3-4 times and centrifuge briefly 
5. Incubate the reaction mixture on thermal cycler using the cycling conditions 
described in Table 2.3.  
6. Transform 1-5 µL of each Golden Gate assembly reaction into 20-50 µL 



















*Restriction enzymes have different heat inactivation temperatures. Refer to 
vendor information to set the proper inactivation time and temperature. 
 
2.4 Notes 
2.4.1 Molecular Specifications for Algorithmic DNA Assembly 
Choice of type IIS restriction endonuclease. Many type IIS restriction 
endonucleases can be used in an algorithmic DNA assembly pipeline, including BsaI, BbsI, 
AarI, and SapI. Selection of suitable restriction endonuclease is influenced by (i) 
differences in cohesive end size (i.e. 3-base overhangs generated by enzymes like EarI 
vs 4-base overhangs generated by enzymes like BsmBI) and (ii) frequency of recognition 
site in vectors or parts. Smaller cohesive ends generate smaller vestigial scars, but also 
decrease the number of fragments that can be reasonably assembled in a single reaction. 
More commonly, selection of restriction endonuclease is based on the frequency of the 
recognition sites in the substrate genetic parts or assembly vectors. These sites will have 
to be removed via synonymous mutations to ‘domesticate’ genetic parts that will enter the 
assembly pipeline. For example, AarI recognition sites are less frequent than BbsI 
Step Temperature Time 





16°C 5 minutes 
37°C 1 minute 
16°C 1 minute 
Ligase Heat inactivation 50°C 5 minutes 
Restriction enzyme 
Heat inactivation 
65°C* 10-20 minutes* 




recognition sites in Streptomyces genes, so using AarI would be preferred for building 
multigene pathways from Streptomyces genes. 
Choice of selectable marker in vector backbones. The vector backbone for initial, 
intermediate, and final constructs should be tailored for the specific assembly project. One 
failure mode for every DNA assembly method is the growth of colonies resulting from 
undigested substrate plasmids. This is easily avoided by changing selection markers in 
successive ‘levels’ in a DNA assembly pipeline. For example, ‘monocistron’ plasmids 
(Figure 2.4) contain a kanamycin resistance marker while ‘partial cluster’ plasmids contain 
an ampicillin marker. Using two unique selectable markers is sufficient for creating an 
infinite cloning loop (Figure 2.3). Undigested destination vectors can be easily identified 
if a lacZα reporter cassette is included between the Golden Gate cloning scars (Figure 
2.3 and 2.4). 
Choice of origin of replication in vector backbones. High-copy origins of replication 
provide the best plasmid yields following purification, and thus are suggested for all 
vectors holding intermediate assembly constructs (i.e. partial clusters). However, the use 
of low- or medium-copy origins of replication might mitigate potential toxicity of constructs. 
The final destination vector should be customized for the expression host. Origin of 
replication copy number as well as the choice between replicative or chromosome-
integrating vectors will depend on the specific project requirements.  
 
2.4.2 Failure Mode, Screening Techniques and Troubleshooting  
When screening plasmids to verify the fidelity of DNA assembly reactions, it is 
good to consider the common failure modes of individual methods. These are summarized 
in Table 2.4, where we consider Golden Gate cloning from previously sequence-verified 
plasmid substrates, not PCR products.  
 
2.4.3 Strengths and Weaknesses of Assembly Techniques 
PCR-Ligation. The advantage of PCR-ligation is its utility to generate large 
combinatorial library with relatively small amount of primers. It is particularly suited to 
building out large libraries of promoter-RBS pairs in a combinatorial fashion. Primer 
requirement scales with the sum of parts, not the product of parts, so assembling 10 
promoter sequences and 10 RBS sequences into 100 combinations only requires 




junctions, which can be useful between regulatory sequences in the 5′-UTR that are 
sensitive to relative spacing. Lastly, this is a restriction enzyme-independent technique 
which limits sequence constraints. The largest weakness of PCR-ligation is that it is limited 
to small genetic parts that can be fully encoded in an oligonucleotide primer. Another 
weakness is the most common failure mode of small deletions at the ligation junction, 
which require sequence verification and add to the validation costs. 
 
 
Figure 2.4. Example of an algorithmic DNA assembly pipeline incorporating isothermal 
assembly, PCR-ligation, and Golden Gate assembly. 
(A)Plasmid designs of destination vectors for different DNA assembly levels. The resistance 
cassette on the destination vectors alternates between apramycin and kanamycin to facilitate 
selection of desired constructs. The destination vectors were constructed using Isothermal 
assembly to introduce various combinations of Golden Gate assembly scar site. (B) PCR-ligation 
is used to build promoter/RBS and terminator part plasmids. Level 1 assembly starts with a DV1, 
part plasmids of promoter/RBS, terminator and reporter gene, and CisReg construct is assembled 
by BbsI Golden Gate reaction. Level 2 assembly starts with CisReg plasmid and a target CDS 
stored in pCDS plasmid, and a monocistron is assembled by a SapI Golden Gate reaction. Level 3 




reaction. Level 4 assembly uses multiple partial clusters as substrates and a final cluster is 
assembled by SapI Golden Gate reaction.Green arrow represents reporter gene. GGCS, Golden 
Gate Cassette Site. DV, destination vector. The black arrow contains the name of Type IIS 
restriction enzyme used in individual level of Golden Gate assembly. 
 
Table 2.4. Failure modes and screening methods for assembly methods described here. 
 
Isothermal Assembly. Isothermal assembly is an incredibly useful method with 
diverse applications. Primer design is straightforward, and there are few sequence-
constraints since it is restriction enzyme-independent. The ease of building scarless 
constructs allows the genetic engineer to specify every base in a plasmid design. Further, 
many fragments can be assembled in a single reaction with high efficiency. Drawbacks to 
isothermal assembly are that it does not lend itself to combinatorial assembly. Joining 
parts need ~20 bases of homologous sequence for the reaction to proceed meaning that 
for combinatorial libraries, either (i) a 20 base scar needs to be designed between 
neighboring genetic parts, or (ii) primers need to be designed to accommodate every 
possible unique part junction to avoid scars. This latter option would make oligonucleotide 
requirements scale by the product of parts (i.e. a 10 promoters x 10 RBSs library would 
require ~100 oligonucleotides). Isothermal reactions aimed to produce constructs greater 
than ~12 kb require many-fold more substrate DNA, so this technique does not lend itself 
to large construct assembly. Lastly secondary structure in the substrate fragments, for 
example that caused by high-GC DNA, can reduce the efficiency of this technique. 
Assembly Techniques Failure Modes Best Screening Method 
PCR-ligation Small deletions at site of ligation 
Point mutations in construct 
introduced through PCR 
DNA sequencing 
Isothermal Assembly Point mutations in the construct 
introduced through PCR or junction 
gap-filling 
Low efficiency due to too many 
fragments, high GC fragments, or 
extremely long fragments 
DNA sequencing 
Golden Gate Assembly Missing fragments 
 






Golden Gate Assembly. Golden Gate assembly is known for its scalability and high 
efficiency. First, the ability to define annealing cohesive ends allows either scarless 
assembly or combinatorial assembly with small scar sequences. This method can readily 
be used to assemble >10 fragments in a single reaction, although reaction efficiencies 
decrease with more parts. Of the methods described here, Golden Gate assembly is the 
best choice for assembling large (>10 kb) constructs. Weaknesses include additional 
complexity in primer design compared with the other methods that requires substantial 
practice to become experienced. Also, as a restriction enzyme-dependent technique, 
substrate parts and vectors need to be domesticated prior to entry into the pipeline. 
However, this can be leveraged as an advantage, where substrate fragments are 
domesticated and cloned into a plasmid before entry into the pipeline. Sequencing of these 
substrate plasmids decreases future validation costs and starting with plasmid substrates 
increases the efficiency of the reaction. 
 
2.4.4 Sample DNA Assembly Pipeline with Integrated Expression Analysis 
Figure 2.4 shows an example DNA assembly pipeline designed to accommodate 
differences in promoter strength, RBS strength, gene order, and operon occupancy. Prior 
to the assembly, the destination vectors (DVs) are constructed using isothermal assembly. 
Libraries of promoter-RBS combinations (represented in a thin arrow) and terminators 
(represented as Ts) are built using PCR-ligation. The coding sequences are domesticated 
in the pCDS vector via Golden Gate assembly (details steps shown in the pipeline.) The 
first step of the pipeline is the BbsI Golden Gate assembly of promoter-RBS, terminator 
and reporter gene, resulting in a transcription unit containing cis-regulation elements 
(CisReg construct). The reporter gene in the CisReg construct has two functions. First, it 
serves as a place holder that will be swapped out in the next assembly stage. Second, it 
allows the users to characterize expression strength of promoter::RBS combination in the 
pipeline. Third, the reporter gene is swapped out by the desired coding sequence by 
Golden Gate assembly using SapI, resulting a monocistronic construct (Cistron). Third, 
multiple monoscitronic constructs are pieced together by AarI Golden Gate assembly to 
yield a partial cluster. Third, partial clusters are pieced together by SapI assembly to yield 
a final cluster. Theoretically, by alternating the last two type IIS restriction endonucleases, 






Chapter 3 Semi-synthesis of the Neuroprotective 
Metabolite, Serofendic Acid 
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Summary 
Serofendic acid is a natural neuroprotective molecule found in fetal calf serum. It is able 
to protect neurons against mechanisms of cell death associated with neurodegenerative 
disease. Because only trace quantities are present in fetal calf serum and complete 
chemical syntheses are long and inefficient, its development as a therapeutic agent has 
been slow. We engineered a heterologous metabolic pathway in Streptomyces to produce 
a late-stage synthetic intermediate, ent-atiserenoic acid, at high titers. We completed the 
total synthesis of serofendic acid from this intermediate in four steps.  
 
3.1 Introduction 
Acute and chronic neurodegenerative diseases are responsible for 13% of deaths 
in the USA each year and cause a combined annual economic burden in excess of $300B 





caused by programmed cell death. This tissue damage is irreversible, as cells in the 
central nervous system have limited regenerative capabilities. Neurodegenerative 
diseases are drug-poor, with only a small number of clinically approved therapeutics 
available for treatment. Recently, serofendic acid (1) (Figure 3.1a) has been identified as 
a diterpenoid natural product [92] that has potent (nanomolar) bioactivity in decreasing 
tissue damage caused by stroke [93], [94], neurodegenerative disease [95], and other 
ischemic injuries [96] and improving recovery outcomes in animal models [94]. 
Despite its promise in pre-clinical investigations, the lack of a scalable source for 
the compound has limited its development. It is only present in trace quantities in fetal calf 
serum (3.1 mg isolated from 250 L of fetal calf serum) [92], and total chemical synthesis 
is challenging due to the nine chiral centers. Several total syntheses have been reported 
[97]–[100], but the many steps and low overall yields (around 1%) make these impractical 
to support pre-clinical development or clinical trials. 
Heterologous production in a microorganism is an attractive solution to this 
problem. In recent years, several groups have engineered microbes to produce clinical 
drugs or drug-precursors, including opioid painkillers [54], anti-malarial agents [101], and 
anti-cancer agents [102]. Each of these projects benefited from the existence of a known 
producing organism from which biosynthetic genes could be identified and used in 
engineering. In contrast, the producer of 1 is unknown. The ent-atisane diterpene scaffold 
is unprecedented as a mammalian metabolite and the required biosynthetic genes are not 
present in the cow’s genome. Without a known producing organism, we had to design and 
build a metabolic pathway using genes present in public sequence databases. 
Here we describe our approach to produce 1 at scales needed for pre-clinical 
development. We make a late stage diterpene intermediate, ent-atiserenoic acid (2), via 
a heterologous metabolic pathway engineered in an industrial host organism. Compound 
2 is converted to 1 and analogs via a short chemical synthesis. With optimized strains able 
to produce 2 at high titers, we have established a reliable and economical source of the 








We first set out to identify enzymes that could be used for the biosynthesis of 1. 
Atisane-derived scaffolds are found in other bioactive natural products including ent-19-
hydroxy-atis-16-ene-3,14-dione (3), platencin (4), and spiramines (5) (Figure 3.1a). The 
lack of a known organism producing 1 precluded genome mining as an approach to obtain 
biosynthetic genes. Instead, we performed a retro-(bio)synthetic analysis using reactions 
either described in the literature or proposed based on chemical logic (Figure 3.1b). The 
methylsulfinyl group at C17 and the hydroxyl group at C15 are predicted to be late-stage 
tailoring modifications of 2. This compound is predicted to derive from a six-electron 
oxidation of the C19 methyl of ent-atiserene (6), analogous to the first tailoring step in 
gibberellin biosynthesis [103]. As a labdane diterpene, 6 originates from a type-I 
cyclization of an ent-copalyl diphosphate intermediate (7). Finally, 7 would come from a 
type-II cyclization of geranylgeranyl diphosphate (8), the common intermediate in all 
diterpene metabolism. Our preliminary goal was to reconstitute a biosynthetic pathway to 
produce 2, which can be converted to 1 via a four-step chemical synthesis. 
 
 





(a) Examples of bioactive natural products containing atisane scaffold [93], [104]–[106]. (b) Retro-
(bio)synthetic analysis of 1 from primary metabolites required for isoprenoid biosynthesis. (c) 
Schematic representation of DNA assembly pipeline from genetic parts (top) to synthetic gene 
clusters (SGCs, bottom). Key type IIS restriction enzymes used in assembly (left of arrows) and 
representative assembly efficiencies (right of arrows; reported as a fraction of correct constructs 
over total colonies tested) are shown on the schematic. Circle with x in it, 4-bp MoClo assembly 
scar site; orange circle, start codon; yellow circle, stop codon. (d) Characterization of library of 
promoter-RBS combinations in 60-hour fermentation in two growth media. Black bar, PCNM 
medium; white bar, ISM3 medium. Error bars denote standard deviation from three replicates over 
multiple days. *expression detected after 96-hour fermentation (Figure S4). (e) DNA assembly 
graph for initial seven SGCs built for this study. P denotes promoter; R denotes RBS; T denotes 
terminator; eAS, ent-atiserene synthase; eCDPS, ent-copalyl diphosphate synthase; GGDPS, 
geranylgeranyl diphosphase synthase; αKG-DDO, α-ketoglutarate dependent dioxygenase; eAOx, 
ent-atiserene oxidase;; eAOxFD, ent-atiserene oxidase ferredoxin. 
 
We surveyed the literature and existing genome sequence databases to select 
genes encoding the desired enzymes. We focused our search in Streptomyces genomes, 
as these bacteria are known to host a large diversity of metabolic enzymes. Further, there 
are sufficient tools for genetic manipulation of model Streptomyces that allow us to avoid 
many hurdles to heterologous expression in distant taxa. Several geranylgeranyl 
diphosphate synthases (GGDPS) have been described in diterpenoid-producing 
Streptomyces that can produce compound 8 from primary metabolites. Further, putative 
ent-copalyl diphosphate synthases (eCDPS) were identified in genomes on known 
labdane-producing Streptomyces by phylogenetic analysis of previously characterized 
ent-copalyl diphosphate synthase, PtmT2 (Supplementary Figure A1.1) [107], [108]. We 
identified several putative ent-atiserene synthases (eAS) in the sequence databases 
based on their homology to the platencin biosynthetic gene ptmT1 (Supplementary 
Figure A1.2). The required six-electron oxidation of a methyl group on 6 has never been 
reported, although a P450 monooxygenase CYP117 was reported to oxidize C19 of the 
methyl group of ent-kaurene, a similar labdane-diterpene scaffold to 6 [109]. We selected 
several putative oxidoreductases and P450 monooxygenases from gene clusters 
containing ptmT1 homologs as likely candidates to perform this reaction. Since our initial 
experiment, Shen et al. have reported the activity of one of these enzymes, the α-
ketoglutarate dependent dioxygenase, PtmO6, as a specific C7 hydroxylase [110]. 
Genes were recoded for entry into a multi-gene DNA assembly pipeline designed 





Figure A1.3). To control and vary individual gene expression of the synthetic gene 
clusters, we used previously published cis-acting regulatory elements including synthetic 
promoters [111] and bacterial terminators [56]. A set of synthetic ribosomal binding site 
sequences of varying translational rates were generated by RBS calculator [112] 
(Supplementary Data File A1, Worksheet 1). Promoter and RBS were concatenated as 
a single genetic part in our genetic design and the collection of promoter-RBS 
combinations were characterized by β-glucuronidase (GUS) assay. To minimize the 
confounding effects of medium composition on small molecule titers/yield, we only 
included used cis-regulatory elements that gave consistent expression of a reporter gene 
in two growth media, ISM3 and PCNM (Figure 3.1d and Supplementary Figure A1.4). 
Combining these natural and synthetic genetic elements using one-pot type IIS restriction 
digestion/ligation reactions [73], an initial set of seven synthetic gene clusters (SGCs) 
were produced (Figure 3.1e). We opted for an iterative DNA assembly pipeline comprising 
modest (4-5 part) assembly reactions to keep the efficiency high at each step. After 
verifying a minimum of 25 reactions of each step, our efficiency (defined as percentage of 
colonies on a plate containing the desired plasmid construct) ranged from 92% (23/25) to 
100% (59/59) (Figure 3.1c). SGC1-7 vary according to the relative expression levels of 
genes encoding the terpene scaffold and according to gene composition for the oxidative 
tailoring reactions. These SGCs were introduced to a Streptomyces albidoflavus J1074 
(formerly S. albus J1074) [113] heterologous host and culture broth was analyzed by LC-
MS.  
Each recombinant strain produced a unique chemical profile with two, SGC4/5, 
producing a predominant peak with a mass-to-charge ratio of 301 amu (Figure 3.2). This 
mass is consistent with the [M-H]- ion of our desired product, 2. The structure was 
confirmed following purification from a 50 mL liquid culture and 1D and 2D NMR 
spectroscopy (Supplementary Figure A1.5-A1.8) [114]. Other strains produced 
prominent peaks with masses in the range expected for diterpenoid metabolites that were 
isolated and their structures determined by spectroscopic methods. These compounds, 
(4E,8E,12E)-14-hydroxy-4,8,12-trimethyltetradeca-4,8,12-trienoic acid (11) and ent-





presumably shunt metabolites derived from biosynthetic intermediates 7 and 8 
(Supplementary Figure A1.16 - A1.17). 
Comparing the genotypes to the chemical profiles from this initial library revealed 
several insights important for the production of compound 2. First, we identified 
WP_030985276, an ortholog of ptmO2, as a cytochrome P450 capable of catalyzing the 
complete six-electron oxidation from compound 6 to 2. Only the subset of SGCs containing 
this gene and its cognate ferredoxin reductase, WP_030990007, accumulate 2 or the 
corresponding oxidized copalyl derivative, 12 (Figure 3.2). Based on primary sequence 
similarity to characterized cytochrome P450’s, WP_030985276 is assigned as the first 
member of a new CYP family, CYP1408A1 (D.R. Nelson, personal communication) and 
is given the shorthand name ent-atiserene oxidase (eAOx). 2D NMR analysis of isolated 
metabolites confirms the regio- and stereo-specificity of the oxidation catalyzed by eAOx 
(Supplementary Figure A1.8). 
 
 
Figure 3.2. LC-MS analyses of key metabolites produced by seven SGCs. 
(a) Schematic of seven SGC designs and keys of genetic parts. (b) The selected ion 
chromatograms correspond to m/z values for the oxidized shunt metabolite (11) of 8 (left), the 






The importance of properly balancing gene expression levels is evident from 
comparing SGCs with identical gene content. SGC1 and SGC5 contain the same set of 
genes, but the genes required for terpene cyclization (GGDPS, eCDPS, and eAS) are 
controlled by promoters and RBSs of different strength (Supplementary Data File A1, 
Worksheet 2). In SGC1, eAS is controlled by promoter-RBS P1R1 with basal activity (2.7 
± 1.4 relative expression unit (REU)), and the shunt metabolite 12 is the major product. In 
contrast, the SGC5 design expresses eAS from a medium-strength promoter P8R8 (21.9 
± 4.6 REU), and the desired compound 2 is produced at 50 mg/L. The shunt metabolite 
12 was only observed in strains containing the P450 monooxygenase, eAOx, suggesting 
this enzyme is promiscuous and can oxidize 7 or 6. Thus, both the eAS and the eAOx 
compete for the common substrate, 7. The expression ratio of these two enzymes 
determines whether 12 or 2 preferentially accumulates during fermentation. 
Lastly, we see evidence that perturbing the expression of on-pathway genes can 
influence shunt metabolite production by endogenous host enzymes. Compound 11 is a 
17-carbon metabolite that we predict arises from (i) the β-oxidation and degradation of 8 
to remove the terminal three carbons, and (ii) hydrolysis of the diphosphate tail 
(Supplementary Figure A1.16). Because 11 accumulates regardless of the complement 
of oxidases encoded by the synthetic gene cluster, it is most likely a shunt product made 
by endogenous host enzymes and not by oxidases encoded within the SGC. Despite this, 
the titer of 11 is affected by the relative ratio of the geranylgeranyl diphosphate (GGDP) 
synthase and the eCDPS, as can be seen by comparing production of 11 in isogenic SGCs 
1-5 and 3-7. In both cases, SGCs in which GGDPS is expressed at higher levels (22.9 ± 
1.0 REU in SGC1 and SGC3 versus 88.0 ± 14.1 REU in SGC5 and SGC7) accumulate 
11 at higher concentrations at the expense of desired downstream metabolites. These 
results reinforce the observation made by others [101], [102] that designing biosynthetic 
pathways such that every gene is maximally expressed is rarely optimal. Additionally, 
these results show metabolic shunting by endogenous host enzymes can be ameliorated 







Figure 3.3. Titer improvement through precursor pool pathways. 
(a) The MEP pathway for isoprenoid precursor supply. (b) Plasmid components of 
MEP pathway optimization SGCs. (c) Relative expression level of the MEP 
pathway genes in SGCs and corresponding titer of 2. Error bars denote standard 
deviation from three replicates measured on multiple days. (d) Photographs of 
crystals (top) obtained from large-scale production of 2 and crystal structure 
obtained by X-ray diffraction (bottom). 
 
To further increase titers of compound 2, we bolstered the supply of precursor 
metabolites by adding genes for the entire methylerythritol phosphate (MEP) pathway plus 
the isopentenyl pyrophosphate-dimethylallyl pyrophosphate (IPP-DMAPP) isomerase, idi, 
to the SGC4 construct. Each of the eight genes were cloned from Streptomyces sp. NRRL 
S-1813 into our coding DNA sequence (CDS) domestication plasmid, pMJS_CDS 
(Supplementary Figure A1.3 and Supplementary Table A1.1). A library of nine SGCs 
was built in which the relative expression levels of each of the eight new genes was 
perturbed (Supplementary Data File A1). Following conjugation into our S. albidoflavus 
J1074 host, two unique recombinant strains of each genotype (designated ‘a’ and ‘b’) were 
fermented in 0.5 mL ISM3 medium for five days. The titer of 2 was determined by LC-MS. 
Eight out of nine constructs produced more 2 than strains harboring SGC5 (Figure 3.3c). 
In 500 mL shake-flask cultures, strain M19a produced 547.9 ± 204.8 mg/L 
(Supplementary Figure A1.18). At this titer, 2 spontaneously crystalizes from an ethyl 





laboratory-scale fermentations without the need for chromatography. Additionally, our use 
of cis-regulatory elements with consistent behavior across growth media allowed us to see 
prodigious production in every medium tested, with titers correlating to cell 
growth/doubling (Supplementary Figure A1.19). 
Using this high-titer bacterial strain to access compound 2, we next used chemical 
synthesis to produce 1. The methyl ester of 2 is a late stage intermediate in several total 
syntheses of 1 [100]. Esterification in acidic conditions led only to methanolysis of the C16 
double bond (compounds 14 and 15, Supplementary Figure A1.20-A1.27). In basic 
conditions with iodomethane as a methylating agent, we attained the methyl ester, 16, 
without any nucleophilic attack on the double bond (Supplementary Figure A1.28-A1.32). 
This constitutes a formal synthesis of 1, as 16 has been converted to 1 with an overall 
yield of 17% in 5 steps [100].  
We hypothesized that protecting the carboxylic acid as a methyl ester was 
unnecessary and designed a more direct total synthesis of 1 using compound 2 as our 
starting material (Figure 3.4). Allylic oxidation of 2 using benzeneseleninic anhydride 
produced enone 17 with same yield previously reported (75%) [100]. The thiomethylation 
step as described in literature [100], monitored by LC-MS, was slow and inefficient using 
17 as substrate. Four successive additions of a methanethiolate in aqueous solution (15% 
m/v, 2eq) every 15 min led to a quantitative conversion of enone to a 1:1 mixture of α- and 
β-thiomethyl ketones 18 and 19. Despite several attempts, this mixture of diastereomers 
was inseparable, similar to what was reported for their methyl ester derivatives [100]. 
Borane proved to be unsuitable as a reducing agent, likely due to attack of the carboxylic 
acid moiety in 18 and 19. However, sodium borohydride led to the exclusive reduction of 
the ketone at C15 to form diastereomers 20 (10% yield from 17), 21 (30% yield from 17), 
22 (39% yield from 17) and 23 (11% yield from 17) which were separable by flash column 
chromatography or semi-preparative HPLC. Finally, use of Davis oxaziridine [99], [100], 
[115] on the isomer 20 led to a mixture of serofendic acids A and B (1A and 1B) in similar 
ratio reported in literature (Supplementary Figure A1.33-A1.58). Davis oxidation of 
diastereomers 21-23 produced serofendic acids isomers 24A and 24B (Supplementary 








Figure 3.4. Total synthesis of 1 from 2. 
Reaction conditions are provided above arrows and isolated yields are provided 
below. The blue bracketed text describes ratios of related diastereomers.  
 
3.3 Discussion 
We have created a pipeline for constructing entire multi-gene SGCs from genetic 
parts and expressing them in model Streptomyces hosts [116]–[120]. DNA synthesis and 
assembly technology has improved dramatically in the past decade to enable genetic 
engineering projects at a much larger scale than previously possible [23]. We designed 
our pipeline to be compatible with Streptomyces hosts to take advantage of their diverse 
metabolic potential and importance in drug development. With a moderate set of synthetic 
cis-regulatory elements, we are able to perturb relative expression levels of pathway 
genes across three orders of magnitude. Further, these regulatory elements behave 
consistently in different growth media, allowing us to focus efforts on genetic optimization 
instead of media optimization. We have made several modifications of the DNA assembly 
pipeline we reported previously [64], including: (i) using Type IIS restriction endonucleases 





(ii) creating an intermediate cloning step that allows all unique combinations of cis-
regulatory elements to have their strength quantified prior to inserting the biosynthetic 
CDS, and (iii) creating destination vectors that allow direct integration into the 
chromosome of Streptomyces spp.  
A defining feature of 1 compared to recent heterologous production targets is the 
fact that the producing organism is unknown. The ent-atisane carbon scaffold is 
unprecedented in mammalian systems, and has only been seen before in a handful of 
plant and microbial metabolites. As such, we did not have a natural host genome from 
which to mine biosynthetic genes [54], [101], [102], [121] and instead had to turn to genes 
present in public databases. We used genes from the publicly available Streptomyces sp. 
NRRL S-1813 that are orthologous to those from the platencin biosynthetic gene cluster 
[17], [110], [122]. Our engineered production of 2 provides access to 1 as well as other 
bioactive ent-atisanes (Figure 3.1a). 
Completing the biosynthesis of 1 from 2 will require the discovery and incorporation 
of enzymes to install the C15 hydroxyl group and the C17 methylsulfinyl group. Several 
plant ent-atisanes with the needed C15 modification have been described, including the 
Eriocatisin A [123] and ent-(1S,6S,15S)-1,5,6,15-tetrahydroxy-14,19-
diacetyloxylatiserene [124] and their producers are candidates for future genome-mining 
to identify a suitable enzyme (Supplementary Figure A1.65). Methylthiolation is often 
seen in drug metabolism studies and there are several theories on the molecular origin of 
the methylthiol group [125]. Since 1 is isolated from fetal calf serum as an epimeric mixture 
at the sulfoxide of diastereomers, we predict that the final oxidation of the methylthiol to a 
methylsulfinyl group occurs non-enzymatically. An intriguing possibility is that production 
of 1 in nature involves a biosynthetic pathway split between different hosts, with the carbon 
scaffold made by a plant or microbe and the final tailoring steps occurring in the cow. 
While efforts to complete the biosynthesis of serofendic acid are ongoing in our lab, 2 is 
an attractive intermediate for medicinal chemistry efforts, as its olefin moiety provides a 
reactive handle to facilitate chemical derivatization for SAR studies. 
In conclusion, we report the design and engineering of a synthetic gene clusters 
to enable the high-titer semi-synthesis of a potent neuroprotectant, 1. We have completed 





and demonstrated the semi-synthesis of several potent structural analogs. This represents 
the first sustainable route towards developing new neuroprotectants based on the 
serofendic acid scaffold. 
 
3.4 Materials and Methods 
3.4.1 Strains and Chemicals 
E. coli DH5α and NEB® Stable were used for routine cloning. E. coli 
ET12567/pUZ8002 was used for intergenic conjugation. S. albidoflavus J1074 was used 
as a heterologous host for screening SGCs. LB medium (10 g/L tryptone, 5 g/L yeast 
extract, 10 g/L NaCl; MP Biomedicals # 113002022) supplemented with proper antibiotics 
was used for strain maintenance and plasmid construction in E. coli strains. Liquid media 
for Streptomyces maintenance and fermentation are R2YE medium (103 g/L sucrose, 10 
g/L glucose, 0.25 g/L K2SO4, 5 g/L yeast extract, 0.1 g/L Difco casamino acid, 100 ml TES 
buffer (5.73%, pH 7.2), 10 ml KH2PO4 (0.5%), 80 ml CaCl2.2H2O (3.68%), 15 ml L-proline 
(20%), 2 ml trace element solution and 5 ml NaOH (1N)), ISM3 medium (15 g/L yeast 
extract, 10 g/L malt extract, 0.5 g/L MgSO4, 0.3 g/L FeCl3·6H2O, 20 g/L glucose, adjusted 
to pH 7.0 with NaOH), PCNM medium (6 g/L yeast extract, 15 g/L malt extract, 6 g/L 
glucose, 20 g/L MOPS, adjust pH to 7.4, then add trace element aseptically), and TSB (30 
g/L tryptic soy broth). Solid medium for Streptomyces spore isolation is IWL-4 (37 g/L Difco 
ISP medium 4, 0.5 g/L yeast extract, 1 g/L tryptone). Fermentations at 500- and 50-mL 
scale were supplemented with 3% w/v hydrophobic resin (Amberlite - XAD16; Alfa Aesar 
L19565-36). Unless stated otherwise, antibiotics apramycin, nalidixic acid, kanamycin, 
and chloramphenicol were supplemented to liquid or solid media at final concentration of 
50 µg /mL, 25 µg /mL, 50 µg /mL and 25 µg /mL, respectively. Media components and all 
other chemicals were purchased from standard commercial sources.  
 
3.4.2 Plasmid Construction 
Promoter and RBS sequences were chemically synthesized as ultramer® 





synthetic promoter, synP, was synthesized as gblocks (Integrated DNA Technologies, 
Coraville, IA). Combinations of promoters and RBSs were organized so that there were 
no additional sequences in between promoter and RBS sequences. All promoter-RBS 
parts were flanked by one of the MoClo scar sequences (4 bp; upstream) and AATG 
(downstream, start codon underlined), CDS parts were flanked by AATG (upstream, start 
codon underlined) and TGAT (downstream, stop codon bolded), and terminators parts 
were flanked by TGAT (upstream, stop codon bolded) and one of the MoClo scar 
sequences (4 bp; downstream). These overhang sequences correspond to 5ʹ overhanging 
single-stranded cohesive ends when digested with type IIs restriction enzymes. Promoter-
RBS part library and terminator part library were constructed by PCR-ligation using 
pMJS2AF as the template using published protocol [73]. Standard PCR was set up using 
Q5® High-Fidelity DNA polymerase (New England Biolabs Inc.; Cat. No. M0491S) and 
manufacturer’s recommended protocols unless stated otherwise.  
Each CDS was PCR-amplified and domesticated by AarI Golden Gate assembly. 
Genomic DNA of Streptomyces sp. NRRL S-1813 was extracted with standard protocol 
[126] and used as template for PCR amplification of target CDS. Each CDS was PCR-
amplified with gene specific primers flanked by AarI restriction sites and a four-nucleotide 
AarI docking sequence. If the native CDSs had internal SapI and/or AarI restriction sites, 
they were removed by introducing synonymous mutations by additional PCR 
amplifications. The mutagenic primers were designed so that each contained homologous 
sequence to at least 18 nucleotides 5ʹ of the internal AarI /SapI sites, a few nucleotides 
that interrupt AarI /SapI site with a single base substitution, an AarI restriction site and a 
four-nucleotide AarI docking sequence. The amplified fragments each had unique 5ʹ 
overhang sequences to allow orderly and seamless assembly. The PCR products were 
analyzed by gel electrophoresis and extracted with standard gel purification protocol 
(Zymoclean Gel DNA Recovery Kit, Zymo Research Cat. No. D4007). Domestication of 
PCR-amplified CDS were done by AarI golden gate reaction with 30 ng of pCDS, three 
equimolar amounts of PCR-amplified CDS fragments and 2 µL of 2X AarI master mix 
(Thermo Fisher Scientific, GeneArt™ Type IIs Assembly Kit, AarI; Cat. No. A15916). The 
incubation parameters are described below: 37oC initial digest for 15 min, initial ligation at 





cycles. Half of the Golden Gate assembly reaction was introduced to E. coli via chemical 
transformation. The clones were verified by Sanger sequencing. 
Three type of destination vectors are constructed: level 1 destination vector for 
cistron storage, level 2 destination vector for partial cluster storage, and level 3 destination 
vector for full cluster storage. Level 1 destination vector library was constructed by 
isothermal assembly with two PCR products, lacZ fragment and a linearized vector with 
apramycin resistance cassette. Level 1 destination vector library has unique combinations 
of upstream and downstream MoClo scar flanked by BbsI and AarI recognition sites. PCR 
was performed with Q5® High-Fidelity DNA Polymerase. First, the linearized vector was 
amplified from pMJS1000 using primers that contain vector-specific sequences and AarI 
recognition site. A lacZ fragment was amplified from pMJS2AF using oligonucleotide 
primers that contain lacZ-specific sequences, a BbsI recognition site, MoClo scar 
sequence, AarI recognition site, and 24 nucleotides homologous to the linearized vector. 
Total of 30 unique, non-redundant combinations of upstream and downstream MoClo sites 
flanking lacZ was analyzed by gel electrophoresis. The PCR fragments were gel purified. 
Isothermal assembly was used to piece together the linearized vector and lacZ fragment. 
Specifically, 100 ng of PCR-linearized vector and three equimolar amounts of lacZ 
fragment were used in individual isothermal assembly (15 µL isothermal assembly pre-
mix and bring the final volume to 20 µL). The isothermal assembly were incubated at 50oC 
for 1 h. The isothermal assembly mixtures were introduced into E. coli DH5α by chemical 
transformation. The clones were verified via Sanger sequencing. 
Level 2 (partial cluster) destination vector library was constructed by BbsI golden 
gate assembly of PCR-amplified lacZ fragment and pMJS1AC, a vector of kanamycin 
resistance. LacZ is amplified from pMJS1AC using oligonucleotide primers that contain 
lacZ-specific sequences, an AarI recognition site, MoClo scar sequence, a SapI 
recognition site, and a BbsI recognition site. Total of 30 unique, non-redundant 
combinations of upstream and downstream MoClo sites flanking lacZ was analyzed by gel 
electrophoresis. The PCR fragments were extracted by gel purification. Forty femtomoles 
of pMJS1AC and three equimolar amounts of purified lacZ fragment were pieced together 
by BbsI Golden Gate assembly. In each reaction, 5 U BbsI (New England BioLabs; Cat. 





DNA substrates and ddH2O were mixed together to make a 10-μL reaction. The incubation 
parameters are the same as the AarI Golden Gate assembly. Half of the Golden Gate 
assembly reaction was introduced to E. coli via chemical transformation. The clones were 
verified by Sanger sequencing. 
Level 3 (full synthetic gene cluster) destination vector library was constructed by 
isothermal assembly with two PCR products, lacZ fragment and a linearized vector with 
apramycin resistance cassette. Level 3 destination vector library has unique combinations 
of upstream and downstream MoClo scar sequence flanked by SapI and AarI recognition 
sequences. PCR was performed with Q5® High-Fidelity DNA Polymerase. First, a lacZ 
fragment was amplified from pMJS2AF using oligonucleotide primers that contain lacZ-
specific sequences, a SapI recognition site, MoClo scar sequence, an AarI recognition 
site, and 24 nucleotides homologous to the vector. The linearized vector was amplified 
from pMJS1000 using primers that contain vector specific sequences and an AarI 
recognition site. Total of 30 unique, non-redundant combinations of upstream and 
downstream MoClo sites flanking lacZ was analyzed by gel electrophoresis. The PCR 
fragments were purified by gel extraction. Isothermal assembly was used to piece together 
the linearized vector and lacZ fragment as described in the level 1 destination vector 
assembly. The isothermal assembly mixtures were introduced into E. coli by chemical 
transformation. The clones were verified via Sanger sequencing. 
 
3.4.3 Synthetic RBS Design 
Ten of novel RBS sequences were designed using RBS calculator 
(https://www.denovodna.com/software/). The following parameters were used: no pre-
sequence was used; Streptomyces-codon optimized eGFP was used as protein coding 
sequence; free energy model version 2.x was used; 16S rRNA of S. albidoflavus J1074 
was used. RBSs were generated with a range of predicted strengths, but actual strengths 






3.4.4 Promoter-RBS Strength Characterization by GUS Assay 
The GUS assay protocol was modified from a previous study [111]. Briefly, the 
synchronization culture of each S. albidoflavus J1074 GUS strains was used to inoculate 
2 mL PCNM and ISM3 in 24-well MTPs. The fermentations were incubated in 28°C shaker 
with 250 rpm for 60 h. The cell pellets were harvested in pre-weighted 1.7 mL Eppendorf 
microcentrifuge tubes at 3,000 rpm for 2 min. The supernatant was removed, and the cell 
pellets were washed with 4°C sterile ddH2O for at least five times or until the supernatant 
was clear to make sure the residual fermentation media were removed as much as 
possible (centrifuged at 3,000 rpm for 1 min per wash). The cells were resuspended in 0.5 
mL sterile ddH2O and frozen at -80°C for 24 h. The frozen samples were then freeze-dried 
for 24 h or until the moisture was removed completely. The freeze-dried samples were 
weighted on precise scales and the dry cell weight (DCW) was calculated. 
All samples and buffers were incubated on ice before measurement. During the 
lysis step of GUS assay, the dried cell samples of S. albidoflavus J1074 GUS strains that 
predicted with low activity were incubated with 450 μL lysis buffer (negative vector control, 
P1R1, P1R3, P4R6, p6R8, P3R5, P5R7) for 20 min at 37°C. The other dried cell samples 
were incubated in 900 μL lysis buffer (50 mM phosphate buffer [pH 7.0], 5 mM dithiothreitol 
(DTT], 0.1% Triton X-100, 1 mg/mL lysozyme) for 20 min at 37°C, and these lysates were 
diluted two-fold by mixing 200 µL lysate with 200 µL base buffer (50 mM phosphate buffer 
[pH 7.0], 5 mM DTT, 0.1% Triton X-100). The samples were centrifuged at 21,300 rcf for 
10 min at 4°C. Samples of 100 µL supernatant from each lysate were transferred to 96-
well plate (Sarstedt microtest plate 96 well F; order no. 82.1581) and keep on ice until 100 
µL GUS buffer (50mM phosphate buffer [pH 7.0], 5mM DTT, 0.1% Triton X-100 
supplemented with 2 mM p-nitrophenyl-β-D-glucuronide) was added to each lysate. The 
absorbance was immediately measured at 415 nm at 25°C for 40 min by plate reader 
(SpectraMax® Plus 384 Microplate Reader). As a reference, 100 µL of supernatant was 
mixed with 100 µL base buffer. The slope of the linear range of the absorption curve was 
used to calculate the enzymatic activity. The relative strength of the promoter was 






3.4.5 Bottom-up Hierarchical DNA Assembly of SGCs 
BbsI golden gate assembly was used to construct CisReg plasmid. Level 1 
destination vector and part plasmids of promoter-RBS, transcriptional terminator, and 
reporter gene (Streptomyces codon-optimized egfp or uidA) were the substrates. Forty 
femtomoles of level 1 destination vector, three equimolar amounts of part plasmids, 5 U 
BbsI, 5 U T4 DNA ligase, 1 µL 10x T4 DNA ligase buffer and water were added to bring 
the final reaction volume to 10 µL. The incubation parameter is the same as the previous 
AarI Golden Gate reaction. Half of the Golden Gate assembly reaction was introduced to 
E. coli via chemical transformation. The clones were verified by Sanger sequencing. 
SapI Golden Gate assembly was used to construct monocistronic plasmids with 
CisReg plasmids and pCDS plasmids. Forty femtomoles of CisReg plasmid, three 
equimolar amounts of pCDS plasmid, 5 U SapI, 5 U T4 DNA ligase, 1 µL 10x T4 DNA 
ligase buffer and water were added to bring the final reaction volume to 10 µL. The 
incubation parameter is the same as the previous AarI Golden Gate reaction. Half of the 
Golden Gate assembly reaction was introduced to E. coli via chemical transformation. The 
monocistrons were verified by either colony PCR using OneTaq® PCR (New England 
Biolabs Inc.; Cat. No. M0480S) or Sanger sequencing. 
AarI Golden Gate assembly was used to construct partial clusters with 
monocistronic plasmid and level 2 destination vector. Thirty nanogram of level 2 
destination vector, three equimolar amounts of monocistronic plasmids, and equivolume 
amount of 2x AarI master mix were used to set up AarI golden gate reaction. The 
incubation parameter is the same as the previous AarI Golden Gate reaction. Half of the 
Golden Gate assembly reaction was introduced to E. coli via chemical transformation. The 
monocistrons were verified by colony PCR. 
SapI Golden Gate assembly was used to construct full cluster plasmids with partial 
plasmids and level 3 destination vectors. Forty femtomoles of level 3 destination vector, 
three equimolar amounts of partial cluster plasmids, 5 U SapI (New England Biolabs Inc; 
Cat. No. R0569S), 5 U T4 DNA ligase, 1 μL 10x T4 DNA ligase buffer and water were 
added to bring the final reaction volume to 10 μL. The incubation parameter is the same 
as the previous AarI Golden Gate reaction. Half of the Golden Gate assembly reaction 





by colony PCR. The colony PCR primers are the same as the CDS cloning primers. One 
gene from each cassette was targeted for colony PCR. 
 
3.4.6 Intergenic Conjugation  
SGCs were introduced into conjugation donor E. coli ET12567/pUZ8002 via 
electroporation (BioRad electrocuvette, 1 mm gap; 1.8 kV; BioRad Gene Pulser Xcell 
electroporation system). The electroporation mixtures were recovered with 1 mL S.O.C. 
media for 1 h in 37°C shaker. Upon recovery, the electroporation mixture was plated on 
LB agar supplemented with kanamycin, chloramphenicol and half concentration of 
apramycin. The transformations were incubated at 37°C overnight. The transformants 
were verified with colony PCR. Two primer pairs (SYH241, SYH242 and SYH 233, 
SYH234) were used as colony PCR primers to amplify the ispH-ispG and ispD-ispE 
junctions in the final MEP SGCs. Each verified transformant was inoculated in 2 mL liquid 
LB supplemented with apramycin, kanamycin, and chloramphenicol and incubated in 
37°C shaker overnight. On the next day, 2 mL of LB supplemented with apramycin, 
kanamycin, chloramphenicol and CaCl2 were added to the overnight culture (20 mM CaCl2 
final concentration) and incubated for four more hours in 37°C shaker.  
Preparation and germination of the spore of the wild type S. albidoflavus J1074 for 
conjugation was performed in the following steps. First, the frozen spore stocks of S. 
albidoflavus J1074 were thawed on ice for 10 min. The thawed spore stocks were 
centrifuged at max speed for 1 min, and the supernatant was removed. Every 50 μL of 
packed spores was resuspended in 500 μL TSB supplemented with 10% (wt/vol) sucrose 
and glycine. Germination of spores was initiated in 28°C shaker for at least 2 h.  
Once conjugation donors were overgrown for 4 h, the cells were pelleted by 
centrifugation at 3,000 rpm for 30 s. The supernatant was removed, and the cell pellet was 
washed gently three times, each time with 1 mL LB at room temperature to remove 
antibiotics. The final cell pellet was resuspended in 250 μL of germinated spore solution. 
The E. coli – Streptomyces conjugation mixtures were centrifuged 3,000 rpm for 1 min 
and the excess supernatant was removed so the final resuspension volume was 50 μL. 





CaCl2 (final concentration) and incubated overnight at 28oC. After 24 h, the entire 
conjugation mixture was scrapped and re-plated on IWL-4 solid media supplemented with 
nalidixic acid and half concentration of apramycin to select for successful Streptomyces 
exconjugants. The final Streptomyces exconjugants were transferred to an IWL-4 agar 
plate supplemented with full concentration of apramycin for maintenance and downstream 
experiments. 
 
3.4.7 Fermentation of S. albidoflavus J1074  
The fermentation protocol of S. albidoflavus J1074 was modified from Deutz and 
colleagues [127]. The Streptomyces fermentation was divided in three stages and they 
were (i) fresh sporulation of strains on solid media, (ii) germination and synchronization of 
cultures and (iii) inoculation of the fermentation media. All 50 mL and 500 mL shake flask 
cultivations were done in 250 mL and 2 L standard baffled Erlenmeyer flasks, respectively. 
High-throughput 2 mL and 0.5 mL microcultivation were done in low-evaporation, 24- or 
96-square-deep-well microtiter plates (MTPs), respectively (Enzyscreen CR1424a and 
CR1496a). At the sporulation stage, the frozen spore stocks of recombinant S. 
albidoflavus J1074 strains were streaked on IWL-4 solid media supplemented with 
apramycin and incubated in 28°C for 2 days to obtain fresh spores. For the spore 
germination stage, fresh spores from each recombinant strain were grown in 2 mL R2YE 
supplemented with apramycin in 15 mL culture tube. The R2YE liquid cultures were 
incubated in 28°C shaker with 250 rpm for 48 h. Each R2YE preculture was used to 
inoculate (1/100 (v/v) inoculum) 2 mL ISM3 supplemented with apramycin in 15 mL culture 
tube to synchronize growth of various strains. The synchronization culture for 500 mL 
fermentation was scaled up to 50 mL ISM3 supplemented with apramycin and was also 
inoculated with 1/100 (v/v) R2YE preculture. The ISM3 cultures were incubated in 28°C 
shaker with 250 rpm for 48 h. Each synchronization culture was standardized so that the 
cell pellet inoculated across samples was the same. Briefly, 1 mL of the synchronization 
culture was gently pelleted in sterile 1.7 mL Eppendorf microcentrifuge tubes with 3,000 
rpm for 30 s. Excess supernatant was removed so the volume of cell pellet and the 





done in 50 mL sterile falcon tubes. The fermentation media were inoculated with 1% of 
the standardized synchronization cultures in 500 mL, 50 mL and 2 mL fermentations. Each 
microfermentation (0.5 mL) was inoculated with 10% of standardized synchronization 
cultures. The fermentation cultures were grown in 28°C shaker with 250 rpm for 4-7 days.  
  
3.4.8 Extraction of Metabolites from Streptomyces Fermentation 
The 50 mL fermentations were transferred to 50 mL conical tubes and centrifuged 
at 4,500 rpm for 15 min. The supernatant was discarded, and the cell-resin pellets were 
washed with de-ionized water (ddH2O) and centrifuged for 30 min at 4600 rpm for three 
times. The samples were frozen at -80°C for 24 h. The frozen samples were then freeze-
dried for 24 h or until the moisture was completely removed (0.01 mbar, -84°C; Labconco 
FreeZone Plus 2.5 Liter Cascade Benchtop Freeze Dry System, catalog number 7670020). 
Each dried sample was extracted in methanol (3 x 5 mL). 
The 500 mL fermentations were centrifuged at 4600 rpm for 30 min. The 
supernatant was discarded, and the cell-resin pellets were washed with ddH2O and 
centrifuged for 30 min at 4600 rpm for three times. The pellets collected were put together 
and the all was extracted with methanol (250 mL and stirring for 15 min) 6 times. The 
solutions collected were put together, evaporated under vacuum pressure and the residue 
was extracted with ethyl acetate (3 x 50 mL). The organic solution was then washed with 
brine (2 x 50 mL), dried over anhydrous magnesium sulfate, filtrated, and evaporated 
under vacuum pressure. The powder obtained was washed with n-hexane and was 
collected over a frit to afford 2 as white powder (356.1 mg, 24%). For 1H and 13C NMR 
data, see Supplementary Figure A1.5-A1.8. The NMR attributions are in agreement with 
the ones previously reported in literature [114]. HRESIMS: m/z calculated for C20H29O2- 
[M-H+]- 301.2173, found 301.2173. 
The 96-well MTP containing 0.5 mL fermentations was frozen at -80°C for 24 h. 
The frozen samples were then freeze-dried for 24 h or until the moisture was completely 






3.4.9 Liquid Chromatography–mass Spectrometry (LC-MS) Analysis  
LC-MS analyses were performed on Thermo Scientific MSQ plus mass detector 
equipped with Ultimate 3000 Rapid Separation (RS) system. The extracts were diluted in 
100% MeOH, and 10 μL of each extract was loaded onto a Thermo Scientific analytical 
BetaSil C18 column (2.1 x 150 mm, 3 μm). Chromatography was performed at flow rate 
of 500 μL/min using 10 mM ammonium formate buffer (solvent A, pH 8.3) and 100% 
acetonitrile (solvent B) with the following gradient: 0 – 0.5 min, 95 % solvent A; 0.5 – 14.5 
min, 95% solvent B; 14.5 – 16 min, 95% solvent B; 16 – 18 min, 95% solvent A; 18 – 23 
min, 95% solvent A. The initial parameters of MSQ plus mass detector for analyzing 2 and 
shunt metabolites were described below: ionization mode, electrospray; cone ionization, 
75 V; capillary probe temperature, 350°C. Full negative MS spectra were acquired for the 
mass range m/z 150 to 500 for all samples. The optimized parameters for the detection of 
2 were described below: ionization mode, electrospray; cone ionization, 110 V; capillary 
probe temperature, 450°C. Full negative MS spectra were acquired for the mass range 
m/z 150 to 500 for all samples. 
 
3.4.10 Phylogenetic Analysis of Biosynthetic Genes for Production of 2  
Amino acid sequence of ent-atiserene synthase PtmT1 (accession ACO31274.1) 
was used to perform BlastP search of publicly available genome sequences. A total 100 
amino acid sequences were reported in the initial result. Redundant or partial sequences 
were removed from the list. Total of 92 amino acid sequences were used to construct 
phylogenetic tree of PtmT1 (Supplementary Data File A1, Worksheet 5). The sequence 
alignment was performed by ClustalW multiple alignment application (1000 bootstraps) to 
calculate protein distance matrix. The phylogenetic analysis was performed in Fitch-
Margoliash method in PHYLIP, and the phylogenetic tree was plotted in FigTree.  
Phylogenetic tree of ent-copalyl diphosphate synthase PtmT2 (accession 
ACO31274.1) was constructed likewise with 69 amino acid sequences (Supplementary 






3.4.11 General Materials and Methods for Chemical Synthesis 
All chemicals and reagents were purchased from commercial sources and used 
directly without further purification. All non-aqueous reactions were performed under an 
atmosphere of argon in flame-dried glassware. Reaction progress was monitored by thin-
layer chromatography (TLC) using silica gel plates (silica gel 60 F254). Eluted TLC plates 
were visualized with UV light (254 nm) and dyed using either ethanol acidified with sulfuric 
acid (5% v/v) or iodine vapors. Compounds were purified either by flash silica gel (230-
400 mesh) column chromatography or by Büchi C-700 chromatograph apparatus with 4 g 
Büchi FlashPure EcoFlex cartridges. Diastereoisomers were purified by HPLC (Ultimate 
3000 Rapid Separation (RS) system) using a semi-preparative column Betasil C18, 250 x 
10 mm, 5µm particle size (Thermo Scientific) and the products were observed at 210 nm. 
Chromatography was performed at flow rate of 1.5 mL/min using 10 mM ammonium 
formate buffer (solvent A, pH 8.3) and 100% acetonitrile (solvent B) with the following 
gradients: for 20 and 21: 0 – 1 min, 95 % solvent A; 1 – 3 min, 95% solvent B; 3 – 7 min, 
95% solvent B; 7 – 9 min, 95% solvent A; 9 – 18 min, 95% solvent A. For 1 and 24: 0 – 
0.5 min, 95 % solvent A; 0.5 – 1 min, 75% solvent A; 1 – 10 min, 75% solvent A; 10 – 11 
min, 50% solvent A; 11 – 18 min, 50% solvent A; 18 – 19 min, 95% solvent B; 19 – 21 min, 
95% solvent B; 21 – 22 min, 95% solvent A; 22– 25 min, 95% solvent A. The fractions 
collected were first concentrated by removing acetonitrile and second the aqueous 
fractions were extracted with ethyl acetate. NMR experiments were performed on Bruker 
Advance III 500 MHz (Broadband Observe SmartProbe) or Bruker Advance 700 MHz (5-
mm triple resonance cryoprobe) spectrometers. Chemical shifts were reported as ppm 
relative to either chloroform-d (7.26 ppm for 1H, 77.16 ppm for 13C) or methanol-d4 (3.31 
ppm for 1H and 49.00 ppm for 13C). 1H constant coupling (J) are expressed in hertz (Hz), 
and multiplicity is described as follows: s = singlet, d = doublet, t = triplet, br = broad, m = 
multiplet. Compounds were analyzed by ESI-MS (Thermo Scientific MSQ plus mass 
detector) and HR-ESI-MS (ThermoScientific, Q Exactive, Quadrupole, Orbitrap, Heated-






3.4.12 Synthesis of ent-16-methoxyatisan-19-oic Acids (14-15) 
To a solution of 2 (17.9 mg, 0.06 mmol) in methanol (4.0 mL) cooled down to 0°C 
was added dropwise thionyl chloride (17.6 mg, 0.15 mmol). Once the addition done, the 
mixture was heated under reflux for 2 h. After completion, the solution was concentrated 
under vacuum pressure and the residue was purified by column chromatography with a 
n-hexane to n-hexane/ethyl acetate (9:1 v/v) gradient to afford the two diastereoisomers 
of 14 (6.4 mg, 32%) and 15 (6.6 mg, 34%) as white solids. For 1H and 13C NMR data, see 
Supplementary Figure A1.21-A1.24 (14) and Supplementary Figure A1.25-A1.27 (15). 
HRESIMS, 14: m/z calculated for C21H33O3- [M-H+]- 333.2435, found 333.2435, 15: m/z 
calculated for C21H33O3- [M-H]- 333.2435, found 333.2435. 
 
3.4.13 Synthesis of methyl ent-atis-16-en-19-oate (16) 
To a solution of 2 (10.7 mg, 0.04 mmol) in anhydrous methanol (500 µL) under 
argon atmosphere was added diisopropylethylamine (22.9 mg, 0.18 mmol). The resulting 
mixture was vigorously stirred and after 5 min methyl iodide was added (25.1 mg, 0.18 
mmol). After reaction completion (96 h), the mixture was acidified with acetic acid and 
diluted in water (5 mL) and extracted with ethyl acetate (2 x 5 mL). The combined organic 
extracts were washed with brine (5 mL), dried over anhydrous magnesium sulfate, filtered 
and the solvent was evaporated with a rotary evaporator. The residue was purified by 
column chromatography to afford 16 as a white solid (10.2 mg, 91 %). For 1H and 13C 
NMR data, see Supplementary Figure A1.29-A1.32 The NMR attributions are in 
adequation with the ones previously reported in literature [100], [114]. Single-quad ESIMS: 
m/z calculated for C21H33O2 [M+H]+ 317.2, found 317.8. 
 
3.4.14 Synthesis of ent-15-oxoatis-16-en-19-oic Acid (17) 
Under argon atmosphere, a solution of 2 (56.5 mg, 0.19 mmol) and 
benzeneseleninic anhydride (70.6 mg, 0.196 mmol) in benzene (36 mL) was refluxed for 
4 h. The solution was then concentrated under vacuum pressure and the residue was 
purified by silica gel column chromatography using a n-hexane to n-hexane / ethyl acetate 





see Supplementary Figure A1.34-A1.36. The NMR attributions are in adequation with 
the ones previously reported in literature.[100] HRESIMS: m/z calculated for C20H27O3- [M-
H]- 315.1966, found 315.1966. 
 
3.4.15 Synthesis of ent-17-methylsulfenyl-15-oxoatisan-19-oic Acids (18-19) 
To a solution of 17 (167.3mg, 0.53 mmol) in THF (30 mL) was added every 15 min 
an aqueous solution of sodium thiomethoxide (15% m/v, 512 µL, 1.06 mmol). After the 
fourth addition the medium was stirred for 15 min and brine (50 mL) was added to the 
solution. The mixture was extracted with ethyl acetate (2 x 50 mL) and the organic phase 
was washed with hydrochloric acid 1 M (2 x 20 mL). The organic solvent was then dried 
over anhydrous magnesium sulfate, evaporated under vacuum pressure. The solid 
collected was dried thoroughly under vacuum pressure overnight to afford a mixture of 
inseparable diastereoisomers of 18 and 19 (186.1 mg, 97%) as a white solid. HRESIMS: 
18: m/z calculated for C21H27O3S- [M-H]- 363.1999 (100%), [M+2-H]- 365.1968 (4%), found 
363.2013 (100%), 365.1966 (4%), 19: m/z calculated for C21H27O3S- [M-H]- 363.1999 
(100%), [M+2-H]- 365.1968 (4%), found 363.2013 (100%), 365.1967 (4%). 
 
3.4.16 Synthesis of ent-15-hydroxy-17-methylsulfenylatisan-19-oic Acids (20-23) 
To a solution of sodium borohydride (185.2 mg, 4.90 mmol) in ethanol (200 proof, 
15 mL) cooled down to -5° - 0° C was added dropwise a mixture of 18 and 19 (178.5 mg, 
0.49 mmol) in ethanol (200 proof, 5.0 mL). After 25 min of stirring at -5° - 0° C hydrochloric 
acid 1M was added to mixture until the bubbling stopped. The solution was then 
evaporated, and the residue was dissolved in ethyl acetate (20 mL), washed with brine 
(10 mL), dried over anhydrous magnesium sulfate and concentrated. Column 
chromatography using an n-hexane to n-hexane/ethyl acetate (7:3 v/v) gradient allowed 
the isolation of a mixture composed of 20 and 21, 22 (69.8 mg, white powder, 39%) and 
23 (19.5 mg, white powder, 11%). Semi preparative HPLC purification on the latter mixture 
allowed the separation of 20 (17.8 mg, white powder, 10%) from 21 (53.0 mg, white 
powder, 30%). For 1H and 13C NMR data, see Supplementary Figure A1.40-A1.42 (20), 





Supplementary Figure A1.49-A1.51(23). The NMR attributions for 20 and 21 are in 
adequation with the ones previously reported in literature [100]. HRESIMS: 20: m/z 
calculated for C21H29O3S- [M-H]- 365.2156 (100%), [M+2-H]- 367.2114 (4%) found 
365.2155 (100%), 367.2113 (4%), 21: m/z calculated for C21H29O3S- [M-H]-365.2156 
(100%), [M+2-H]- 367.2114 (4%) found 365.2155 (100%), 367.2113 (4%), 22: m/z 
calculated for C21H29O3S- [M-H]- 365.2156 (100%), [M+2-H]- 367.2114 (4%) found 
365.2155 (100%), 367.2113 (4%), 23: m/z calculated for C21H29O3S- [M-H]-365.2156 
(100%), [M+2-H]- 367.2114 (4%) found 365.2155 (100%), 367.2113 (4%). 
 
3.4.17 Synthesis of Serofendic Acids and Diastereoisomers (1, 24) 
To a solution of sulfides 20 and 21 (9.7 mg, 26.5 µmol) in chloroform (500 µL) was added 
Davis’ oxaziridine (2-benzenesulfonyl-3-phenyloxaziridine) (7.3 mg, 27.8 µmol). After 
completion (1 h) the mixture was purified on silica gel column chromatography using a 
dichloromethane to dichloromethane/methanol (10:1 v/v) gradient to yield 24A (3.2 mg, 
33%) and a mixture composed of 1A, 1B and 24B (6.1 mg). Semi preparative HPLC 
purification on the latter mixture allowed the separation of 24B (4.2 mg, 43%) from 1A 
(0.43 mg, in mixture with 1B (0.91:0.09, 1A:1B), 4%) and 1B (0.85 mg, in mixture with 1A 
(0.81:0.19, 1B:1A), 9%). For 1H and 13C NMR data, see Supplementary Figure A1.52-
A1.56 (1A), Supplementary Figure A1.55-A1.58 (1B), Supplementary Figure A1.59-
A1.61 (24A) and Supplementary Figure A1.62-A1.64 (24B). The NMR attributions for 
1A and 1B are in agreement with the ones previously reported in literature [97]. HRESIMS: 
m/z calculated for C21H29O4S- [M-H]- 381.2105 (100%), [M+2-H]- 383.2063 (4%), found 
1A: 381.2109 (100%), 383.2068 (4%), 1B: 381.2110 (100%), 383.2068 (4%), 24A: 
381.2109 (100%), 383.2068 (4%), 24B: 381.2110 (100%), 383.2068 (4%). 
 
Additional methods and supplementary figures can be found in the Appendix 1 and 






Chapter 4 Rational Search of Genetic Design Space to 
Improve Terpene Production in Streptomyces 
 
The contents of this chapter are currently in preparation for publication. MJS designed the 
5-level Plackett-Burman matrix. SYH planned and performed all the experiments. Colony 
morphology photography was assisted by Jihaeng Lee. SYH wrote the original draft. SYH 
and MJS reviewed and edited the manuscript. 
Summary 
Modern tools in DNA synthesis and assembly give genetic engineers complete control 
over the nucleotide-level design of complex, multi-gene systems. Systematic approaches 
to explore genetic design space and optimize the performance of genetic constructs are 
lacking. Here we demonstrate the application of a five-level Plackett-Burman fractional 
factorial design to improve the titer of a heterologous terpene biosynthetic pathway. 
Combinatorial perturbation of a refactored methylerythritol phosphate (MEP) pathway 
expression affects the titer of the target diterpenoid, ent-atiserenoic acid (eAA) over two 
orders of magnitude. A library of 125 prototypes of synthetic gene clusters encoding a 
natural MEP pathway was constructed and introduced into Streptomyces albidoflavus 
J1047 for heterologous expression. The eAA production titer of all strains was measured, 
which showed surprisingly robust isoprenoid metabolism; the changes in average eAA 
titer did not change significantly when the expression of seven of eight genes was 
changed. Analysis of Plackett- Burman design identifies that the expression of dxs, the 
first and the flux-controlling enzyme, is the most dominant gene on eAA titer with negative 
correlation. This study showed Plackett-Burman design is as an effective screening 
approach as the analysis of the experiments replicate the same finding, which is that DXS 
is the bottleneck of MEP pathway in the literature. 
 
4.1 Introduction 
The recent advances in DNA synthesis and assembly allow scientists to engineer 
more complex genetic systems at various scales. For example, biosynthesis of 





genetic circuits [132], [133] and organisms with synthetic chromosomes [88], [134]–[136] 
have all been built from scratch. A common feature of these systems is the requirement 
to coordinate gene expression of 10s to 1000s of genes for the system to work. 
Optimizing gene expression to improve performance in such systems becomes a 
combinatorial problem. Common design variables that impact relative gene expression 
include promoters [137], ribosomal binding sites [26], intergenic region sequences [138], 
[139], codon usage[140], [141], gene order [65], [66], [142], and gene orientation [143]–
[145]. The exponential scaling of the multi-dimensional design space makes an exhaustive 
search impossible or impractical given limits on time and labor resources. For instance, 
production of hydrocodone required overexpression of 26 genes [146]. Testing five design 
variants of each expression cassette in a full-factorial design would require 526 (~1.49 x 
1018) unique synthetic constructs to be analyzed. A new challenge that emerges in 
designing multi-gene systems is that of accelerating genetic optimization and reducing 
cost by maximizing the information content of each iterative design cycle [147]. 
Statistical design of experiments (DoE) is a rational approach that can guide the 
design of synthetic genetic constructs. It has been used effectively in optimizing media 
compositions [148], [149], recombinant protein production [150] and industrial processes 
[151]. DoE employs statistical methodologies to systematically design and analyze 
experiments. It can be used to specify the minimal number of experiments needed to 
rigorously identify the relative impacts of each variable on system performance. Various 
DoE approaches have been used to guide library design of multigene systems and have 
been applied to improve nitrogen fixation rates [64] and production titers of 6-aminocaproic 
acid [152], itaconic acid [153] and violacein [154], [155]. All of these studies aimed to 
measure the effects of the input (gene expression strength or media composition) on 
system performance and explore the genotype-phenotype landscape of the multigene 
systems. 
Plackett-Burman design is a type of fractional factorial experimental design that 
allows the variables in a system to be prioritized based on their overall importance (main 
effect) to system performance [156]. Plackett-Burman design is especially advantageous 
when the experimenters need to study large number of variables of a system which they 





design is commonly used in which each variable is set at a high level and a low level to 
screen the variable’s effect on the output. A two-level Plackett-Burman only requires a 
small set of experiments to identify the most important variables. For instance, an 8-
experiment design can screen up to 7 variables of which each variable is tested at low 
and high level. In practice, experimenters design Plackett-Burman matrices that can 
accommodate more variables than they will interrogate in their system [148], [157], [158]. 
The extra ‘dummy variables’ function as negative controls during data analysis and 
provide the required context to calculate experimental error and statistical significance 
[159]–[161]. Another method to increase the accuracy in measuring main effects is to use 
a Plackett-Burman design with more than two levels per variable. This is particularly true 
for genetic systems, where setting the gene expression variables to target levels is 
imprecise. Including more levels for each variable decreases the likelihood that a primary 
effect will be erroneous due to noise in setting the level. 
In this chapter, I present the investigation of the effectiveness of a five-level 
Plackett-Burman design to screen important genes encoding the methyl-erythritol 
phosphate (MEP) pathway for the production of a diterpene acid, ent-atiserenoic acid (eAA) 
[74], in Streptomyces albidoflavus J1074. eAA is a labdane diterpene whose carbon 
scaffold is present in a number of bioactive natural products [74], [124], [162] We quantify 
the effects of the expression level of seven genes of the MEP pathway (dxs, dxr, ispD, 
ispE, ispF, ispG, and ispH) plus the gene encoding isopentenyl-diphosphate delta-
isomerase (idi). We chose the MEP pathway as a model multigene system for several 
reasons. First, the MEP pathway produces C5 building blocks to terpenoids, a highly 
industrially and medicinally relevant group of molecules in the biomanufacturing field 
[163]–[165]. Second, it is an excellent testbed for new method development, as there is a 
substantial body of literature for MEP pathway engineering to which experimental results 
can be compared. Lastly, there are seemingly contradictory reports on MEP pathway 
optimization, with many different enzymes in the pathway identified as the rate limiting 







4.2.1 Design of a Five-level Plackett-Burman Experiment via Cyclic Permutation 
A five-level Plackett-Burman design was used to determine which gene’s 
expression has the largest effect on eAA titer. Specifically, the independent variables 
being screened are the expressions of seven genes of the MEP pathway plus idi and their 
effect on the response variable, the eAA titer. A five-level Plackett-Burman design 
comprising a 125 × 31 matrix was designed as described previously [156]. The matrix is 
balanced in that each column (i.e. variable) contains an equal number of rows in each of 
the five levels (i.e. 1-5). When rows are grouped into five sets of 25 based on the values 
in a single column, each of the other columns will contain a balanced number of variable 
states 1-5 in each set. In other words, assuming that the variables are completely 
independent, the effects of all other system variables cancel out when grouping the 
experiments in a way to examine the effect of a variable of interest. (Supplementary Data 
File A1). In this Plackett-Burman matrix, each column represents an independent variable, 
and each row represents the overall genetic design of a full cluster which is constructed 
and tested. Thus, the 125 x 31 matrix allowed for screening of up to 31 independent 
variables. When less than 31 independent variables are tested, the remaining columns 
represent ‘dummy variables’ that do not correspond to any physical changes in the genetic 
system and can serve as negative controls during data analysis to determine experimental 
error.  
The seven genes of the MEP pathway and idi were selected as the independent 
variables, and they are ispH (X1), ispG (X2), dxs (X3), dxr (X4), ispD (X5), ispE (X6), ispF 
(X7), and idi (X8). Each gene was represented at five gene expression levels: 1 for low 
level, 2 for medium-low level, 3 for medium level, 4 for medium-high level, 5 for high level 
(Figure 4.1b). The production titer of ent-atiserenoic acid (eAA) is measured as the 
dependent variable (Y). 
Two of the most important properties of a Plackett-Burman design is that it is 
balanced and orthogonal. Each variable is being tested the same number of times for all 
levels in a balanced experimental design. In the five-level Plackett-Burman genetic design, 
each gene is expressed at each of the 5 expression levels in exactly 25 Synthetic Gene 





independent variables co-vary across the library as a whole. In other words, for the 25 
genetic designs in which dxr is expressed at a low level (i.e. Level 1), each of the other 
genes are present in all 5 levels an equal number of times. This is important, as it allows 
the experimenter to measure the main effect of one variable by plotting the average 
performance of sub-groups of gene clusters wherein a gene is expressed at levels 1-5. 
The impact of other genes on those sub-group averages cancels out due to the orthogonal 
design. There is an underlying assumption in Plackett-Burman designs that the variables 
are completely independent, or uncorrelated. While this is a prior not expected to be the 
case for genetic systems, PB designs are still effective so long as the correlation factor is 
not high. This is evident from the successful application of PB designs to optimize complex 
systems such as fermentation media [168]. 
Eight columns were chosen to minimize the number of intermediary DNA 
assemblies and maximize re-use of DNA parts for the construction of the Plackett-Burman 
Full Cluster (PBFC) library. The resulting 125 × 8 matrix was used as the blueprint of the 
genetic design of the synthetic gene cluster library encoding natural MEP pathway 
(Supplementary Figure A2.1). The rest of columns are treated as dummy variables which 
do not correspond to any variables in our physical system.  
 
4.2.2 Hierarchical Assembly of 125 Synthetic Gene Clusters Encoding eAA 
Biosynthesis with Variant Expression of MEP Pathway Genes 
To control proper gene expression level in Streptomyces, we used a previously 
characterized Streptomyces promoter-RBS library [74]. The promoter-RBS parts were 
ranked by the log10-transformed expression strength. Then, a set of five unique promoter-
RBS parts were selected for each gene to tune the expression of the five levels 
represented in the Plackett-Burman design.  
Total of 125 unique PBFC designs were generated based on the selected eight 
columns from the Plackett-Burman matrix. We used an iterative, hierarchical assembly 
strategy to construct PBFC designs in parallel from small functional genetic parts and 
intermediary partial clusters, to obtain full clusters encoding MEP pathway plus idi 
(Supplementary Figure A2.1). The assembly started with each gene pieced together with 





Four monocistronic units were grouped as partial clusters: the upper partial clusters 
(ispH/ispG/dxs/dxr) and lower partial clusters (ispD/ispE/ispF/idi). Next, one upper and 
one lower partial cluster were assembled to form each full cluster. All full clusters contain 
three invariant modules: (i) genes for terpene cyclization and eAA oxidation, (ii) apramycin 
resistance gene for selection, and (iii) ΦC integrase gene to integrate full cluster into S. 
albidoflavus J1074 genome [113] for stable expression. Every stage of the assembly was 
done by plasmid-based Golden Gate assembly. 
In total, the library design requires 40 unique monocistronic parts, 25 unique upper 
and lower partial clusters, and 125 unique full clusters (FCs) (Figure 4.1c). All but one FC 
(#81) were successfully assembled and verified in E. coli via colony PCR (Supplementary 
Figure A2.2).  FC #81 assembly failed despite multiple efforts, suggesting an unexpected 
toxic effect from the combination of genetic parts [57]. FCs were conjugated into S. 
albidoflavus J1074 and verified colonies were obtained for all but FC #34, and #108. Again, 
the failure of these constructs despite multiple attempts suggests they are toxic in the 











(a) The MEP pathway and (b) the promoter-RBS combinations used to control the expression of 
eight genes are shown. Each gene is designed to express at five different levels; level 1, 2, 3, 4, 
and 5 correspond to low, medium-low, medium, medium-high, and high expression level. The 
shades of greens indicate the expression strength, with darker meaning stronger. The expression 
strength was measured previously as ΔABS415nm per minute per gram dried cell weight by beta-
glucuronidase reporter assay [74]. The architecture of the full cluster reflects the gene order in the 
constructs. (c) The bottom-up assembly plan of PBFC library is shown. The top section lists the 
individual DNA parts. The strength of promoter-RBS parts is ranked from the weakest to the 
strongest (left to right). The second section lists monocistronic units. The third section lists partial 
clusters. PC1-25 and PC26-50 are upper and lower partial clusters, respectively. The bottom 
section lists the full clusters. Abbreviations are: P, promoter; R, RBS; ispH, 4-hydroxy-3-methylbut-
2-enyl diphosphate reductase; ispG, 4-hydroxy-3-methylbut-2-en-1-yl diphosphate synthase; dxs, 
1-deoxy-D-xylulose-5-phosphate synthase; dxr, 1-deoxy-D-xylulose 5-phosphate 
reductoisomerase; ispD, 2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase; ispE, 4-
diphosphocytidyl-2-C-methyl-D-erythritol kinase; ispF, 2-C-methyl-D-erythritol 2,4-
cyclodiphosphate synthase; idi, isopentenyl-diphosphate delta-isomerase;  MT, monocistronic unit; 
PC, partial cluster; FC, full cluster. 
 
4.2.3 Performance of PBFC library in S. albidoflavus J1074 
The PBFC strains were fermented in duplicate in 0.5 mL of ISM3 medium for five 
days in high-throughput 96 deep-well plates. The cultures were freeze-dried, extracted 
with methanol, and analyzed by LC-MS to quantify the eAA production titer. PBFC 34, 81 
and 108 did not yield any S. albidoflavus J1074 exconjugants, so their eAA production 
titers were considered as 0.0 mg/mL in data analysis. The eAA production titer spans from 
0.0 mg/L (non-detectable) to 152.2 ± 4.8 mg/L with FC#44 as the highest producer (Figure 
4.2a). The distribution of eAA titer of the PBFC library is lognormal, with a median titer of 
10.8 mg/L and an interquartile range of 20.7 mg/L.  
Interestingly, many PBFC strains displayed different colony morphologies from the 
S. albidoflavus J1074-empty vector control when grown on solid media. We used six basic 
colony morphology features, shape, margin, color, opacity, elevation, and texture, to 
categorize the PBFC strains into ten morphology classes (Figure 4.2b). Most notably, the 
PBFC strains in morphology classes 7, 8 and 9 have translucent colonies which partially 
or completely lost the sporulation phenotype even after extensive incubation at 28°C. 
Strains in morphology class 2 exhibited smooth concentric ring morphology that was not 
previously observed in wild-type S. albidoflavus J1074. Class 1, 5, 7, and 10 have more 










Figure 4.2. Expression level, eAA titer and morphological features of strains of PBFC library. 
(a) The shades of green indicate the expression level of individual genes, which is the same as in 
Figure 4.1. The shades of purple indicate different morphology classes and morphological features, 
with lightest purple representing Class 1, and darkest purple representing Class 10. Yellow means 
no exconjugants were obtained for the specific genetic designs.  The average eAA production titer 
(grey bar) of each PBFC strain plotted on a semi-log scale (n = 2, standard deviation plotted). 
PBFC#44 is the highest eAA producer in this library (red text). (b) Morphological feature 
representation of 10 morphology classes in the PBFC library. MC abbreviates for morphology class; 
S, shape; M; margin; C, color, O, opacity; E, elevation; T, texture. The PBFC strains were fermented 
on two different days.  
 
4.2.4 Main effect of overexpression of MEP pathway genes on eAA production titer 
We analyzed the output of this pathway, eAA production, by one-way analysis of 
variance (ANOVA) to screen the genes that have the largest effect on the eAA titer. Since 
the distribution of PBFC library eAA titer is lognormal, the titer data were log10-
transformed prior to any statistical analysis. The ‘log eAA titer’ from now on represents 
‘log10-transformed eAA titer’ to prevent any confusion.  For each gene expression group, 
the arithmetic mean of log eAA titer was calculated to quantify the effect of each gene on 
the eAA production. Figure 4.3a shows the overall changes in the average log eAA titer 
caused by changing expression levels. One-way ANOVA showed that only dxs expression 
is statistically significant on the eAA titer. 
Next, we analyzed the correlation between a gene’s expression level and the 
average eAA titer. An ordinary least square regression analysis was used to fit a linear 
model of the effects of each gene on the mean log eAA titer. The ‘main effect’ can be 
approximated by the slope of the linear regression. The statistical significance of the slope 
of each linear regression was evaluated by t-test. The most dominant variable over eAA 
titer is dxs, with lower expression correlating with higher titer (Figure 4.3b and Figure 4.3c). 
The gene expression of ispF has weak positive correlation with eAA titer. The gene 
expressions of ispH, ispG, dxr, and idi have weak negative correlations with the eAA titer. 
Gene expression of ispE has little or no association with titer. Although the linear fit of the 
genes other than dxs is not statistically significant to the eAA titer, the analysis reveals a 





Interestingly, the optimal expression level of ispG, dxr, ispE, is at the lowest (level 1); dxs 
and idi, at medium low (level 2); ispH, medium (level 3); ispD, highest level (level 5).  
The main effects of 21 dummy variables (unassigned columns) were also 
calculated to estimate experimental error used in statistical interpretation. If the 
components of a system are independent from each other and their two- or higher-order 
interactions are negligible, the level changes of dummy variables should not influence the 
system performance. In a perfectly independent system, changes in the levels of dummy 
variables should not correlate with eAA titer at all, and the main effect/slope of the linear 
regression line would be zero. The fact that a handful of the dummy variables have effect 
(non-zero) on eAA titers (Figure 4.3c), indicates either the presence of interaction 
between the genes or a non-trivial amount of stochastic experimental noise/variance. 
The dummy variables serve as negative controls during data analysis. In Figure 4. 
3c we plotted the distribution of eAA titer variance (between the five sets of 25 grouped 
rows) and calculated main effect for each of the 23 dummy variables. The distribution of 
the main effects of the dummy variables tightly clustered around zero, indicating the 
overall statistical variance caused by experimental error or higher-order interactions are 
quite small; the distribution of the variation of average titer clustered around 0.1. The 
experimental error was not to a statistically significant as the indicated by T-test. 
Importantly, plotting the experimental variables on the same axes as the dummy 
variables in Figure 4.3c shows that five of the eight variables fall outside of 2 standard 
deviations of the negative controls. This is not expected to result from random chance, 
and supports that conclusion that our PB library design returned actionable information 
about the system that stands out from the stochastic noise that is inherent in Streptomyces 
fermentations.    
Across the range of expression values that we tested in this experiment, ispD is 
the only gene with a meaningful positive main effect (i.e. increase in titer corresponding to 
increase in ispD expression). Three genes, dxs, dxr, idi, and ispH, have a meaningful 
negative main effect, with lower expression levels preferred (Figure 4.3c), however it is 
noteworthy that this negative main effect is in some cases driven primarily by low titers 
only at the highest expression level (e.g. ispH and idi in Figure 4.3b). For these genes, 











Figure 4.3. Main effects of MEP pathway genes plus idi on eAA titer. 
(a) overall magnitude of average eAA titer changes caused by gene expression. 
(b) Expression level of each genes (in log10 scale) is plotted against eAA titer of 
strains containing that specific expression level. The geometric mean of the eAA 
titer of each gene expression group is plotted as a black dot. A linear regression is 
represented as the grey line.  Grey area denotes 95% confidence interval. ɑ= 0.05. 
(c) Main effects and variation of average log eAA titer changes caused by genes 





slope of the linear regression fit. Variation of average log eAA titer is calculated as 
the standard deviation of the geometric average of eAA titer of five expression 
levels.  The five shades of green correspond to the expression level in Figure 4.1. 
* represents the p-value <0.05. 
 
4.2.5 Contribution of discrete genetic motifs to overall eAA titer 
We decomposed the activity of the final eAA gene cluster into the activities of its 
constituent parts, namely the monocistronic unit and partial clusters. Here we attempt to 
analyze the extent of how the system behavior can be predicted by the combination of its 
parts using additive, multiplicative and dominant negative effect models which are used 
routinely in genetic interaction studies [169], [170]. 
First, the contribution of each intermediate genetic motif to full cluster performance 
was evaluated by calculating the arithmetic mean of log eAA titer of the strains containing 
the specific part. We define this value as a ‘part fitness.’ Figure 4.4a showed the log10 
ratio of each part fitness value is to the average full cluster fitness, 𝑓𝑎𝑣𝑒 , which is defined 
as the arithmetic mean of the entire log eAA titer data (10.5 mg/L eAA). If a part has higher 
fitness than the average full cluster fitness, then the bar is above zero; worse, than below 
zero.  
Based on the part fitness values, a retroactive prediction of full cluster performance 
is calculated using three models. First, the additive model predicts the full cluster fitness 
to be the average of the corresponding single part fitness values. Second, the 
multiplicative mode predicts the full cluster fitness to be the product of the corresponding 
single part fitness values. Third, the dominant negative effect model assumes that a full 
cluster is only as good as its worse part and would be true if genetic motifs with low part 
fitness values have a dominant effect over motifs with high part fitness values. (Fig 4.4b). 
The analysis showed that the multiplicative model has the highest R2 value amongst the 
three models, indicating better predictability of the full cluster fitness. Overall, multiplicative 
model using partial cluster fitness is a better predictor of full cluster fitness than MT fitness 
in all models, as 39.23% of all the variance in the fitness can be accounted for by the 
partial cluster multiplicative model. This result is likely due to smaller genetic context 





pathway components interacts on a non-linear scale rather than the linearly, which is also 
observed in anthocyanin biosynthesis [171], [172]. 
 





(a) fitness values of monocistronic unit (yellow bars) and partial clusters (magenta 
bars), presented as a log ratio normalized to mean fitness value of PBFCs, are 
shown. Part names corresponding to the assembly graph in Figure 1c are labeled 
above bars. 𝑓𝑎𝑣𝑒 is the geometric mean eAA titer of the PBFC library. (b) Predicted 
full cluster activity is plotted against measured activity. Colored points represent 
the 125 full cluster constructs. Level of correlation to the y = x line improves at 
more advanced levels of assembly from R2 = 0.0875, 0.3313, and 0.0361 for 
monocistronic units (yellow) and R2 = 0.3355, 0.3923, and 0.2740 for partial 




The expression level of two genes, dxs and ispD, were shown to have the most 
noticeable effect on eAA production. Previous research has shown that DXS is the major 
flux-controlling enzyme [173], and its overexpression leads to increase isoprenoid 
production titer [26], [167], [173], [174]. In our system, overexpression of dxs leads to lower 
eAA titers, and the best expression level for dxs is medium-low (level 2). Others have 
reported a negative effect for dxs overexpression on cell growth and productivity [175]–
[177]. One plausible explanation for the negative correlation between dxs expression and 
eAA production is that overexpression of dxs which causes carbon and energy burden in 
the host cell. Dxs catalyzes the condensation of pyruvate and glyceral-aldephyde-3-
phsophate, two key glycolytic intermediates for generating amino acid building block, 
reducing equivalents, and ATP. While glycolysis displays a certain tolerance to flux 
perturbations [178], overexpression of dxs diverts too much carbon flux towards MEP 
pathway and robs the cellular resources from central metabolism to function properly, 
eventually sabotages the eAA production level. Overall, the MEP pathway is quite robust, 
as the gene expression changes in six out of eight genes do not leads to significant 
changes in the eAA titer. Our result may explain why there are so many different results 
as to which enzyme is the rate-limiting step in the MEP pathway literature. 
Previously, a few publications highlighted the nonlinearity of the fitness/production 
landscape of the MEP pathway [102], [173], [179]. Similarly, we observed multiplicative 
(non-linear) interaction of partial clusters and monocistronic units can better predict the 





We have two hypotheses to explain the origin of the nonlinearity of the eAA landscape. 
The first hypothesis is the observed nonlinearity is an artifact of the gene expression noise 
[180], rather than the real nonlinearity caused by higher-order interaction of the MEP 
pathway components. The promoter-RBS parts used in the full clusters were 
characterized in isolation, and their actual behaviors in a full cluster may vary from 
expected due to genetic context effect [14], [57], [181].  To mitigate the potential effect of 
genetic expression noise, we chose the five-level Plackett-Burman design, instead of the 
usual two-level seen in the literature, to build in redundancy of testing multiple level of 
gene expression. 
Our second hypothesis is that the observed nonlinearity represents the higher-
order interactions of MEP pathway components. In this work, the only modification to the 
S. albidoflavus J1074 genome is the integration of the refactored MEP pathway. The 
endogenous MEP pathway and regulatory processes still operate in the background, 
which may confound the result of Plackett-Burman library. The flux of the refactored MEP 
pathway may be regulated at multiple layers just like how endogenous MEP pathway is 
regulated [182]. One of the regulations of MEP pathway is at the protein level; the activity 
of DXR and IspD is modulated by phosphorylation of key active site residues. Another 
regulation mechanism is through metabolite control including feedback inhibition of DXS 
by IPP/DMAPP [183], and feed-forward activation of ispF by MEP [184]. MEP pathway 
also interacts with other cellular processes. For example, the MEP pathway intermediate, 
MEcPP, modulates the stress response at the transcription level. DXP, another pathway 
intermediate, is a precursor to pyridoxal and cofactor biosynthesis. In addition, the first 
step of MEP pathway draws from two primary metabolites of glycolysis (glyceraldehyde-
3-phosphate and pyruvate). The complex interplay of the MEP pathway and other 
metabolic processes is also reflected in the diverse morphological changes in PBFC 
strains. However, it is unclear how the MEP pathway modulates morphology development 
in Streptomyces.  
A weakness of implementation of Plackett-Burman design is that the analysis 
assumes the effect of independent variables has a linear relationship of with the overall 
system performance [185]. The linear assumption of the main effect makes the 





effect of variables. For example, the width of the confidence interval of the linear 
regression of expression of ispH, ispF, and idi are quite large, indicating a weak correlation 
with eAA production titer (Figure 4.3b). However, the distributions of the grouped average 
log eAA titer in ispH, ispF and idi suggests a non-linear correlation with the gene 
expression, and therefore a linear model with polynomial terms or a quadratic model may 
be more appropriate to fit the curvature effects. Another weakness of Plackett-Burman 
design is its aliasing structure, meaning that the main effects can be partially confounded 
by second- or higher-order interactions. Therefore, Plackett-Burman design is assumed 
to be effective in estimating true main effects when the effect of higher-order interactions 
is negligible. When a main effect is large, it is less likely to be masked by higher-order 
interactions. Plackett-Burman design is not capable of tease apart interaction effect and 
main effect when the main effect is small, and will require either advance statistical 
analyses [186], [187] or more experiments to de-confound interaction effects and main 
effects.  
While it has become increasingly easy to explore the genetic design space, we 
have demonstrated that a subset of carefully chosen designs from a full-factorial design 
is sufficient to the systematically explore and understand the landscape of isoprenoid 
biosynthesis in Streptomyces. Other may argues to increase coverage of the design space 
and gain maximal information about the landscape. This has been demonstrated by 
generation of diverse genetic variants of multi-gene systems with targeted directed 
evolution [167], [188], in vivo mutagenesis[189], and combinatorial assemblies [64], [102]. 
A limitation of these diversification-driven methods is that they are difficult to apply to the 
cases which multi-gene systems do not have phenotypes compatible with current high-
throughput screening methods. In contrast, fractional factorial designs like Plackett-
Burman design is effective to identify the variable that has large main effect on the overall 
system performance with minimal number of experiments.  
DoE can be considered as a complementary framework to systematically reduce 
library size and design-build-test cycle time.  In this work, we were able to identify dxs as 
the important genes on eAA titer with a small library of 125 unique genetic designs, which 
covers 0.032% of the entire design space (125 designs of all 58 possible designs). By 





us to compare our DoE-based screening results to the large body of literature and rank 
order the effects of these eight genes. The result of this study showed that Plackett-
Burman design was able to replicate the findings that dxs is the rate-limiting step and 
provided additional insights to MEP pathway with a medium library size. Plackett-Burman 
design also allows systematic access to unexplored sequence-function space landscape. 
In sum, Plackett-Burman design is an effective method in screening and prioritizing 
variables in order to optimize a model multi-gene system, which gives us confidence that 
Plackett-Burman design can be extended to study less characterized genetic systems.  
 
4.4 Material and Methods 
4.4.1 Strains and Chemicals 
E. coli DH5α and NEB® Stable were used for routine cloning. E. coli 
ET12567/pUZ8002 was used for intergenic conjugation. E. coli NEB ® Stable/pUZ8002 
was used as an alternative intergenic conjugation strain for the PBFC21 which was not 
able to be conjugated by using E. coli ET12567/pUZ8002. S. albidoflavus J1074 was used 
as a heterologous expression host for screening PBFCs and FFCs. LB medium (10 g/L 
tryptone, 5 g/L yeast extract, 10 g/L NaCl; MP Biomedicals # 113002022) supplemented 
with proper antibiotics was used for strain maintenance and plasmid construction in E. coli 
strains. Streptomyces liquid media for maintenance and fermentation include R2YE 
medium (103 g/L sucrose, 10 g/L glucose, 0.25 g/L K2SO4, 5 g/L yeast extract, 0.1 g/L 
Difco casamino acid, 100 ml TES buffer (5.73%, pH 7.2), 10 ml KH2PO4 (0.5%), 80 ml 
CaCl2.2H2O (3.68%), 15 ml L-proline (20%), 2 ml trace element solution and 5 ml NaOH 
(1N)), ISM3 medium (15 g/L yeast extract, 10 g/L malt extract, 0.5 g/L MgSO4, 0.3 g/L 
FeCl3·6H2O, 20 g/L glucose, adjusted to pH 7.0 with NaOH and TSB (30 g/L tryptic soy 
broth). Solid medium for Streptomyces spore isolation is ISP4 (37 g/L Difco ISP medium 
4). Fermentations at 500- and 50-mL scale were supplemented with 3% w/v hydrophobic 
resin (Amberlite – XAD16; Alfa Aesar L19565-36). Unless stated otherwise, antibiotics 
apramycin, nalidixic acid, kanamycin, and chloramphenicol were supplemented to liquid 
or solid media at final concentration of 50 µg /mL, 25 µg /mL, 50 µg /mL and 25 µg /mL, 





commercial sources. T4 DNA ligase (Promega; Cat. No. M1794) and its 10X buffer used 
in this study were purchased from Promega unless stated otherwise. 
 
4.4.2 Generation of E. coli NEB ® Stable/pUZ8002 
Plasmid pUZ8002 (www.lifescience-market.com; Cat. No. PVT12448) was 
electroporated into electrocompetent E. coli NEB ® Stable cells (BioRad electrocuvette, 1 
mm gap; 1.8 kV; BioRad Gene Pulser Xcell electroporation system). The electroporation 
mixture was plated on LB solid media supplemented with kanamycin to select for 
transformants. The plate was incubated at 37°C overnight. The colonies appeared on 
selective solid media were transferred to liquid LB medium supplemented with kanamycin.  
 
4.4.3 Statistical Analysis 
Microsoft Excel and Python were used for statistical analysis in this study. 
 
4.4.4 Generation of Five-level Plackett-Burman Design 
A five-level Plackett-Burman design is generated by cyclic permutation as 
described previously [156]. Specifically, the design cycles through five numbers, which 
are 1, 2, 3, 4 and 5. The orthogonality is verified in JMP’s design diagnostics. The resulted 
Plackett-Burman matrix is found in Supplementary Data File A2, Worksheet 1. The 
columns selected to guide genetic design of synthetic MEP pathway are highlighted in 
grey in the Supplementary Data File A2, Worksheet 1. 
 
4.4.5 DNA Parts Construction 
The DNA assembly strategy, DNA parts, and plasmids used to construct synthetic 
MEP pathway prototypes in this study is the same as previously described in chapter 3 
and [74]. The promoter-RBS parts, and terminator parts were chemically synthesized as 
Ultramer® DNA Oligonucleotides (Integrated DNA Technologies, Coraville, IA). 
Subsequently, the DNA parts were assembled into part storage vector. The CDSs of ispH, 





amplification with gene specific primers flanked by AarI restriction sites and a four-
nucleotide AarI docking sequence. The domesticated CDS are free of any internal SapI 
and/or AarI restriction sites. Eight genes were cloned from genomic DNA of Streptomyces 
sp. NRRL S-1813. The PCR-amplified CDS fragments were domesticated by AarI Golden 
Gate assembly into CDS domestication vector pCDS. Each PCR-amplified CDS fragment 
was analyzed by gel electrophoresis and extracted with standard gel purification protocol 
(Zymoclean Gel DNA Recovery Kit, Zymo Research Cat. No. D4007). Domestication of 
PCR-amplified CDS were done by minimized AarI Golden Gate reaction with minor 
modifications to the manufacture’s protocol: 30 ng of pCDS, three equimolar amounts of 
PCR-amplified CDS fragments and 2 µL of 2X AarI master mix (Thermo Fisher Scientific, 
GeneArt™ Type IIs Assembly Kit, AarI; Cat. No. A15916), and water to final volume of 4 
µL. The reaction mixtures were incubated as per manufacturer’s AarI Golden Gate 
incubation protocol, which is described below: 37°C initial digest for 15 min, initial ligation 
at 16°C for 5 min, then cycling between 37°C for 1 min and 16°C for 1min for at least 20 
cycles. Half of the Golden Gate assembly reaction was introduced to E. coli via chemical 
transformation. The clones were verified by Sanger sequencing. 
 
4.4.6 Bottom-up Hierarchical DNA Assembly of Synthetic Gene Clusters 
The method of hierarchical DNA assembly is the same as described in chapter 3. 
The workflow of DNA assembly pipeline is summarized in Supplementary Figure A2.1 
Three type of destination vectors were used: level 1 destination vector for cisReg/cistron 
storage, level 2 destination vector for partial cluster storage, and level 3 destination vector 
for full cluster storage. Level 1 (CisReg/Cistron) destination vector library has unique 
combinations of upstream and downstream MoClo scars flanked by BbsI and AarI 
recognition sites and apramycin resistance cassette. Each of the level 2 (partial cluster) 
destination vector has unique combinations of upstream and downstream MoClo scars 
flanked by AarI and SapI recognition sites and kanamycin resistance cassette. Level 3 
(full synthetic gene cluster) destination vector has of upstream and downstream MoClo 
scar sequences A and E flanked by SapI and AarI recognition sequences and apramycin 





BbsI golden gate assembly was used to construct CisReg plasmid. Level 1 
destination vector and part plasmids of promoter-RBS, transcriptional terminator, and 
reporter gene (Streptomyces codon-optimized egfp) were the substrates. Forty 
femtomoles of level 1 destination vector, three equimolar amounts of each part plasmids, 
5 U BbsI, 5 U T4 DNA ligase, 1 µL 10x T4 DNA ligase buffer and water were added to 
bring the final reaction volume to 10 µL. The incubation parameter is the same as the 
previous AarI Golden Gate reaction. Half of the Golden Gate assembly reaction was 
introduced to E. coli via chemical transformation. The clones were verified by Sanger 
sequencing. 
SapI Golden Gate assembly was used to construct monocistronic plasmids with 
CisReg plasmids and pCDS plasmids. Forty femtomoles of CisReg plasmid, three 
equimolar amounts of pCDS plasmid, 5 U SapI (New England Biolabs Inc; Cat. No. 
R0569S), 5 U T4 DNA ligase, 1 µL 10x T4 DNA ligase buffer and water were added to 
bring the final reaction volume to 10 µL. The incubation parameter is the same as the 
previous AarI Golden Gate reaction. Half of the Golden Gate assembly reaction was 
introduced to E. coli via chemical transformation. The monocistrons were verified by either 
colony PCR using OneTaq® PCR (New England Biolabs Inc.; Cat. No. M0480S) or 
Sanger sequencing. 
AarI Golden Gate assembly was used to construct partial clusters with 
monocistronic plasmid and level 2 destination vector. Thirty nanogram of level 2 
destination vector, three equimolar amounts of monocistronic plasmids, 2 µL 2X AarI 
master mix, and water to final volume of 4 µL. The incubation parameter is the same as 
the previous AarI Golden Gate reaction. Half of the Golden Gate assembly reaction was 
introduced to E. coli via chemical transformation. The monocistrons were verified by 
colony PCR. 
SapI Golden Gate assembly was used to construct full cluster plasmids with partial 
plasmids and level 3 destination vectors. Forty femtomoles of level 3 destination vector, 
three equimolar amounts of partial cluster plasmids, 5 U SapI, 5 U T4 DNA ligase, 1 μL 
10x T4 DNA ligase buffer and water were added to bring the final reaction volume to 10 
μL. The incubation parameter is the same as the previous AarI Golden Gate reaction. Half 





transformation. The monocistronic part were verified by colony PCR. The colony PCR 
primers are the same as the CDS cloning primers. One gene from each cassette was 
targeted for colony PCR. 
 
4.4.7 Intergenic Conjugation  
Final synthetic gene clusters were introduced into conjugation donor E. coli 
ET12567/pUZ8002 or E. coli NEB® stable/pUZ8002 via electroporation (BioRad 
electrocuvette, 1 mm gap; 1.8 kV; BioRad Gene Pulser Xcell electroporation system). The 
electroporation mixtures were recovered with 1 mL S.O.C. media for 1 h in 37°C shaker. 
Upon recovery, the electroporation mixture was plated on LB agar supplemented with 
kanamycin, chloramphenicol, and half concentration of apramycin. The transformations 
were incubated at 37°C overnight. The transformants were verified with colony PCR. Two 
primer pairs (SYH241-SYH242 and SYH 233-SYH234) were used as colony PCR primers 
to amplify the ispH-ispG and ispD-ispE junctions in the full clusters (Supplementary 
Figure A2.2). Alternative primer pairs (SYH237-SYH238 and SYH 243-SYH244) were 
used as colony PCR primers to amplify ispG-dxr and ispE-ispF junction. Each verified 
transformant was inoculated in 2 mL liquid LB supplemented with apramycin, kanamycin, 
and chloramphenicol and incubated in 37°C shaker overnight. On the next day, 2 mL of 
LB supplemented with apramycin, kanamycin, chloramphenicol and CaCl2 were added to 
the overnight culture (20 mM CaCl2 final concentration) and incubated for four more hours 
in 37°C shaker. 
Preparation and germination of the spore of the wild type S. albidoflavus J1074 for 
conjugation was performed in the following steps. First, the frozen spore stocks of S. 
albidoflavus J1074 were thawed on ice for 10 min. The thawed spore stocks were 
centrifuged at max speed for 1 min, and the supernatant was removed. Every 50 μL of 
packed spores was resuspended in 500 μL TSB supplemented with 10% (wt/vol) sucrose 
and glycine. Germination of spores was initiated in 28°C shaker for at least 2 h. 
Once conjugation donors were overgrown for 4 h, the cells were pelleted by 
centrifugation at 3,000 rpm for 30 s. The supernatant was removed, and the cell pellet was 
washed gently three times, each time with 1 mL LB at room temperature to remove 





The E. coli – Streptomyces conjugation mixtures were centrifuged 3,000 rpm for 1 min 
and the excess supernatant was removed so the final resuspension volume was 50 μL. 
Each conjugation mixture was plated on ISP4 solid media supplemented with 20 mM 
CaCl2 (final concentration) and incubated overnight at 28°C. After 24 h, the entire 
conjugation mixture was scrapped and re-plated on ISP4 solid media supplemented with 
nalidixic acid and half concentration of apramycin to select for successful Streptomyces 
exconjugants. The final Streptomyces exconjugants were transferred to an ISP4 solid 
medium supplemented with full concentration of apramycin for maintenance and 
downstream experiments. 
The PBFC plasmid were verified via colony PCR. All PBFC constructs except 
PBFC81 were successfully electroporated into E. coli ET12567/pUZ8002 or E. coli NEB® 
stable/pUZ8002 as the conjugation donor. With four failed attempts, we confirmed that 
was not able to be introduced into E. coli ET12567/ pUZ8002 for unknown reason. Instead, 
PBFC21 was introduced into E. coli NEB stable®/ pUZ8002 and confirmed with colony 
PCR. Intergenic conjugation of PBFC plasmids into S. albidoflavus J1074 were successful 
except for PBFC 34 and 108. PBFC 34, 81 and 108 could not yield any S. albidoflavus 
J1074 exconjugants so we considered their eAA production titers as 0 mg/L in data 
analysis. 
 
4.4.8 Fermentation of S. albidoflavus J1074  
The fermentation protocol of S. albidoflavus J1074 was the same as previously 
described in chapter 3 and [74]. The Streptomyces fermentation was divided in three 
stages and they were (i) fresh sporulation of strains on solid media, (ii) germination and 
synchronization of cultures and (iii) inoculation of the fermentation media. All 50 mL and 
500 mL shake flask cultivations were done in 250 mL and 2 L standard baffled Erlenmeyer 
flasks, respectively. High-throughput 2 mL and 0.5 mL microcultivation were done in low-
evaporation, 24- or 96-square-deep-well microtiter plates (MTPs), respectively 
(Enzyscreen CR1424a and CR1496a).  
At the sporulation stage, the frozen spore stocks of recombinant S. albidoflavus 
J1074 strains were streaked on ISP4 solid media supplemented with apramycin and 





sporulate fully, their vegetative mycelia were used for inoculation. At the spore germination 
stage, fresh spores from each recombinant strain were grown in 2 mL R2YE 
supplemented with apramycin in 15 mL culture tube. The R2YE liquid cultures were 
incubated in 28°C shaker with 250 rpm for 48 h. Each R2YE preculture was used to 
inoculate (1/100 (v/v) inoculum) 2 mL ISM3 supplemented with apramycin in 15 mL culture 
tube to synchronize growth of various strains. The synchronization culture for 500 mL 
fermentation was scaled up to 50 mL ISM3 supplemented with apramycin and was also 
inoculated with 1/100 (v/v) R2YE preculture. The ISM3 cultures were incubated in 28°C 
shaker with 250 rpm for 48 h. Each synchronization culture was standardized so that the 
cell pellet inoculated across samples was the same. Briefly, 1 mL of the synchronization 
culture was gently pelleted in sterile 1.7 mL Eppendorf microcentrifuge tubes with 3,000 
rpm for 30 s. Excess supernatant was removed so the volume of cell pellet and the 
supernatant were 1 to 1 ratio. Each microfermentation (0.5 mL) was inoculated with 10% 
of standardized synchronization cultures. The fermentation cultures were grown in 28°C 
shaker with 250 rpm for 4-7 days. 
 
4.4.9 Extraction of Metabolites from Streptomyces Fermentation 
The 50 mL fermentations were transferred to 50 mL conical tubes and centrifuged 
at 4,500 rpm for 15 min. The supernatant was discarded, and the cell-resin pellets were 
washed with de-ionized water (ddH2O) and centrifuged for 30 min at 4600 rpm for three 
times. The samples were frozen at -80°C for 24 h. The frozen samples were then freeze-
dried for 24 h or until the moisture was completely removed (0.01 mbar, -84°C; Labconco 
FreeZone Plus 2.5 Liter Cascade Benchtop Freeze Dry System, catalog number 7670020). 
Each dried sample was extracted in methanol (3 x 5 mL).   
The 96-well MTP containing 0.5 mL fermentations was frozen at -80°C for 24 h to 
48 h. The frozen samples were then freeze-dried for 24 h or until the moisture was 






4.4.10 Liquid Chromatography–mass Spectrometry (LC-MS) Analysis  
LC-MS analyses were performed on Thermo Scientific MSQ plus mass detector 
equipped with Ultimate 3000 Rapid Separation (RS) system. The extracts were diluted in 
100% MeOH, and 10 μL of each extract was loaded onto a Thermo Scientific analytical 
BetaSil C18 column (2.1 x 150 mm, 3 μm). Chromatography was performed at flow rate 
of 500 μL/min using 10 mM ammonium formate buffer (solvent A, pH 8.3) and 100% 
acetonitrile (solvent B) with the following gradient: 0 – 0.5 min, 95 % solvent A; 0.5 – 14.5 
min, 95% solvent B; 14.5 – 16 min, 95% solvent B; 16 – 18 min, 95% solvent A; 18 – 23 
min, 95% solvent A. The parameters of MSQ plus mass detector for analyzing eAA were 
described below: ionization mode, electrospray; cone ionization, 110 V; capillary probe 
temperature, 450°C. 
 
4.4.11 One-way ANOVA 
One-way ANOVA was used to calculate the significance of the expression of each 
gene to eAA titer. To conduct ANOVA properly, the eAA titer data, which follows a 
lognormal distribution, is required to be transformed to normal data. To make zero values 
in the dataset countable, 1.0 mg/L was added to each of data point. Then the log10-
transformed eAA titer data 𝑦  were used in one-way ANOVA. Microsoft Excel Data 
Analysis ToolPak was used to conduct one-way ANOVA. 
 
4.4.12 Main Effects Calculation 
First, the effect 𝐸 of each expression level 𝐿 of individual genes is calculated by 
taking the arithmetic mean of log10-transformed eAA titer 𝑦 of the number 𝑛 of PBFC 
strains containing that specific expression level 𝐿.  
𝑬𝑳 = [∑ 𝐲(𝑷𝑩𝑭𝑪𝒊, 𝑷𝑩𝑭𝑪𝒋 , … 𝑷𝑩𝑭𝑪𝒌)]/𝒏 (Equation 4.1) 
In this case, 𝑛 = 25 for each 𝐿.  
Then the effect 𝐸  is plotted against the actual log10-transformed expression 
strength 𝑥 corresponding to the expression level 𝐿. An ordinary least squares model (OLS) 
function in the Python statsmodel package was used to conduct linear regression and 





defined as the slope 𝛽 of the simple linear fit model. The linear regression line has an 
equation of the form: 
𝑦 = 𝑎 +  𝛽𝑥 (Equation 4.2) 
The statistical significance of the linear fit was calculated by t-test. 
 
4.4.13 Contribution of Discrete Genetic Motifs to Overall eAA Titer 
The fitness 𝑓 of a genetic motif 𝑥, whether for a monocistronic unit 𝑀𝑇 or a partial 
cluster 𝑃𝐶 in the assembly, is defined as the arithmetic mean of the log10-transformed eAA 
titer of full clusters containing that part.  
Genetic motif fitness is shown for monocistronic unit and partial clusters in Figure 
4.4 as the logarithm of the ratio of individual part fitness to average part fitness. Better-
than-average parts fall above the x-axis and worse-than-average parts fall below the x-
axis.  
 
4.4.14 Using Genetic Motif Fitness to Predict Full Cluster Activity 
Additivity, multiplicity, and dominant negative models were used to retroactively 
calculate the predicted fitness of a full cluster  𝑓𝑃𝐵𝐹𝐶𝑖  from the part fitness values of 
monocistronic units  𝑓𝑀𝑇 or of partial clusters 𝑓𝑃𝐶. 
The additivity model predicts the full cluster fitness to be the average fitness of its 









(𝑓𝑢𝑝𝑝𝑒𝑟_𝑃𝐶 + 𝑓𝑙𝑜𝑤𝑒𝑟_𝑃𝐶) 
The multiplicativity model predicts the full cluster fitness to be the product fitness 
of its constituent monocistronic units or partial clusters: 
𝑓𝑃𝐵𝐹𝐶𝑖 = 𝑓𝑀𝑇𝑖 ·  𝑓𝑀𝑇𝑖𝑖 ·  𝑓𝑀𝑇𝑖𝑖𝑖 · 𝑓𝑀𝑇𝑖𝑣 · 𝑓𝑀𝑇𝑣 · 𝑓𝑀𝑇𝑣𝑖 · 𝑓𝑀𝑇𝑣𝑖𝑖 · 𝑓𝑀𝑇𝑣𝑖𝑖𝑖 
or 





The multiplicativity model predicts the full cluster fitness to be the product fitness 
of its constituent monocistronic units or partial clusters: 
𝑓𝑃𝐵𝐹𝐶𝑖 = min (𝑓𝑀𝑇𝑖, 𝑓𝑀𝑇𝑖𝑖 , 𝑓𝑀𝑇𝑖𝑖𝑖 , 𝑓𝑀𝑇𝑖𝑣, 𝑓𝑀𝑇𝑣 , 𝑓𝑀𝑇𝑣𝑖, 𝑓𝑀𝑇𝑣𝑖𝑖 , 𝑓𝑀𝑇𝑣𝑖𝑖𝑖) 
or 
𝑓𝑃𝐵𝐹𝐶𝑖 = min (𝑓𝑢𝑝𝑝𝑒𝑟_𝑃𝐶 , 𝑓𝑙𝑜𝑤𝑒𝑟_𝑃𝐶) 
 
4.4.15 Streptomyces Morphology Photography 
Plates of ISP4 solid medium were made using automatic plate pourer two days 
before streaking PBFC strains. Each plate had 22 mL of ISP4 medium (100 x 15 mm petri 
dishes, VWR, cat. No 25384-342). On the day of streaking, ISP4 plates were pre-warmed 
in 28°C incubator for 20 minutes. Frozen glycerol stocks of PBFC strains were placed on 
ice to prevent thawing. Each PBFC strain was streaked onto ISP4 plate supplemented 
with 50 ug/mL Apramycin. These plates were incubated at 28°C for seven days.  
Nikon stereo zoom microscope (SMZ-2B), Meiji Techno RZBD/LED focus stand, 
AmScope microscope digital camera (MU1000-HS-CK) were used for photography of 
PBFC colonies. The photography setup is shown in Supplementary Figure A2.3. The left 
arm of the AmScope LED Dual Gooseneck Illuminator (item #: T9FM99286) was used as 
an additional light source. The light source from the Amscpe illuminator was 5 inch above 
the plate. The angle of the lighting is approximately 45°. The brightness of lighting was set 
at 8.00.  
Images of PBFC colony morphology were captured using Amscope digital camera 
and its Amscope software for MU series (https://www.amscope.com/software-
download#toup1; version v3.7.13522). Before the photography, the white balance was 
adjusted a plate that had more than one colony in the edge with white paper as the 
reference in the background. The color temperature was 6243 and the tint was 1000. The 
parameters of exposure and resolution were set at follows: exposure target, 120; exposure 
time, 92.536 ms; analog gain, 1.00; The parameters of capture and resolution were set as 






Additional methods and supplementary figures can be found in the Appendix 2 and 





Chapter 5 Conclusion 
 
Summary 
Dr. Richard Feynman’s well-known quote “What I cannot create, I do not 
understand” echoes the sentiment of efforts to determine the underlying principles of 
biosynthetic multi-gene systems by reconstructing them at the DNA level. While many 
questions remain to be answered and new ones have surfaced, I have presented a 
platform to rapidly construct metabolic pathway and efficiently balance the expression of 
genes encoding the biosynthesis of natural products in Streptomyces. In the quest to 
identify relative expression levels that lead to optimal performance of a multi-gene system, 
algorithmic DNA assembly enables the rapid, robust generation of complex, diverse 
libraries. 
In this dissertation, I have described multiple contributions I made during my 
doctoral work to advance field of Streptomyces natural product discovery with the focus 
of engineering expression level of multi-gene systems. These contributions centered on 
learning how to efficiently balance gene expression in a refactored metabolic pathway. 
The two technologies I developed, a high-throughput algorithmic assembly of synthetic 
BGCs and a library of synthetic promoter-RBS parts to combinatorial control gene 
expression, resulted in a platform for rapid metabolic pathway prototyping in Streptomyces 
bacteria. In addition, my doctoral work also explores novel strategies for the optimization 
of multi-gene systems with a focus on isoprenoid metabolism. The main hypothesis is that 
mathematical optimization paradigms, which have long been used in industrial and 
chemical engineering, can be extended to well-defined genetic systems. As a proof of 
concept, a multivariate DoE method called Plackett-Burman design is used to guide the 
design of a library of 125 synthetic gene clusters encoding a natural MEP pathway. Each 
MEP pathway synthetic gene cluster is composed of monocistronic unit of eight gene and 
the relative expression level of these eight genes are designed tuned to one of five 
possible expression level. The library of 125 synthetic gene clusters only covers 0.032% 
of the entire design space (125 designs of all 58 possible designs). Although it seems that 
the tradeoff for smaller library size is the resolution of the MEP pathway landscape, we 





identified DXS as the same bottleneck enzyme of the MEP pathway as previously reported. 
The approach provided confidence that Plackett-Burman design can be used reliably to 
identify important genetic features for the optimization of less well-characterized multi-
gene systems.    
 During my PhD, I overcame a few technical challenges in designing prototypes of 
multi-gene systems to address the main questions of re-engineering BGCs. First, the 
traditional way of restriction-enzyme based cloning is labor-intensive and usually requires 
case-by-case optimization. Generating different genetic prototypes is low-throughput and 
thus creates a major bottleneck prior to the hypothesis testing step. To overcome the 
challenge, I established an algorithmic high-throughput DNA assembly pipeline. In other 
words, the process of this DNA assembly is an algorithm: a defined series of Golden Gate 
assembly-based steps a user always performs, one after another. While it is possible to 
assemble the final multi-gene construct from small, standardized DNA parts in a single 
cloning reaction, the assembly efficiency drops drastically as the number of DNA 
fragments increases. To minimize the number of transformants that needed to be 
screened to validate assembly reactions, we limited the complexity of each DNA assembly 
step. The first step combines CDSs with cis-regulatory elements like promoters, CDSs 
and terminators, which form a ‘CisReg’ plasmid, which is a storage plasmid that contains 
cis-regulatory elements. CisReg plasmid is also used to quantitatively measure the 
promoter strength. The second step is a scarless replacement of the reporter gene with 
the desired CDS, forming a monocistronic unit. The third step is bringing multiple 
monocistronic units together to form a partial cluster; and finally, multiple partial clusters 
to form a full cluster.  
Banking all intermediate plasmids during the hierarchical assembly plan has a few 
technical benefits. First, plasmids can be amplified in cloning strains if the subsequent 
assemblies require more of a particular plasmid as substrate. Second, the intermediary 
and final assemblies in a plasmid format can be stored long term, reducing the need to 
repeat assembly reactions. Third, Golden Gate assembly achieves higher efficiency with 
plasmids as substrates when compared to linear DNA fragments (unpublished data). 





DNA parts stored in standardized format ensure design compliance to the algorithmic DNA 
assembly pipeline, which reduces overall engineering and design time. 
In sum, the features of this algorithmic DNA assembly pipeline are carefully 
incorporated to optimize assembly efficiency, accuracy, and throughput. This algorithmic 
DNA assembly pipeline serves as a universal scheme that can be applied to any genetic 
system construction project and shortens the time between prototyping and testing. This 
innovation to the traditional cloning is analogous to the transition to mass production of 
standardized goods from craft production during the Industrial Revolution.  
Second, a central challenge to constructing a functional multi-gene system is the 
proper control of its gene expression. When I started my dissertation project in 2015, the 
number of characterized synthetic cis-regulatory elements to control gene expression in 
Streptomyces was limited. To address the need of controlling expression for multiple 
genes, I constructed a library of synthetic, constitutive promoter-RBS (combined promoter 
and RBS parts) to tune gene expression at the levels of transcription and translation. For 
my project, the ideal properties of a synthetic expression control element are: (i) the ability 
to activate gene expression (ii) the ability to bypass the host regulatory machinery and (iii) 
consistent activity at different environmental conditions. I also attempted to use a native, 
strong constitutive Streptomyces promoter called ermE* as a benchmark in the expression 
strength measurement. However, domesticating ermE* to make it compatible with the 
algorithmic DNA assembly pipeline, which introduced a single point mutation to remove 
an internal AarI restriction site in the ermE* sequence, completely abolished its activity 
(unpublished data). So, my work has therefore been fully focused on building synthetic 
regulatory elements in the first year of my PhD work. A handful of synthetic promoter 
sequences with varying expression strengths were selected from the synthetic promoter 
library constructed by Siegl et [111]. However, these synthetic promoters were 
concatenated with the native RBS region of the reporter gene gusA for expression strength 
measurement in the original work. To add control at the level of translation, 10 de novo 
RBS sequences of varying translational initiation efficiency were generated by the RBS 
calculator [26], [112]. The synthetic promoter and RBS sequences were chemically 
synthesized to form diverse sequences, yielding 21 unique promoter-RBS parts. This 





magnitude. Another benefit of synthetic promoter-RBS parts is that media components do 
not interfere with the expression strength of promoter-RBS parts, as their expression 
levels are consistent in two different media. As most BGCs reach maximal expression 
during stationary phase, replacing their native promoters and RBSs with synthetic 
expression elements decouples their expression from the temporal control of the host 
regulation; the synthetic, promoter-RBSs are constitutive and tightly coupled with growth, 
allowing accumulation of the encoded product at earlier growth phase. This is observed in 
the time-dependent accumulation of eAA in a 2L flask fermentation in chapter 3.  
The technology developments of the algorithmic DNA assembly pipeline and the 
library of synthetic promoter-RBS enables the scale up of agile genetic prototyping. As a 
result, I was able to assemble a small library of 14 prototypes to constitute eAA 
biosynthesis in Streptomyces and another library of 125 prototypes to investigate the 
robustness of isoprenoid precursor metabolism. The main goal of constructing the initial 
library of seven eAA synthetic gene clusters was to study the relationship between the 
genotype and chemotype as well as identify the gene encoding the cognate atisane 
oxidation enzyme. The genes were selected based on their predicted biochemical 
functions. The genes are first paired with individual promoter-RBS and terminator parts to 
create monocistronic units, subsequently they were assembled together to form the final 
eAA synthetic gene clusters. The genetic design permutated the gene content in the 
oxidation cassette, which contained genes encoding an alpha-ketoglutarate dependent 
dioxygenase (PtmO6), a cytochrome P450 (PtmO2), or a ferredoxin (PtmO9) or 
combinations of these genes. The second design consideration was to perturb the gene 
expression level of the predicted ent-atiserene synthase PtmT1 to verify its function. 
Based on these design considerations, the eAA gene cluster prototypes were constructed 
and revealed a few insights about eAA biosynthesis. First, tuning the relative expression 
level of genes encoding the eAA pathway created chemical diversity at the metabolite 
level. Each variant produced different ratios of shunt metabolites and the target compound, 
eAA. The shunt metabolite species identified in this work are novel chemical entities, 
which are derived from two pathway intermediates, geranylgeranyl diphosphate and ent-
copalyl diphosphate. We also identified a novel cytochrome P450 enzyme, PtmO2, which 





final product eAA. In addition, we found that the relative expression of PtmO2 and the ent-
atiserene synthase, PtmT1, is crucial to the production titer of eAA. PtmO2 was found to 
oxidize the intermediate ent-copalyl diphosphate, the substrate of PtmT1, and form a 
shunt metabolite if PtmT1 expression is too low. Based on the eAA synthetic gene cluster 
as the model system, the second iteration of synthetic gene cluster (SGC) library design 
aimed to perturb the relative expression level of eight genes encoding the MEP pathway. 
We increased the eAA titer from 50 mg/L to 500+ mg/L by adding genes for the entire 
MEP pathway plus the isopentenyl pyrophosphate-dimethylallyl pyrophosphate (IPP-
DMAPP) isomerase, idi, to one of the synthetic eAA gene clusters. Surprisingly, the 
genetic designs of the best producers from the eAA library only have the ferredoxin gene 
expressed at the highest level and the rest of the gene expressed at medium level. This 
is contrary to the conventional wisdom in metabolic engineering, which is to use strong 
promoters to drive strong expression of individual genes. The lesson learned from 
constructing a synthetic eAA biosynthetic pathway support the emerging concept that 
production titer is not linear with the expression level [102]. 
Once the utility of the synthetic biology platform I developed was validated by the 
eAA synthetic gene cluster model system, I moved on to build a more elaborate library of 
125 prototypes of the synthetic gene clusters of the natural MEP pathway. The main goal 
was to investigate the relationship between the expression levels for the MEP pathway 
genes and the performance of the isoprenoid precursor metabolism, ultimately to optimize 
the isoprenoid production titer. The design approach for this specific library is based on 
unbiased, multivariate statistical DoE method rather than a heuristic approach like the 
previous library. The conventional approach to characterize a pathway and its optimization 
is an iterative process in which one variable is changed at a time while keeping other 
variables fixed to identify the optimal genetic design. A downside to this approach is that 
it might miss the global optimal solution, as the quality of the search is determined by the 
starting point. The basis of variable selection in DoE either requires a priori knowledge or 
uses random starting points. Another disadvantage is that it is often impractical to test all 
possible genetic designs. To address these issues of identifying optimal genetic design, I 
used Plackett-Burman design, which simultaneously changes the variables to maximize 





the isoprenoid titer. Based on the synthetic biology platform and a five-level Plackett-
Burman design, I built 125 prototypes of an eight-gene system encoding a synthetic MEP 
pathway. In this library design, the gene order and gene content remain constant; the 
variable is the expression level of individual gene, which is set at one of the five expression 
strengths. A full factorial experiment requires 58 (= 32,768) experiments, while a 5-level 
Plackett-Burman design only needs 125 combinations to fully gather the effect of individual 
gene expression. The screening of the entire 125 variants has revealed a surprising 
degree of robustness in actinobacterial secondary metabolism. The MEP pathway 
metabolism is quite robust, as perturbation of the expression of 6 out of 8 genes does not 
substantially change the average production titer. In addition, the analysis of the Plackett-
Burman result replicated findings reported in the MEP pathway literature, which identify 
dxs, the gene encoding the first and flux-controlling enzyme of the MEP pathway,  as the 
most dominant gene to influence the isoprenoid titer. This gives us confidence that 
Plackett-Burman design is an effective DoE method to identify the most important variable 
in a extensively studied multi-gene system like the MEP pathway, and can be extended to 
screen important genes in other multi-gene system with little or no working knowledge. 
 
 Future directions 
For the immediate future, I propose a few potential projects as the expansion of 
research presented in this dissertation. The first project will be to understand the 
mechanism of action of serofendic acid, a neuroprotective drug candidate. I tested eAA, 
serofendic acid and the structural analogs synthesized by Dr. Dimitri Perusse in the yeast 
chemical-genetics platform developed by Dr. Chad Myers’ group (University of Minnesota, 
Department of Computer Science and Engineering). The results, which were quantitative 
chemical-genetic interaction profiles, contained functional information useful to predict 
bioprocess targets of serofendic acid. Sarah Jo DeVore (a Bioinformatics and 
Computational Biology master student), is currently tasked with performing the 
bioinformatic analysis to predict the molecular target of serofendic acid.  
The second potential project will be to complete the biosynthesis of serofendic acid, 





to the structure of eAA. I propose two approaches to discover the enzymes performing 
these specific reactions. First, creating a cDNA library of cytochrome P450 genes from 
Isodon eriocalyx [123] and Lepidolaena clavigera [124], the two plant species reported to 
produce ent-atisanoid with a specific C15 hydroxyl group. The second approach is using 
the panels of previously published cytochromes P450 of fungi known for biotransformation 
of xenobiotics. As for installing a sulfur-containing functional group on eAA, liver 
microsomes of different organisms could be an interesting tool as they catalyze unspecific 
methylthiolation [125], [190]. 
The third project will be the follow-up project of chapter 4, the rational search of 
genetic designs for optimal isoprenoid production. The insights provided by the analyses 
of Plackett-Burman design and the part fitness will be used to design a second iteration of 
the synthetic MEP pathway library. The screening result of this second library can be used 
to evaluate the predictive power of the rules identified in the Plackett-Burman design and 
part fitness analysis. We plan to validate the findings resulted from the analysis of Plackett-
Burman design. Specifically, A synthetic gene cluster will be constructed with eight genes 
with the optimal expression level identified in Figure 4.3. The further optimization 
improvement will be focused on constructing additional FCs from PCs with the highest 
fitness values (Figure 4.4a). Three upper PCs were selected, and they are PC8, PC19, 
and PC11. Three lower PCs were selected, and they are PC28, PC30, and PC42. A library 
of full factorial combination (3 × 3) of partial clusters will be constructed. RNA-seq analysis 
can be performed on the best producer to measure the transcriptional profile of the 
synthetic MEP pathway. It would be interesting to see how the overexpression of the 
synthetic MEP pathway alters the global transcription landscape of the host cell. 
Furthermore, it would be powerful to integrate kinetics data of MEP pathway enzymes, 
transcriptomics data, and flux-based analysis to establish a MEP pathway model in 
Streptomyces.  
In addition to enabling bioproduction of value-added isoprenoids [101], [102], 
[191]–[194], we are hoping to apply our findings about MEP pathway for new terpene 
scaffold discovery. The recent whole genome data reveals that the Streptomyces 
genomes harbor many novel terpene synthases which potentially encode new 





tsukubadiene [196], fusicomycins [197], labdanmycins [198], and tiancilactone [199], just 
to name a few. The bottleneck of discovering novel terpene synthases is that (i) either 
activity loss in heterologous expression host of a more distance genetic relationship (i.e. 
E. coli), or (ii) tightly regulated pools of isoprenoid building blocks for specialized 
metabolism in the native host, which leads to little or non-detectable level of encoded 
products. By designing and introducing a synthetic MEP pathway gene cluster into the 
Streptomyces strains harboring new terpene synthase genes, their isoprenoid production 
would be potentiated for production of novel terpene scaffold. Alternatively, the 
Stretpomyces terpene synthase genes can be expressed in a model Streptomyces 
isoprenoid overproducing strain. The high-throughput DNA assembly methodology I 
developed during my doctoral training can increase the scale of refactoring Streptomyces 
cryptic gene clusters for novel natural product discovery. The first goal will be to increase 
the yield of the encoded product, which is useful for its detection, isolation, and 
characterization. There is also an opportunity for combinatorial biosynthesis, as the 
algorithmic DNA assembly pipeline is readily amenable for generating combinatorial 
libraries from smaller modular expression cassettes. For example, a plug-and-play 
approach allows swapping novel genes encoding terpene synthases and tailoring 
enzymes for scaffold and functionalization discovery. 
I believe an automated platform which incorporates robotics, DNA design and 
assembly, and high-throughput screening can substantially increase the productivity in 
natural product discovery. The two technologies I developed during my PhD have the 
potential to be integrated with existing automated workflows, which will further streamline 
the ‘design’ and ‘build’ aspect of the “design-build-test-learn” cycle in synthetic biology. 
There are already software packages dedicated to automating the generation of 
multivariate statistical DoE designs (e.g. JMP, Minitab, and R).  The methodical 
experimentation approach can be used to optimize an objective function of a multi-gene 
system, as scientists are becoming more capable of precisely tuning expression of 
multiple genes. In a refactored system, the expression levels may be tuned as variables 
analogous to independent variables in an industrial process (time or quantity) The 
implementation of algorithmic DNA assembly is repeatable, straightforward, and the steps 





group identified major staff time savings in automated DNA assembly for a large number 
of assemblies; assemblies of 42 constructs required 51 minutes of manual  execute time 
and 15 minutes of automated time [200]. During the last five years, I have manually 
assembled and validated at least 550 plasmids for my doctoral project, which are 
approximately equivalent to 8.2 megabases of DNA. I speculate that an automated DNA 
assembly workflow can potentially assemble the same number of plasmids only half of 
time. The automation of the DNA assembly will also encourage a formalized protocol for 
better sharing of reliable results and reproducibility. 
In the last two decades, the developments in de novo synthesis and combinatorial 
DNA assembly have allowed us to perform more sophisticated experiments. Specifically, 
the ability to synthesize user-defined oligonucleotides and long DNA sequences improves 
access to the unexplored nucleotide sequence space. Novel combinatorial assembly 
methods increase the throughput of generating complex, diverse multi-gene constructs 
from libraries of standardized, functional DNA parts. These technological capabilities 
provide unprecedented opportunities to radically engineer the regulation of multi-gene 
systems like natural product BGCs at the DNA level. My dissertation provides a platform 
of rapid prototyping of metabolic pathway and the application of multivariate statistical 
approach to optimize designed multi-gene system in Streptomyces, in the hopes to 
augment the contribution of more data-driven reasoning to design, construct, and test 
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Figure A1. 1. Phylogenetic analysis of 68 primary amino acid sequences similar to ent-
copalyl diphosphate synthase PtmT2 (accession ACO31276.1) from Streptomyces 
platensis. 
WP_037839300.1 (highlighted in red) is a hypothetical protein and later confirmed as ent-copalyl 







Figure A1.2. Phylogenetic analysis of 91 primary amino acid sequences similar to ent-
atiserene synthase PtmT1 (accession ACO31274.1) from Streptomyces platensis. 
WP_0309852 (highlighted in red) is a hypothetical protein, and later confirmed as an ent-atiserene 








Figure A1.3. Plasmid maps and overall scheme for DNA assembly pipeline. 
(A) Plasmid maps for backbone vectors used in the assembly pipeline. Ori: origin of replication; 
GGCS: golden gate cloning site. (B) Plasmids and enzymes used during DNA assembly. Top row 
shows construction of CisReg (cis-regulatory) plasmids containing a reporter gene CDS for part 
characterization. Second row shows replacement of reporter CDS with CDS from biosynthetic gene. 
Third row shows assembly of three monocistronic expression cassettes to a partial cluster. Bottom 
row shows assembly of multiple partial clusters to a full cluster plasmid. Black arrows are labeled 







Figure A1.4. Characterization of promoter-RBS strength in 96-hour fermentation in 2-mL 
PCNM (black bar) and ISM3 (white bar) media in 24-well MTP.  








ent-atis-16-en-19-oic acid (2) 
 
Annotated NMR data for 2 in chloroform-d. 
No. δH (#H, mult., J(Hz)) δC 
1 0.85 (1H, td, 3.3, 13.2) 39.6 
 1.59 (1H, m)  
2 1.40 (1H, m) 18.8 
 1.87 (1H, m)  
3 1.01 (1H, m) 38.3 
 2.15 (1H, d, 14.0)  
4 - 43.9 
5 1.05 (1H, dd, 1.5, 12.1) 57.2 
6 1.75 (1H, m) 20.2 
 1.82 (1H, m)  
7 1.11 (1H, m) 39.6 
 1.47 (1H, td, 2.9, 13.2)  
8 - 33.6 
9 1.13 (1H, m) 52.2 
10 - 38.5 
11 1.40 (1H, m) 28.7 
 1.59 (1H, m)  
12 2.22 (1H, m) 36.6 
13 1.54 (1H, m) 27.3 
 1.60 (1H, m)  
14 1.00 (1H, m) 28.3 
 1.97 (1H, m)  
15 1.88 (1H, d, 16.6) 48.3 
 2.04 (1H, d, 16.6)  
16 - 152.6 
17 4.56 (1H, d, 1.9) 104.7 
 4.73 (1H, d, 1.9)  
18 0.90 (3H, s) 12.1 
19 - 185.0 
20 1.24 (3H, s) 29.0 
 
 






Key NOESY correlations 
 
























ent-isocupressic acid (12) 
 
Annotated NMR data for 12 in chloroform-d. 
No. δH (#H, mult., J(Hz)) δC 
1 1.04 (1H, m) 38.5 
 2.15 (1H, m)  
2 1.51 (1H, m) 20.0 
 1.85 (1H, m)  
3 1.81 (1H, m) 38.1 
 2.16 (1H, m)  
4 - 44.3 
5 1.32 (1H, dd, 2.8, 11.9) 56.4 
6 1.87 (1H, m) 26.4 
 1.97 (1H, m)  
7 1.88 (1H, m) 38.8 
 2.40 (1H, m)  
8 - 148.1 
9 1.56 (1H, d, 11.0) 55.6 
10 - 40.6 
11 1.43 (1H, m) 22.2 
 1.62 (1H, m)  
12 1.05 (1H, m) 39.2 
 1.85 (1H, m)  
13 - 140.7 
14 5.38 (1H, t, 6.8) 123.1 
15 4.14 (2H, m) 59.5 
16 1.66 (3H, s) 16.5 
17 4.52 (1H, s) 106.6 
 4.85 (1H, s)  
18 0.59 (3H, s) 12.9 
19 - 183.7 
20 1.23 (3H, s) 29.1 
 







Key NOESY correlations 
ESIMS m/z [M-H+]- 319.23, found 319.0 
 


















(4E,8E,12E)-14-hydroxy-4,8,12-trimethyltetradeca-4,8,12-trienoic acid (11) 
 
Annotated NMR data for 11 in chloroform-d. 
No. δH (#H, mult., J(Hz)) δC 
1 - 177.1 
2 2.44 (2H, t, 7.3) 32.7 
3 2.30 (2H, t, 7.3) 34.5 
4 - 132.9 
5 5.15 (1H, bt, 7.0) 125.0 
6 2.08 (2H, m) 26.5 
7 1.98 (2H, m) 39.5 
8 - 134.8 
9 5.10 (1H, bt, 7.0) 124.2 
10 2.12 (2H, m) 26.2 
11 2.04 (2H, m) 39.6 
12 - 139.9 
13 5.42 (1H, bt, 7.1) 123.5 
14 4.17 (2H, d, 7.0) 59.6 
15 1.68 (3H, s) 16.5 
16 1.59 (3H, s) 16.1 




Key COSY (bold) and HMBC (arrows) correlations 
ESIMS m/z [M-H+]- 279.20, found 279.00 
 

























Figure A1.16. Putative biosynthesis of shunt metabolite 11 from intermediate 8.  














Figure A1.18. Production titer of 2 in 500 mL ISM3 fermentation medium over seven days. 








Figure A1.19. Dried cell weight versus titer of 2 for S. albidoflavus J1074 SGC5 cultured in 
2 mL of PCNM (●), ISM3 (▲), or TSB (■) medium in 24-well MTP. 
Data points represent mean of at least three experimental replicates over multiple days with error 














ent-(16S)-16-methoxyatisan-19-oic acid (14)  
 
Annotated. NMR data for 14 in chloroform-d. 
No. δH (#H, mult., J(Hz)) δC 
1 0.84 (1H, td, 3.9, 13.3) 39.9 
 1.59 (1H, m)  
2 1.40 (1H, m) 18.9 
 1.86 (1H, m)  
3 1.01 (1H, m) 38.4 
 2.15 (1H, d, 13.3)  
4 - 44.0 
5 1.02 (1H, m) 57.5 
6 1.72 (1H, m) 20.3 
 1.78 (1H, m)  
7 1.02 (1H, m) 40.0 
 1.43 (1H, m)  
8 - 33.4 
9 0.95 (1H, dd, 7.3, 11.0) 51.6 
10 - 38.4 
11 1.30 (1H, td, 2.6, 6.9) 25.2 
 1.56 (1H, m)  
12 1.74 (1H, m) 33.5 
13 1.20 (1H, m) 22.1 
 1.86 (1H, m)  
14 1.01 (1H, m) 27.0 
 1.83 (1H, m)  
15 1.02 (1H, m) 55.8 
 1.37 (1H, d,13.7)  
16 - 76.6 
17 1.21 (3H, s) 24.6 
18 0.89 (3H, s)) 12.5 
19 - 183.2 
20 1.23 (3H, s) 29.1 







Key COSY (bold) and HMBC (arrows) correlations 
 
 
Key NOESY correlations 
 


























ent-(16R)-16-methoxyatisan-19-oic acid (15) 
 
Annotated NMR data for 15 in chloroform-d. 
No. δH (#H, mult., J(Hz)) δC 
1 0.90 (1H, m) 39.6 
 1.60 (1H, d, 13.0)  
2 1.41 (1H, m) 18.9 
 1.86 (1H, m)  
3 1.01 (1H, td, 4.3, 13.1) 38.1 
 2.14 (1H, d, 13.1)  
4 - 43.9 
5 1.06 (1H, m) 57.3 
+6 1.74 (1H, m) 20.3 
 1.79 (1H, m)  
7 1.07 (1H, m) 39.9 
 1.39 (1H, m)  
8 - 33.5 
9 1.17 (1H, m) 50.6 
10 - 38.4 
11 1.07 (1H, m) 23.4 
 1.84 (1H, m)  
12 1.76 (1H, m) 33.4 
13 1.44 (1H, m) 23.7 
 1.57 (1H, m)  
14 0.83 (1H, m) 27.4 
 1.88 (1H, m)  
15 1.22 (2H, m) 55.8 
16 - 76.4 
17 1.22 (3H, s) 24.1 
18 0.88 (3H, s) 12.2 
19 - 183.9 
20 1.23 (3H, s) 29.0 
21 3.16 (3H. s) 49.1 
 







Key NOESY correlations 
 



























methyl ent-atis-16-en-19-oate (16) 
 
Annotated NMR data for 16 in chloroform-d. 
No. δH (#H, mult., J(Hz)) δC 
1 0.84 (1H, m) 39.8 
 1.58 (1H, bd, 13.6)  
2 1.40 (1H, m) 18.9 
 1.83 (1H, m)  
3 1.01 (1H, m) 38.3 
 2.17 (1H, bd, 13.6)  
4 - 43.6 
5 1.03 (1H, m) 57.3 
6 1.74 (2H, m) 20.4 
7 1.11 (1H, m) 39.8 
 1.47 (1H, bd, 13.6)  
8 - 33.6 
9 1.13 (1H, m) 52.2 
10 - 38.5 
11 1.40 (1H, m) 28.8 
 1.59 (1H, m)  
12 2.22 (1H, br s) 36.7 
13 1.59 (2H, m) 27.4 
14 0.99 (1H, m) 28.4 
 1.95 (1H, m)  
15 1.88 (1H, br d, 17.0) 48.3 
 2.02 (1H, br d, 17.0)  
16 - 152.5 
17 4.56 (1H, br s) 104.6 
 4.73 (1H, br s)  
18 0.78 (3H, s) 12.0 
19 - 178.1 
20 1.18 (3H, s) 28.9 








Key COSY (bold) and HMBC (arrows) correlations 
 
 
Key NOESY correlations 
 
























Figure A1.33. Total synthesis of 1 from 2. 







ent-15-oxoatis-16-en-19-oic acid (17) 
 
Annotated NMR data for 17 in chloroform-d 
No. δH (#H, mult., J(Hz)) δC 
1 0.85 (1H, m) 39.8 
 1.62 (1H, m)  
2 1.42 (1H, m) 18.7 
 1.86 (1H, m)  
3 1.02 (1H, m) 37.9 
 2.17 (1H, d, 13.5)  
4 - 43.9 
5 1.05 (1H, m) 56.3 
6 1.84(1H, m) 19.6 
 1.92 (1H, m)  
7 1.50 (1H, m) 30.6 
 1.83 (1H, m)  
8 - 45.3 
9 1.32 (1H, dd, 6.8, 11.4) 46.7 
10 - 39.3 
11 1.57 (1H, m) 28.4 
 1.71 (1H, m)  
12 2.76 (1H, br s) 36.2 
13 1.72 (2H, m) 26.2 
14 1.25 (1H, m) 24.8 
 2.23 (1H, ddd, 3.2, 11.2, 
14.3) 
 
15 - 204.0 
16 - 147.3 
17 5.20 (1H, d, 1.3) 117.0 
 5.94 (1H, d, 1.3)  
18 1.01 (3H, s) 12.8 
19 - 182.6 
20 1.27 (3H, s) 29.0 
 







Key NOESY correlations 
 



















ent-17-methylsulfenyl-15-oxoatisan-19-oic acid (18 and 19) 
 
Figure A1.37. Structure of compounds 18 and 19 


















ent-(15S,16R)-15-hydroxy-17-methylsulfenylatisan-19-oic acid (20) 
 
Annotated NMR data for 20 in chloroform-d. 
No. δH (#H, mult., J(Hz)) δC 
1 0.88 (1H, m) 39.9 
 1.63 (1H, m)  
2 1.42 (1H, m) 18.9 
 1.85 (1H, m)  
3 1.03 (1H, m) 37.6 
 2.15 (1H, m)  
4 - 43.8 
5 1.08 (1H, m) 56.6 
6 1.80 (2H, m) 19.7 
7 1.12 (1H, dt, 2.7, 13.1) 33.2 
 1.69 (1H, m)  
8 - 36.5 
9 1.61 (1H, m) 47.4 
10 - 38.1 
11 1.48 (1H, m) 29.3 
 1.53 (1H, m)  
12 1.66 (1H, m) 30.0 
13 1.30 (1H, m) 21.3 
 1.53 (1H, m)  
14 0.74 (1H, td, 6.5, 13.1) 27.5 
 1.97 (1H, m)  
15 2.95 (1H, d, 3.7) 81.1 
16 1.54 (1H, m) 42.1 
17 2.53 (2H, d, 7.8) 39.3 
18 0.91 (3H, s) 13.0 
19 - 182.5 
20 1.25 (3H, s) 29.0 
21 2.14 (3H, s) 15.7 
 
 







Key NOESY correlations 
 


















ent-(15S,16S)-15-hydroxy-17-methylsulfenylatisan-19-oic acid (21) 
 
Annotated NMR data for 21 in chloroform-d. 
No. δH (#H, mult., J(Hz)) δC 
1 0.88 (1H, m) 40.1 
 1.63 (1H, m)  
2 1.41 (1H, m) 18.8 
 1.87 (1H, m)  
3 1.02 (1H, m) 38.0 
 2.15 (1H, m)  
4 - 43.8 
5 1.02 (1H, m) 57.0 
6 1.72 (1H, m) 20.1 
 1.78 (1H, m)  
7 1.06 (1H, m) 37.6 
 1.80  
8 - 35.6 
9 0.99 (1H, m) 49.3 
10 - 38.5 
11 1.37 (1H, m) 29.3 
 1.48 (1H, m)  
12 1.54 (1H, m) 30.4 
13 1.27 (1H, m) 20.9 
 1.64 (1H, m)  
14 1.47 (1H, m) 20.3 
 1.64 (1H, m)  
15 3.45 (1H, d, 8.8) 77.8 
16 1.97 (1H, m) 40.4 
17 2.51 (1H, dd, 5.3, 12.2) 34.4 
 2.89 (1H, m)  
18 0.94 (3H, s) 13.1 
19 - 182.5 
20 1.25 (3H, s) 29.0 







Key COSY (bold) and HMBC (arrows) correlations 
 
 
Key NOESY correlations 
 


















ent-(15S,16S)-15-hydroxy-17-methylsulfenylatisan-19-oic acid (22) 
 
Annotated NMR data for 22 in chloroform-d. 
No. δH (#H, mult., J(Hz)) δC 
1 0.92 (1H, m) 40.1 
 1.58 (1H, m)  
2 1.40 (1H, m) 18.7 
 1.80 (1H, m)  
3 1.01 (td, 4.2, 13.5, 17.6) 38.0 
 2.14 (1H, m)  
4 - 43.9 
5 1.10 (1H, m) 56.7 
6 1.70 (1H, m) 20.0 
 1.78 (1H, m)  
7 1.11 (1H, m) 34.0 
 1.70 (1H, m)  
8 - 35.8 
9 1.63 (1H, m) 41.7 
10 - 38.2 
11 1.1 (1H, m) 22.5 
 1.63 (1H, m)  
12 1. 51 (1H, m) 31.3 
13 1.47 (2H, m) 27.8 
14 0.89 (1H, m) 26.9 
 1.95 (1H, m)  
15 3.46 (1H, d, 8.8) 74.6 
16 1.97 (1H, m) 40.1 
17 2.51 (1H, dd, 4.8, 12.1) 34.9 
 2.87 (t, 11.8)  
18 0.90 (3H, s) 12.7 
19 - 184.4 
20 1.23 (3H, s) 29.0 
21 2.15 (3H, s) 15.8 
 
 







Key NOESY correlations 


















ent-(15R,16S)-15-hydroxy-17-methylsulfenylatisan-19-oic acid (23) 
 
Annotated NMR data for 23 in chloroform-d. 
No. δH (#H, mult., J(Hz)) δC 
1 0.84 (1H, m) 39.9 
 1.62 (1H, m)  
2 1.41 (1H, m) 18.8 
 1.87 (1H, m)  
3 1.01 (1H, m) 38.0 
 2.16 (1H, m)  
4 - 43.8 
5 1.02 (1H, m) 57.1 
6 1.77 (2H, m) 20.0 
7 1.03 (1H, m) 35.5 
 1.70 (1H, m)  
8 - 36.2 
9 0.86 (1H, m) 50.8 
10 - 38.5 
11 1.16 (1H, dd, 6.4,13.9) 22.8 
 1.51 (1H, m)  
12 1.65 (1H, m) 29.3 
13 1.47 (1H, m) 20.2 
 1.66 (1H, m)  
14 1.47 (1H, m) 27.6 
 1.58 (1H, m)  
15 2.92 (1H, dd, 1.7, 4.4) 84.4 
16 1.61 (1H, m) 46.7 
17 2.53 (2H, m) 39.1 
18 0.92 (3H, s) 12.5 
19 - 183.9 
20 1.24 (3H, s) 29.0 
21 2.13 (3H, s) 15.7 
 
 







Key NOESY correlations 


















Serofendic acid A (1A) 
 
Annotated. NMR data for 1A in methanol-d4. 
No. δH (#H, mult., J(Hz)) δC 
1 0.88 (1H, m) 41.2 
 1.62 (1H, m)  
2 1.38 (1H, m) 20.0 
 1.89 (1H, m)  
3 1.03 (1H, m) 39.2 
 2.13 (1H, d, 13.0)  
4 - 44.7 
5 1.04 (1H, m) 57.9 
6 1.79 (1H, m) 20.9 
 1.86 (1H, m)  
7 1.07 (1H, m) 34.3 
 1.71 (1H, m)  
8 - 37.7 
9 1.57 (1H, m) 42.8 
10 - 39.2 
11 1.41 (1H, m) 30.0 
 1.59 (1H, m)  
12 1.77 (1H, m) 32.2 
13 1.38 (1H, m) 22.2 
 1.64 (1H, m)  
14 0.83 (1H, m) 28.2 
 2.02 (1H, ddd, 2.8, 11.8, 14.1)  
15 2.93 (1H, d, 4.4) 81.3 
16 1.92 (1H, m) 44.4 
17 2.83 (1H, dd, 6.1, 13.1) 60.9 
 2.95 (1H, dd, 9.3, 13.1)  
18 0.95 (3H, s) 13.4 
19 - 181.7 
20 1.20 (3H, s) 29.6 







Key COSY (bold) and HMBC (arrows) correlations 
 
 
Key NOESY correlations 






























Serofendic acid B (1B) 
 
Annotated NMR data for 1B in methanol-d4. 
No. δH (#H, mult., J(Hz)) δC 
1 0.96 (1H, m) 41.3 
 1.62 (1H, m)  
2 1.38 (1H, m) 20.1 
 1.92 (1H, m)  
3 1.04 (1H, m) 39.4 
 2.13 (1H, br. d, 13.2)  
4 - 44.3 
5 1.04 (1H, m) 57.9 
6 1.79 (1H, m) 21.0 
 1.86 (1H, m)  
7 1.06 (1H, m) 34.3 
 1.69 (1H, m)  
8 - 37.7 
9 1.58 (1H, m) 42.9 
10 - 39.2 
11 1.42 (1H, m) 29.9 
 1.59 (1H, m)  
12 1.75 (1H, m) 30.8 
13 1.40 (1H, m) 21.9 
 1.62 (1H, m)  
14 0.82 (1H, ddd, 6.2, 12.2, 14.0) 28.4 
 2.04 (1H, ddd, 3.0, 11.7, 14.0)  
15 2.91 (1H, d, 4.4) 81.2 
16 1.88 (1H, m) 44.3 
17 2.88 (1H, dd, 9.3, 13.1) 59.8 
 3.00 (1H, dd, 6.8,13.1)  
18 0.95 (3H, s) 13.5 
19 - 181.0 
20 1.19 (3H, s) 29.6 







Key COSY (bold) and HMBC (arrows) correlations 
 
 
Key NOESY correlations  
 












(15S,16S)-ent-15-hydroxy-17-methanesulfinylatisan-19-oic acid (24A) 
 
Annotated NMR data for 24A in chloroform-d. 
No. δH (#H, mult., J(Hz)) δC 
1 0.95 (1H, m) 41.3 
 1.67 (1H, m)  
2 1.39 (1H, m) 20.0 
 1.91 (1H, m)  
3 1.05 (1H, m) 39.1 
 2.13 (1H, d, 13.1)  
4 - 44.6 
5 1.05 (1H, m) 58.0 
6 1.74-1.78 (2H, m) 21.3 
7 1.08 (1H, m) 38.5 
 1.75 (1H, m)  
8 - 36.7 
9 1.08 (1H, m) 50.7 
10 - 39.5 
11 1.46 (1H, m) 29.9 
 1.57 (1H, m)  
12 1.69 (1H, m) 31.1 
13 1.34 (1H, m) 21.6 
 1.68 (1H, m)  
14 1.49 (1H, m) 21.0 
 1.66 (1H, m)  
15 3.36 (1H, d, 9.2) 78.1 
16 2.33 (1H, m) 38.9 
17 2.78 (1H, dd, 7.6, 13.2) 55.3 
 3.29 (1H, dd, 7.6, 13.2)  
18 0.98 (3H, s) 13.6 
19 - 181.6 
20 1.20 (3H, s) 29.4 
21 2.67 (3H, s) 38.5 
 







Key NOESY correlations 
 


















(15S,16S)-ent-15-hydroxy-17-methanesulfinylatisan-19-oic acid (24B) 
 
Annotated. NMR data for 24B in methanol-d4 
No. δH (#H, mult., J(Hz)) δC 
1 0.93 (1H, m) 41.5 
 1.67 (1H, m)  
2 1.38 (1H, m) 20.2 
 1.94 (1H, m)  
3 1.01 (1H, m) 39.2 
 2.14 (1H, br. d, 13.2)  
4 - 45.0 
5 1.00 (1H, m) 58.3 
6 1.80 (2H, m) 21.4 
7 1.03 (1H, m) 38.5 
 1.71 (1H, m)  
8 - 36.8 
9 1.06 (1H, m) 50.7 
10 - 39.5 
11 1.45 (1H, m) 30.1 
 1.58 (1H, m)  
12 1.56 (1H, m) 32.7 
13 1.34 (1H, m) 21.9 
 1.67 (1H, m)  
14 1.48 (1H, m) 21.0 
 1.67 (1H, m)  
15 3.39 (1H, m) 77.4 
16 2.42 (1H, m) 37.8 
17 2.54 (1H, dd, 4.0, 12.7) 57.1 
 3.40 (1H, m)  
18 0.99 (3H, s) 13.7 
19 - 182.5 
20 1.17 (3H, s) 29.7 
21 2.65 (3H, s) 38.7 
 
 







Key NOESY correlations 



















Figure A1.65. Chemical structures of C15-hydroxylated atisane compounds. 
They are Eriocatisin A (left) from Isodon eriocalyx, and ent-(1S,6S,15S)-1,5,6,15-tetrahydroxy-






Table A1.1. Name, nucleotide length, and predicted function of the genes used in building 
SGCs. 













synthase (MEP pathway) 
WP_037839917 
eAS 927 ent-atiserene synthase WP_030985278 
eCPDPS 1602 ent-copalyl diphosphate synthase WP_037839300 
GGDPS 1047 geranylgeranyl diphosphate synthase WP_078889660 
eAOx 1326 cytochrome P450 WP_030985276 
αKG-
DDO 
843 α-ketoglutarate dependent dioxygenase WP_078889904 
eAOxFD 336 ferredoxin WP_030990007 
dxr 1275 
1-deoxy-D-xylulose-5-phosphate 

























Table A1.2. Crystal data and structure refinement of 2. 
______________________________________________________________ 
Identification code  17104c 
Empirical formula  C20H30O2 
Formula weight  302.44 
Temperature  123(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P212121 
Unit cell dimensions  a = 11.6388(11) Å α = 90° 
 b = 13.4757(16) Å β = 90° 
 c = 21.856(2) Å γ = 90° 
Volume 3427.9(6) Å3 
Z 8 
Density (calculated) 1.172 Mg/m3 
Absorption coefficient 0.073 mm-1 
F(000) 1328 
Crystal color, morphology Colourless, Plate 
Crystal size 0.230 x 0.120 x 0.030 mm3 
Theta range for data collection 2.312 to 28.275° 
Index ranges -15 ≤ h ≤ 10, -17 ≤ k ≤ 13, -29 ≤ l ≤ 28 
Reflections collected 23054 
Independent reflections 8437 [R(int) = 0.0436] 
Observed reflections 6753 
Completeness to theta = 25.242°  99.8%  
Absorption correction Multi-scan 
Max. and min. transmission 0.7457 and 0.6872 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 8437 / 0 / 407 
Goodness-of-fit on F2 1.029 





R indices (all data) R1 = 0.0679, wR2 = 0.1177  
Absolute structure parameter -0.9(6) 






Captions of Supplementary Data File A1. (separate file) 
 
The file titled ‘Supplementary Data A1.xlsx’ contains six worksheets.  
 
Worksheet 1 (Genetic Parts): 
Column A: Name of genetic parts 
 Column B: Sequence of genetic parts 
 Column C: Sources of genetic parts 
 Column D: Reference of genetic parts 
Column 25-45F: Average value of relative expression level of promoter-RBS 
parts in 60-hour fermentation in ISM3 medium. Relative expression level is 
measured as changes in absorbance at 415 nm per minute per grams of dried 
cell weight. The value is calculated from three biological replicates. 
Column 25-45G: Standard deviation of the value of relative expression level of 
promoter-RBS parts in 60-hr fermentation in ISM3 medium. Relative expression 
level is measured as changes in absorbance at 415 nm per minute per grams of 
dried cell weight. The value is calculated from three biological replicates. 
Column 25-45H: Average value of relative expression level of promoter-RBS 
parts in 60-hour fermentation in PCNM medium. Relative expression level is 
measured as changes in absorbance at 415 nm per minute per grams of dried 
cell weight. The value is calculated from three biological replicates. 
Column 25-45I: Standard deviation of the value of relative expression level of 
promoter-RBS parts in 60-hour fermentation in PCNM medium. Relative 
expression level is measured as changes in absorbance at 415 nm per minute 
per grams of dried cell weight. The value is calculated from three biological 
replicates. 
 
Worksheet 2 (SGC Compositions): 
Column A: Construct name, with ‘SGC’ denoting a synthetic gene cluster variant, 
‘M’ a MEP pathway variant, ‘A’ indicating an independent exconjugant A from the 
same conjugation, and ‘B’ an independent exconjugant B from the same 
conjugation. 
Column B-BH: Parts composition, with ‘P’ denoting a promoter part, ‘R’ an RBS 
part, ‘T’ a transcriptional terminator part, and ‘scar’ a 4-bp MoClo scar sequence. 
  
Worksheet 3 (SGC Sequences): 
Column A: Construct name, with ‘SGC’ denoting a synthetic gene cluster variant, 
‘M’ a MEP pathway variant, ‘A’ indicating an independent exconjugant A from the 
same conjugation, and ‘B’ an independent exconjugant B from the same 
conjugation. 
Column B: Complete nucleotide sequence of a construct 
  
Worksheet 4 (SGC Characterization): 
Column A: Construct name, with ‘SGC’ denoting a synthetic gene cluster variant, 





same conjugation, and ‘B’ an independent exconjugant B from the same 
conjugation. 
Column B: Media type 
Column C: Fermentation volume (mL) 
Column D-I: biological replicates of production titer of ent-atiserenoic acid (eAA). 
Unit: mg/mL 
Column J: Average production titer of of ent-atiserenoic acid (eAA). Unit: mg/mL 
Column J: Standard deviation of production titer of of ent-atiserenoic acid (eAA). 
Unit: mg/mL 
 
Worksheet 5 (eAs Phylogenetic Analysis): 
Column A: Accession number of protein sequence used to construct 
phylogenetic analysis of ent-atiserene synthase (eAs) 
 
Worksheet 6 (eCDPS Phylogenetic Analysis): 
Column A: Accession number of protein sequence used to construct 









Supplementary Materials for 
 





This appendix includes: 
 
Figure A2.1 to A2.3 
Table A2.1 
Captions for Data File A2 
 
Other Supplementary Materials for this manuscript include the following:  
 














Figure A2.2. DNA gel electrophoresis of PCR products from colony PCR experiment. 
Template DNA used in each lane are: purified plasmid of PBFC81 (lane 1; positive control), purified 
plasmid of PBFC21 (lane 2; positive control), purified plasmid of CisReg-DE-P12R10-GUS-T7 (lane 
3; negative control), genomic DNA from a single E. coli NEBstable transformant of PBFC21 (lane 







Figure A2.3. Microscope set up for colony morphology photography. 
Note the Amscope digital camera was not shown in this picture, and the LED light was not turn on. 
During photography, the Amscope digital camera replaced the eye piece and is connected to a 






Table A2.1. Images of colony morphology of PBFC strains. 

















































































































































































































































































































































































































































































































Captions of Supplementary Data File A2. (separate file) 
 
The file titled ‘Supplementary Data File A2.xslx’ contains six worksheets.  
 
Worksheet 1 (1. PB matrix): 
This worksheet contains the 125 x 31 Plackett-Burman matrix. Column A through 
column H, which are highlighted in grey, are used to guide the expression level design. 
The unhighlighted columns (column I - AE) are not use in the genetic design but are 
used as dummy variables (dv).  
 
Worksheet 2 (2. Genetic Design): 
This worksheet describes the architecture of the PBFC design at monocistronic level and 
partial cluster level.  
 Column A – G: The genetic design details of each monocistronic unit.  
Column A: expression level corresponding to PB matrix in worksheet 1 
Column B: The name of monocistronic units. This corresponds to the ‘MT’ 
name in Figure 4.1c.  
Column C, G: MoClo scars flanking the monocistronic unit 
Column D,F: Promoter-RBS and terminator part controlling the 
expression of the gene of interest. 
Column E: gene of interest in each monocistronic unit 
Column I – P: The genetic design details of each partial cluster. 
Column I: The name of upper and lower partial clusters. The name 
corresponds to the ‘PC’ names in Figure 4.1c. 
Column J: This indicates the type of partial cluster, either upper or lower. 
Column K, P: MoClo scars flanking the partial cluster 
Column L – P: The detailed makeup of each partial cluster in terms of 
monocistronic units. The composition order reflects the gene order in the 
genetic design. 
Column R – V: The genetic design details of each Plackett-Burman full cluster in 
terms of partial clusters. 
Column R: The name of PBFC. The name corresponds to the ‘FC’ names 
in Figure 4.1c. 
Column S, V: MoClo scars flanking the full cluster 
Column T, U: The detailed makeup of each full cluster in terms of partial 
cluster. The composition order reflects the cluster order in the genetic 
design. 
Column X – AH: The genetic design details of each Plackett-Burman full cluster 
in terms of monocistronic units. 
Column X: The name of PBFC. The name corresponds to the ‘FC’ names 
in Figure 4.1c. 
Column Y, AH: MoClo scars flanking the full cluster 
Column Z – AG: The detailed makeup of each full cluster in terms of 







Worksheet 3 (3. Exp,Titer, Morph): 
This worksheet describes the expression strength of individual genes and dummy 
variables, eAA production titer data, and colony morphology features of each PBFC. 
 Column A: Plackett-Burman full cluster name 
 Column B – H: expression level of individual genes corresponding to the 
promoter-RBS parts controlling the expression. The genetic design is reflected in 
Worksheet 2 Column Z – AG. 
Column J – AF: The levels of dummy variables dv1 through dv23. These 
columns are used as negative control in the experimental error calculation. 
 Column AG, AH: The composition of PBFC in terms of partial clusters 
 Column AI – AL: eAA production titer measurement of each PBFC strain.  
  Column AI, AJ: biological duplicate measurement of eAA titer 
  Column AK, AL: average value of eAA titer at linear scale and log10 scale 
 Column AM: FC relative fitness. This value is calculated by taking average log10 
eAA titer of each PBFC strain and divide by the average log10 eAA titer of the overall 
PBFC library. 
 Column AN – AT: Morphological class and features of PBFC strains. 
  Column AN: Morphological classes 
Column AO – AT: Morphological features defining each morphological 
class. The features are colony shape, margin, color, opacity, elevation, 
and texture. 
  
Worksheet 4 (4. DNA Parts and Vectors): 
This worksheet describes promoter-RBS, terminator, and CDS parts and vectors used to 
construct PBFCs. 
 
Worksheet 5 (5. Fitness Calculation): 
This worksheet contains fitness value of monocistronic units and partial clusters.  
Column A – C: The column structure is identical to worksheet 2 Column R- V, 
excluding the scar information. The partial cluster name is replaced with its 
calculated fitness value. 
Column D - F: Predicted fitness value of full clusters based on partial cluster 
fitness values using additive, multiplicative, or dominant negative model. 
Column H – P: The column structure is identical to worksheet 2 Column X- AH, 
excluding the scar information. The monocistronic unit name is replaced with its 
calculated fitness value. 
Column Q – S: Predicted fitness value of full clusters based on the fitness value 
of monocistronic units using additive, multiplicative, or dominant negative model. 
 
Worksheet 6 (6. Morphology Description): 
Column A- G: Text-based description of morphology features of each 
morphology class. 
Column I – O: Discretized, numerical representation of morphological features of 
each morphology class. 
 
